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Abstract 
AMP-activated protein kinase (AMPK) has been proposed to be a potential 
therapeutic target for patients with Type 2 diabetes and the metabolic syndrome. 
While the role of AMPK in muscle and liver is relatively well-characterised, less is 
known about the role of AMPK in the other principal metabolic tissue, adipose. 
Obesity is associated with the chronic, sub-clinical inflammation of adipose tissue. 
Characteristic hypertrophic adipocytes and the elevated infiltration and activation 
of macrophages stimulate production of cytokines and chemokines, including 
tumour necrosis factor- (TNF-), interleukin-1 (IL-1), interleukin-6 (IL-6) and 
monocyte chemoattractant protein-1 (MCP-1). These have autocrine, paracrine 
and endocrine effects which have been suggested to play a key role in the 
development of peripheral insulin resistance. Increasing evidence suggests that 
AMPK has anti-inflammatory actions, independent of its effect on carbohydrate 
and lipid metabolism. Previous work in our laboratory has demonstrated that AMPK 
inhibits TNF--stimulated MCP-1 secretion and monocyte adhesion in endothelial 
cells. The role of AMPK in the regulation of inflammatory signalling in adipocytes 
is currently poorly characterised. 
To address this, the effect of AMPK activation on the phosphorylation of TNF-/IL-
1 and IL-6 signalling pathway intermediates was initially assessed in cultured 3T3-
L1 adipocytes. Furthermore, the molecular mechanism by which AMPK elicits 
these effects was investigated. In addition, the effect of AMPK activation on 
downstream functional consequences of proinflammatory signalling in 3T3-L1 
adipocytes and RAW 264.7 macrophages were examined. Finally, the effect of 
macrophage AMPK activation on inflammation-induced insulin resistance in 3T3-
L1 adipocytes was also investigated.  
A769662 and infection with adenovirus expressing a constitutively active AMPK 
mutant suppressed IL-1-stimulated NFB nuclear translocation in 3T3-L1 
adipocytes. Conversely, this was abrogated upon adenoviral expression of a 
dominant negative AMPK mutant. In line with this, phosphorylation of upstream 
IB and IKK were also ameliorated upon AMPK activation. In parallel, A769662-
mediated AMPK activation inhibited TNF-/IL-1-stimulated phosphorylation of 
JNK, ERK1/2 and p38 MAPKs in 3T3-L1 adipocytes. Furthermore, A769662-
3 
mediated inhibition of TNF-/IL-1 proinflammatory signalling was likely to be 
independent of endothelial nitric oxide synthase (eNOS) activation and subsequent 
nitric oxide production. The target of AMPK may be downstream of TAK1, as IKK, 
JNK and p38 are inhibited in response to both TNF- and IL-1; however the 
mechanism by which AMPK elicits these effects remains to be elucidated. 
A769662-mediated AMPK activation inhibited phosphorylation of IL-6-stimulated 
STAT3 (signal transducer and activator of transcription 3) in 3T3-L1 adipocytes 
independently of phosphatase action, yet A769662 was unable to inhibit 
constitutive Janus kinase (JAK)-mediated phosphorylation of STAT3, suggesting 
AMPK may inhibit JAK activity. Inhibition of mTOR was found to suppress STAT3 
phosphorylation in a manner mutually exclusive with A769662 stimulation, 
potentially via activation of T cell protein tyrosine phosphatase (TC-PTP). Adipose 
tissue from AMPK1-/- mice demonstrated increased basal JNK and STAT3 
phosphorylation, further providing evidence for an anti-inflammatory role for 
AMPK in adipose tissue. In 3T3-L1 adipocytes, A769662 abrogated cytokine-
stimulated MCP-1 gene expression, and secretion of chemokines IP-10 (CXCL10), 
KC (CXCL1) and MCP-1. Furthermore, AMPK activation reduced secretion of IL-5, 
MCP-1 and MIP-1, but not TNF-, from proinflammatory RAW 264.7 macrophages. 
Preliminary results indicated that chronic IL-6 and acute TNF- or IL-1 exposure 
suppressed insulin-stimulated glucose transport in 3T3-L1 adipocytes. Conditioned 
medium from activated RAW 264.7 macrophages also inhibited 3T3-L1 adipocyte 
insulin sensitivity; however, prior AMPK activation failed to attenuate this, 
potentially as a result of the presence of TNF-. 
Overall these results suggest that activation of AMPK inhibits activation of multiple 
distinct proinflammatory signalling pathways in adipocytes and macrophages. 
AMPK activation may suppress IL-6 signalling via regulation of JAK, while the 
AMPK-mediated inhibition of IKK and concomitant suppression of MAPKs in 
response to TNF-/IL-1 suggests TAK1 as a potential AMPK target. Finally, 
proinflammatory stimuli induce insulin resistance in adipocytes, however whether 
this can be rescued by AMPK activation remains to be fully elucidated.
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 Chapter 1 - Introduction 
1.1 Adipose Tissue 
1.1.1  Adipose tissue composition and function 
Adipose tissue is composed of several cell types, including adipocytes, pre-
adipocytes, fibroblasts, and cells from the vascular, immune and nervous systems. 
At the whole-body level, it can be divided into SCAT (subcutaneous adipose tissue) 
and VAT (visceral adipose tissue) depots, and is further classified as being white 
(WAT) or brown (BAT). VAT tends to be located around abdominal viscera and is 
more metabolically active than SCAT, exhibiting increased lipolysis (Arner 2005) 
as well as an increase in inflammatory cells (Bruun et al. 2005). Indeed, increased 
VAT accumulation is associated with an elevated risk of Type 2 diabetes (Fox et 
al. 2007). WAT and BAT have distinct functions; adipocytes within WAT are the 
primary site for energy storage, while adipocytes within BAT allow energy 
dissipation by thermogenesis. 
1.1.1.1 White adipose tissue 
A physiological role of WAT is to function as an energy storage organ: energy is 
stored during periods of caloric excess as TG [triacylglycerol (trigyceride)] within 
white adipocytes, forming the core lipid droplet. This energy reserve can then be 
broken down to liberate fatty acids which can be utilised as fuel for muscle and 
other tissues when energy expenditure exceeds intake. The amount of energy 
stored in adipose tissue is regulated via the anabolic and catabolic processes, 
lipogenesis and lipolysis, respectively. Furthermore, WAT functions as an 
endocrine organ, secreting proteins which produce autocrine, paracrine and 
endocrine effects. 
1.1.1.2 Brown adipose tissue 
BAT contains high numbers of mitochondria which express UCP1 (uncoupling 
protein 1) which physiologically uncouples ATP synthesis from substrate oxidation. 
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Interestingly, clusters of adipocytes expressing UCP1 with thermogenic 
capabilities have recently been identified within WAT in response to various 
stimuli (Vitali et al. 2012). These adipocytes have been termed ‘beige’ or ‘brite’ 
and are similar to classical brown adipocytes insofar as they exhibit multilocular 
lipid droplet morphology, contain high numbers of mitochondria and express 
UCP1. Key differences distinguishing beige from classical brown adipocytes are 
that they are not derived from the same embryonic precursors (Seale et al. 2008), 
and importantly, that classical brown adipocytes express UCP1 and other 
thermogenic genes under basal conditions, while beige adipocytes only express 
these genes in response to activation by cold exposure, -adrenergic receptor 
agonists or PPAR (peroxisome proliferator-activated receptor ) (Rosenwald et al. 
2013, Petrovic et al. 2010, Wu, Cohen, and Spiegelman 2013). It is not clear 
whether beige adipocytes arise from white adipocytes through 
transdifferentiation in response to stimuli, as suggested by Vitali and coworkers 
(Vitali et al. 2012) or from the de novo differentiation and maturation of 
preadipocytes (Wang et al. 2013). Intriguingly, it has been suggested that the 
thermogenic profile of beige adipocytes is fully reversible. Cold-exposure induced 
beige adipocytes lose UCP1 expression when mice are transferred to warmer 
conditions; however UCP1 expression is induced again within the same cells upon 
re-exposure to cold, indicating beige adipocytes are retained and may function 
similarly to white adipocytes until induced to function as brown adipocytes 
(Rosenwald et al. 2013). There is increasing interest in the capacity of beige and 
brown adipocytes to counteract obesity-related disorders, such as Type 2 
diabetes; indeed increased brown and beige adipocytes are associated with 
obesity resistance in many mouse models (Cederberg et al. 2001, Seale et al. 
2011). 
1.1.2  Lipogenesis 
Lipogenesis is the de novo synthesis of fatty acids (FAs) from non-lipid substrates 
such as glucose, and is stimulated by insulin during the fed state in adipocytes as 
shown in Figure 1.1. Insulin secretion stimulates glucose uptake by initiating a 
signalling pathway which culminates in the translocation of the glucose 
transporter GLUT4 to the plasma membrane (Saltiel and Kahn 2001), thereby 
facillitating glucose uptake. Glucose is then metabolised by glycolysis in the 
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cytosol, where it is broken down via a series of steps first to an intermediate 
dihydroxyacetone phosphate (DHAP), which is then converted to glycerol-3-
phosphate (G3P) by glycerol-3-phosphate dehydrogenase. DHAP is also 
metabolised to pyruvate which is converted to acetyl CoA in the mitochondrion. 
Acetyl CoA can be shunted back to the cytoplasm to act as a substrate for the 
formation of FA via the action of ACC (acetyl CoA carboxylase) and FAS (fatty acid 
synthase) (Wakil 1989, Wakil, Stoops, and Joshi 1983). The action of insulin on 
target tissues activates ACC, which catalyses the carboxylation of acetyl CoA to 
form the intermediate malonyl CoA (Tong 2005). FAS is a multienzyme complex 
which is arranged around a central acyl carrier protein and functions to synthesise 
FA from both acetyl CoA and malonyl CoA in an NADPH-dependent manner. FAs 
can also be obtained from the hydrolysis of circulating vLDL (very low density 
lipoproteins) or chylomicrons by LPL (lipoprotein lipase)-mediated lipolysis and 
are transported into the adipocyte (Figure 1.1). 
 
Figure 1-1: Regulation of lipogenesis in adipocytes 
G3P and FA are esterified to form TGs in response to insulin. Glucose is 
metabolised to G3P and acetyl CoA which is converted to FA via the enzymes ACC 
and FAS. FAs are also obtained from the LPL-mediated hydrolysis of circulating 
lipoproteins. Abbreviations: G4, GLUT4; DHAP, dihydroxyacetone phosphate; 
G3P, glycerol-3-phosphate; DGAT, diacylglycerol acetyltransferase. 
 
TG is formed from G3P and FA via a series of steps. In order for FA to be utilised 
in TG synthesis they must first be activated via esterification to Coenzyme A by 
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fatty acyl CoA synthetase (Watkins 1997). Phosphatidate is formed via the addition 
of two FA to G3P, catalysed by glycerol phosphate acyltransferase. Finally, 
phosphatidate is hydroysed by a phosphatase to yield diacylglyceride, which is 
then acylated to a TG by diacylglycerol acetyltransferase (DGAT) (Coleman and 
Lee 2004). 
1.1.3 Lipolysis 
In the fasted state, or during prolonged physical activity, the catabolic process of 
lipolysis occurs in order to yield FAs and glycerol, for use by other tissues such as 
muscle and liver for generation of ATP or hepatic gluconeogenesis, respectively. 
Binding of lipolytic hormones and neurotransmitters such as noradrenaline to 
adipocyte -adrenergic receptors triggers an increase in cAMP via adenylyl 
cyclase, as demonstrated in Figure 1.2. This increase in cAMP within the cell then 
activates PKA (protein kinase A) (Collins, Cao, and Robidoux 2004, Holm et al. 
2000), which subsequently phosphorylates perilipin and HSL (hormone-sensitive 
lipase). PKA phosphorylates HSL at Ser563, increasing its intrinsic activity, and 
Ser659 and Ser660, which are involved in the translocation of HSL to the lipid 
droplet. Perilipins are proteins found in mature adipocytes which cover the lipid 
droplet and thereby block HSL activity (Londos et al. 1999); phosphorylation of 
perilipins by PKA relieves their inhibition of HSL. Interestingly, it has been 
demonstrated that an absence of perilipin in adipocytes results in failure of HSL 
translocation, and thus failure of lipolysis (Sztalryd et al. 2003). 
Activation of HSL via PKA phosphorylation is the rate-limiting step in hydrolysis of 
TG and induces its translocation from the cytosol to the surface of the lipid droplet 
(Anthonsen et al. 1998) where it hydrolyses TG to form diacylglycerides, and 
diacylglycerides into monoacylglycerides. A second enzyme, known as 
monoglyceride lipase, is necessary for complete hydrolysis of monoacylglycerides 
into non-esterified fatty acids (NEFAs) and glycerol, thus completing the process 
of lipolysis in adipocytes (Fredrikson, Tornqvist, and Belfrage 1986). Conversely, 
insulin negatively regulates lipolysis by initiating a signalling cascade which leads 
to the activation of phosphodiesterase 3B (PDE3B), triggering the hydrolysis of 
cAMP, thus suppressing PKA activation and subsequent HSL action (Shakur et al. 
2001). 
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Figure 1-2: Hormonal control of adipocyte lipolysis 
Lipolysis is stimulated by -AR-mediated stimulation of cAMP production, 
resulting in PKA activation. PKA phosphorylates HSL and perilipins, stimulating 
hydrolysis of TG to MG. MGL further hydrolyses MG to NEFA and glycerol. Insulin 
suppresses lipolysis via stimulation of PDE3B and subsequent hydrolysis of cAMP, 
suppressing PKA activation. Abbreviations: -AR, -adrenergic receptor; PKA, 
protein kinase A; HSL, hormone-sensitive lipase; MGL, monoglyceride lipase; 
NEFA, non-esterified fatty acid; PDE3B, phosphodiesterase 3B. 
 
1.1.4  Insulin-stimulated glucose transport 
Insulin secretion is stimulated in response to glucose by pancreatic -cells. In 
healthy, insulin sensitive individuals, insulin acts on skeletal muscle and 
adipocytes to stimulate glucose uptake via the regulated translocation of vesicles 
containing the glucose transporter GLUT4 to the plasma membrane as shown in 
Figure 1.3. The insulin receptor (IR) is a transmembrane receptor of the RTK 
(receptor tyrosine kinase) family and is composed of two extracellular -subunits 
containing the insulin-binding domains and two transmembrane -subunits linked 
by disulphide bonds (Lee and Pilch 1994). Insulin binding to the extracellular -
subunits induces a conformational change in the -subunits, activating the 
tyrosine kinase activity of the receptor. The kinase activity of each  subunit 
initially phosphorylates tyrosine residues near the catalytic site in the adjacent  
subunit, leading to the subsequent autophosphorylation of tyrosine residues in 
other parts of the cytosolic domain. Specific phosphotyrosine modifications 
stabilise an active conformation of the kinase domain and provide docking sites 
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for downstream signalling molecules, such as proteins containing src homology 2 
(SH2) and phosphotyrosine binding (PTB) domains (Czech and Corvera 1999, Ullrich 
and Schlessinger 1990, Ward and Lawrence 2009). 
IRS (insulin receptor substrate) adaptor proteins contain a PTB domain which 
recognises phosphotyrosines on the IR of the NPXpY motif. The IRS also has an N-
terminal Pleckstrin homology (PH) domain which recognises and associates with 
polar lipids in the plasma membrane, and is also thought to interact with the IR 
kinase (Burks et al. 1997). The bound IRS is then tyrosine-phosphorylated by the 
IR (Ward and Lawrence 2009). IRS-1 and IRS-2 are essential for the insulin-
stimulated transport of glucose into skeletal muscle and adipocytes; indeed both 
IRS1-/- and IRS2-/- mice have been reported to be insulin resistant (Araki et al. 
1994), (Withers et al. 1998); with IRS2 deficiency also causing impaired pancreatic 
-cell function and secretion of insulin (Withers et al. 1998). 
Certain phosphotyrosines of IRS provide docking sites for the Class 1A lipid kinase 
PI3K (phosphatidylinositol-3’-kinase), which is a heterodimer composed of a p85 
regulatory subunit and a catalytic p110 subunit. PI3K binds certain 
phosphotyrosines of IRS via its SH2 domain on p85, which leads to a conformational 
change of the p110 catalytic subunit and activation of the protein. Activated PI3K 
can then phosphorylate the plasma membrane lipid PI(4,5)P2 
(phosphatidylinositol-4,5 bisphosphate) on the 3’ position of the inositol ring, thus 
forming the second messenger PI(3,4,5)P3 (phosphatidylinositol 3,4,5 
trisphosphate) (Vanhaesebroeck et al. 1997). PI(3,4,5)P3 stimulates recruitment 
of two substrates to the plasma membrane: PDK1 (3-phosphoinositide-dependent 
protein kinase-1) and PKB (protein kinase B) (also known as Akt), which both 
contain PH domains that mediate their recruitment to the membrane from the 
cytosol. These two proteins are involved in the translocation of vesicles containing 
GLUT4 to the membrane (Brazil, Yang, and Hemmings 2004, Calleja et al. 2007, 
Currie et al. 1999). The close proximity of PDK1 allows it to phosphorylate PKB at 
Thr308, a residue situated within its kinase domain activation loop (Alessi et al. 
1997). PKB is also phosphorylated by mTORC2 (mammalian target of rapamycin 
complex 2) at Ser473, further stimulating an increase in PKB kinase activity 
(Sarbassov et al. 2005, Hresko and Mueckler 2005). Activation of PKB causes it to 
dissociate from the membrane and go on to phosphorylate various downstream 
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effectors in both the cytoplasm and the nucleus which are involved in mediating 
the cellular effects of insulin, including GSK (glycogen synthase kinase) and AS160 
(Akt substrate of 160kDa). PKB phosphorylates and inhibits AS160, permitting 
GLUT4 to translocate from GLUT4 storage vesicles to the plasma membrane (Sano 
et al. 2003). AS160 is a Rab GTPase-activating protein (RabGAP); when AS160 
becomes phosphorylated its RabGap activity is inhibited, leading to increased 
active Rab-GTP which stimulates trafficking of GLUT4 vesicles from the cytoplasm 
to the plasma membrane (Sakamoto and Holman 2008). 
 
Figure 1-3: Insulin receptor signalling 
Insulin binding stimulates receptor autophosphorylation and tyrosine 
phosphorylation of IRS, facilitating association of IRS with the regulatory p85 
subunit of PI3K, inducing activation. Activated PI3K phosphorylates PIP2, forming 
PIP3, which in turn stimulates recruitment of PDK1 and PKB to the plasma 
membrane. PKB is activated upon phosphorylation by PDK1 at T308 and mTORC2 
at S473, leading to the phosphorylation and inactivation of AS160 and the 
subsequent translocation of GLUT4 to the plasma membrane and glucose uptake. 
Abbreviations: PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5 
bisphosphate; PIP3, (phosphatidylinositol 3,4,5-trisphosphate); PDK1, 3-
phosphoinositide-dependent protein kinase-1; PKB, protein kinase B; mTORC2, 
mammalian target of rapamycin complex 2; AS160, Akt substrate of 160 kDa; GSV, 
GLUT4 storage vesicle. 
 
Sarah Mancini, 2014   Chapter 1, 28 
1.2 Obesity and Inflammation 
1.2.1 Adipocytokines 
It is well accepted that WAT is not simply a site for energy storage during periods 
of caloric excess; it secretes fatty acids and proteins which function in an 
autocrine, paracrine and endocrine fashion to influence metabolism and 
inflammation. These factors are collectively termed ‘adipocytokines’, and include 
leptin, adiponectin, and inflammatory mediators such as MCP-1 (monocyte 
chemoattractant protein-1), TNF- (tumour necrosis factor-), IL-1 (interleukin-
1) and IL-6 (interleukin-6). 
Leptin is primarily secreted from adipocytes during the fed state (Green et al. 
1995), and plasma leptin levels are positively correlated with body fat mass as 
more leptin is released from large hypertrophic adipocytes relative to smaller 
adipocytes (Lönnqvist et al. 1997). Leptin functions at neurons within the 
hypothalamus to regulate satiety. Following a meal, leptin binds to Ob-Rb 
receptors on orexigenic (appetite-stimulating) and anorexigenic (appetite-
suppressing) neurones in the arcuate nucleus of the hypothalamus. Orexigenic 
neurones co-express the peptides neuropeptide Y (NPY) and agouti-related protein 
(AgRP), which, when stimulated, mediate an increase in feeding and decrease in 
energy expenditure by signalling to their receptors on the ventromedial 
hypothalamus (NPY receptor (NPYR) and melanocortin 4 receptor (MC4R), 
respectively) (Zigman and Elmquist 2003). Leptin binding its receptor in orexigenic 
neurones suppresses this signalling. Concommitantly, in anorexigenic neurones, 
leptin binding its receptor stimulates proopiomelanocortin (POMC) which produces 
-melanocyte stimulating hormone (-MSH) (Rouillé et al. 1995), which then binds 
MC4R on the ventromedial hypothalamus. Thus, leptin is a negative-feedback 
signal which results in an overall decrease in feeding and increase in energy 
expenditure following satiety. Ob-Rb is a class I cytokine receptor which activates 
the JAK2-STAT3 (Janus kinase-Signal transducer and activator of transcription) 
signalling pathway in target cells (Frühbeck 2006). STAT proteins dimerise in the 
cytoplasm once phosphorylated and activated by JAKs, and from here translocate 
to the nucleus to initiate transcription of target genes (Figure 1.5), as described 
in more detail in 1.2.2.2. Furthermore, leptin has also been reported to increase 
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FA oxidation in skeletal muscle directly, indicating anti-diabetic actions 
independent of effects on body fat mass (Minokoshi et al. 2002, Muoio et al. 1997, 
Coppari and Bjørbæk 2012). 
Adiponectin is an adipose-specific secreted protein, and plasma levels are 
paradoxically reduced with increasing adiposity (Arita et al. 1999). Adiponectin 
functions to promote peripheral insulin sensitivity; indeed a reduction in 
circulating adiponectin concentrations is associated with insulin resistance and 
hyperinsulineamia (Arita et al. 1999, Hotta et al. 2001). Furthermore, adiponectin 
has been reported to elicit systemic anti-inflammatory effects (Ouchi and Walsh 
2007). Proinflammatory cytokines and chemokines such as TNF-, IL-1, IL-6 and 
MCP-1 are also secreted by WAT, with elevated concentrations associated with 
obesity (Gustafson 2010). Indeed, obesity is associated with dysfunctional 
metabolism and a chronic, sub-clinical proinflammatory environment within WAT 
which plays an important role in the development of systemic insulin resistance 
and Type 2 diabetes (Glass and Olefsky 2012). 
1.2.2  Proinflammatory cytokines and obesity 
1.2.2.1 TNF- and IL-1 signalling to NFB and MAP kinases 
TNF- and IL-1 are proinflammatory cytokines which are secreted primarily by 
macrophages and monocytes, but also by WAT adipocytes in obese states. Plasma 
concentrations of these proinflammatory cytokines have been reported to be 
elevated in obese individuals (Kern et al. 1995, Dandona et al. 1998, Moschen et 
al. 2011). These cytokines trigger proinflammatory effects via simultaneous 
activation of the NFB (nuclear factor kappa B) and MAPK (mitogen activated 
protein kinase) intracellular signalling pathways. Soluble TNF- mediates its 
effects via binding to the ubiquitously expressed receptor TNF-RI, stimulating 
recruitment of specific adaptor molecules TRADD and TRAF2 which are essential 
for the subsequent binding of RIP1 and the E3 ubiquitin ligases cIAP1 or cIAP2 
(Karin and Gallagher 2009, Meloni et al. 1988). Polyubiquitination of downstream 
molecules are necessary for recruitment and activation of TGF-–activated kinase 
1 (TAK1) and IKK complexes and subsequent stimulation of MAPK and NFB 
signalling pathways (Bianchi and Meier 2009, Walczak 2011). IL-1 initiates 
Sarah Mancini, 2014   Chapter 1, 30 
proinflammatory signalling via a similar mechanism. Upon binding of IL-1 to its 
cognate receptor (IL-1RI), IL-1 coreceptor (IL-1RAcP) is recruited. This is followed 
by binding of two intracellular adaptor proteins myeloid differentiation response 
gene 88 (MyD88) and interleukin-1 receptor-activated protein kinase 4 (IRAK4) to 
conserved cytosolic Toll/IL-1 receptor domains, thus forming a stable signalling 
module (O'Neill 2008, Weber, Wasiliew, and Kracht 2010, Brikos et al. 2007). IRAK4 
undergoes autophosphorylation before phosphorylating IRAK1 and 2, prior to 
recruitment and oligomerisation of TRAF6 which serves as an E3 ubiquitin ligase 
(Cao, Henzel, and Gao 1996, Cao et al. 1996). Ubiquitination of signalling 
intermediates triggers the recruitment of TAK1 and IKK complexes; it is here that 
the TNF- and IL-1 signalling pathways can converge to stimulate downstream 
MAPK and NFκB signalling pathways (Yamazaki et al. 2009). 
MAPK signalling pathways are protein kinase cascades in which MAPK kinase 
kinases (MAP3Ks) phosphorylate and activate MAPK kinases (MAP2Ks) which 
subsequently activate MAPK by dual phosphorylation of a TxY motif (Figure 1.4) 
(Kyriakis and Avruch 2012, Rose, Force, and Wang 2010, Muslin 2008). ERK1/2 are 
phosphorylated and activated by MEK1/2 which are, in turn, activated by a variety 
of MAP3Ks including Raf (in response to mitogens), MEKK2/3 and Tlp2 (in response 
to TNF-) (Muslin 2008, Kyriakis and Avruch 2012, Rose, Force, and Wang 2010). 
JNK is phosphorylated and activated by MKK4 and MKK7, which are activated by 
the MAP3Ks MEKK1-4, MLK2/3, TAO1/2, ASK1/2 and TAK1 in response to mitogens, 
cellular stress and proinflammatory cytokines. p38 MAPKs are phosphorylated and 
activated by MKK3 and MKK6 which are substrates for the MAP3Ks MEKK4, MLK2/3, 
ASK1/2 and TAK1, also in response to mitogens, cell stress and proinflammatory 
cytokines (Rose, Force, and Wang 2010, Kyriakis and Avruch 2012, Muslin 2008). 
Upon stimulation, active MAPKs can translocate to the nucleus, thereby 
influencing transcription by phosphorylation of transcription factors such as c-Jun, 
c-fos and ATF-2 (Plotnikov et al. 2011). Activated TAK1 simultaneously stimulates 
the NFB signalling pathway (Figure 1.4) as it activates the IKK complex, which is 
composed of IKK, IKK and NFB essential modulator (NEMO) (DiDonato et al. 
1997, Yamaoka et al. 1998), via phosphorylation of key serine residues (Ser177 
and Ser181) within the activation loop of IKK (Mercurio et al. 1997). Activation 
of IKK results in the phosphorylation of IB family of proteins, most notably IB. 
IB is phosphorylated on Ser32 and Ser36 which facilitates its K48-linked 
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polyubiquitination by a TrCP E3 ubiquitin ligase complex and subsequent 
degradation by the proteasome (Israël 2010). In the absence of stimulation, NFB 
(most commonly the p50-p65 heterodimer) is sequestered in the cytoplasm as it 
is bound to IB; however it is released upon IB degradation and translocates 
to the nucleus where it initiates transcription of target genes including 
proinflammatory cytokines, chemokines, anti-apoptotic proteins and adhesion 
molecules. Full transcriptional activation of NFB is achieved by phosphorylation 
of p65 at Ser536, which has been proposed to be mediated by multiple kinases, 
including IKK, IKK, IKK and TBK1 (TRAF family member-associated (TANK)-
binding kinase 1) (Sakurai et al. 1999, Sakurai et al. 2003, Buss et al. 2004). 
Importantly, NFB induces de novo synthesis of IB, which enters the nucleus 
and effectively strips NFB from the target gene promotors. This IB-NFB 
complex is then exported to the cytoplasm where it remains inactive until further 
stimulation, thereby acting as a rapid negative feedback loop (Zabel and Baeuerle 
1990). 
 
Figure 1-4: MAPK/NFB signalling 
TNF- and IL-1 simultaneously activate the MAPK cascade and the NFB 
pathway, stimulating transcription of proinflammatory genes. Abbreviations: 
MAPK, mitogen activated protein kinase; ERK1/2, extracellular signal regulated 
protein kinase 1/2; p38, p38 MAPK; JNK, c-Jun N-terminal kinase; MEK1/2, 
ERK1/2 kinase; MKK3/6/4/7, MAPK kinase 3/6/4/7; IKK, IB kinase; IB, NFB 
inhibitor; NFB, nuclear factor B; MCP-1, monocyte chemoattractant protein-1. 
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1.2.2.2 IL-6 signalling to JAK/STAT 
IL-6 is a proinflammatory cytokine secreted predominantly by macrophages and 
hypertrophic adipocytes, as found in obese adipose tissue. Plasma IL-6 
concentrations are positively correlated with body mass (Lee et al. 2009); 
interestingly, it has been found that expression of IL-6 is much higher in visceral, 
rather than subcutaneous, adipose tissue (Fried, Bunkin, and Greenberg 1998). 
Elevated levels of IL-6 are associated with an increase in the production of C-
Reactive Protein (CRP) which is a marker for inflammation and is linked to 
cardiovascular disease, hypertension and type 2 diabetes; therefore increased 
plasma IL-6 is a predictor for the development of these conditions (Pradhan et al. 
2001, Ridker, Rifai, et al. 2000, Ridker, Hennekens, et al. 2000). 
In most cell types, IL-6 initially forms a complex with a soluble receptor (sIL-6R) 
before binding the signal-transducing gp130 (glycoprotein 130) receptor 
homodimer. IL-6 signal transduction utilises the tyrosine kinases of the JAK (Janus 
kinase) family and transcription factors of the STAT (Signal transducers and 
activators of transcription) family, as demonstrated in Figure 1.5. JAKs are gp130-
associated kinases which become activated following IL-6/sIL-6R binding the 
gp130 receptor. Activated JAKs then phosphorylate tyrosine residues on the 
cytoplasmic tails of gp130, which in turn function as docking sites for STAT factors. 
STAT1 and STAT3 bind these phosphotyrosines via their SH2 domains (Stahl et al. 
1995, Gerhartz et al. 1996), and are subsequently tyrosine-phosphorylated by the 
JAKs (STAT1 on Tyr701 and STAT3 on Tyr705) (Kaptein, Paillard, and Saunders 
1996, Shuai et al. 1993). STAT3 is more strongly activated by IL-6 than STAT1 and 
binds pYxxQ motifs (Stahl et al. 1995, Gerhartz et al. 1996), while the STAT1 
recruitment site is more restricted (pYxPQ) (Gerhartz et al. 1996). Phosphorylated 
STATs form dimers and translocate to the nucleus, where they regulate 
transcription of target genes, including APP (amyloid precursor protein) genes 
such as CRP (C-reactive protein) (Zhang et al. 1996), transcription factors such as 
AP-1 (activator protein-1) (Coffer et al. 1995), and chemokines such as MCP-1 
(Fasshauer, Klein, et al. 2004); all of which are involved in the inflammatory 
response. Interestingly, although dimerisation of STATs is essential for 
translocation to the nucleus, tyrosine phosphorylation itself is not specifically 
required as artificially dimerised STATs have been shown to have the ability to 
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enter the nucleus (Bromberg et al. 1999, Milocco et al. 1999). SHP-2 (src homology 
domain-containing protein tyrosine phosphatase-2) can also be recruited to 
phosphorylated tyrosine residues of gp130 via SH2 domains, before being 
phosphorylated by JAKs, leading to the activation of the ERK MAPK cascade (Fig. 
1.5) (Fukada et al. 1996). 
 
Figure 1-5: IL-6 signalling 
IL-6 activates the gp130 receptor subunits, initiating their dimerization and 
recruitment and activation of JAK proteins. Activated JAKs phosphorylate gp130 
subunits which function as docking sites for SH2-containing proteins. STAT3 binds, 
is phosphorylated by JAK which induces dimer formation. SHP-2 is also 
phosphorylated by JAKs and initiates the Ras/Raf/MEK signalling pathway, 
activating ERK1/2. STAT3 dimers and ERK1/2 translocate to the nucleus where 
they stimulate the transcription of genes. Abbreviations: SHP-2, src homology 
domain-containing protein tyrosine phosphatase-2; Grb2, growth factor receptor-
bound protein 2; SOS, son of sevenless; MEK, ERK kinase; AP-1, activator protein-
1; SOCS3, suppressor of cytokine signalling 3. 
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1.2.3  Macrophage recruitment and activation in adipose tissue 
Obesity is associated with a low-grade inflammation of WAT as a result of the 
chronic activation of the innate immune system. The cytokine-stimulated NFB, 
MAPK and JAK/STAT pathways described above culminate in the secretion of 
chemokines, including MCP-1, which stimulate the recruitment of macrophages to 
the site of inflammation. The migration of macrophages into WAT is central to the 
development of obesity-associated inflammation of WAT, as demonstrated by 
several in vivo studies (Arkan et al. 2005, Solinas et al. 2007, Odegaard et al. 
2007). Indeed, as many as 50% of cells within obese adipose tissue have been 
proposed to be macrophages, while the macrophage content of lean adipose tissue 
is just 5-10% (Weisberg et al. 2003). 
The initial events which lead to the recruitment of macrophages and the 
development of inflammation in WAT are currently not well understood, however 
it is believed that the increased adipose tissue mass and the characteristic 
hypertrophic adipocytes exhausts the local oxygen supply to the tissue, leading to 
hypoxia within the individual cells, which then in turn activates cellular stress 
pathways resulting in the release of proinflammatory mediators from adipocytes 
(de Luca and Olefsky 2008). Hypoxia may also contribute towards the increased 
adipocyte necrosis observed in obese WAT; indeed obesity-associated adipocyte 
death has been reported to occur primarily via necrosis, rather than apoptosis 
(Cinti et al. 2005). Necrosis is characterised as inflammatory, as the contents of 
the dying cell are released into the extracellular space where they provoke 
proinflammatory responses (Fink and Cookson 2005); moreover, 90% of 
macrophages recruited to WAT of obese mice are reported to be localised to 
necrotic adipocytes, where they scavenge for lipid droplets and aggregate to form 
giant multinucleate cells which are a hallmark of chronic inflammation (Cinti et 
al. 2005). Obesity is often associated with an increase in saturated FA which can 
activate the TLR (Toll-like receptor) family, and can also play a role in the 
recruitment of macrophages to WAT. Indeed, mice with a hematopoietic cell-
specific deletion of TLR4 are protected from HFD (high-fat diet)-induced 
inflammation (Saberi et al. 2009). Taken together, macrophages may be recruited 
to WAT in response to proinflammatory signals secreted by hypertrophic, 
Sarah Mancini, 2014   Chapter 1, 35 
dysfunctional adipocytes, necrosis of these adipocytes and the increased presence 
of saturated FA. 
Upon migration into adipose tissue, macrophages undergo a shift in polarisation 
from an anti-inflammatory ‘alternatively activated’ M2 state, to a ‘classically 
activated’ proinflammatory M1 state (Olefsky and Glass 2010). Adipose tissue 
macrophages are differentially activated depending on the level of adiposity; in 
vivo macrophage pulse-labelling studies have demonstrated that macrophages 
within obese adipose tissue are highly proinflammatory and show increased 
expression of genes associated with adhesion, migration and inflammation 
(Lumeng et al. 2007, Lumeng, Bodzin, and Saltiel 2007). In contrast, macrophages 
within lean adipose tissue tend to be anti-inflammatory (Lumeng, Bodzin, and 
Saltiel 2007). It is important to note that the existence of these M1/M2 
polarisation states has largely been defined in vitro, and tissue macrophages in 
vivo are most likely to be activated along a continuum between these states, 
rather than existing in a completely homogenous M1 or M2 state (Lumeng, Bodzin, 
and Saltiel 2007). Regulation of these activation states in response to various 
stimuli is shown in Figure 1.6. 
Whether adipose tissue macrophages are classically or alternatively activated can 
depend on the secretory products of the adipocytes. As previously described, 
dysfunctional hypertrophic adipocytes of obese adipose tissue secrete 
proinflammatory cytokines and chemokines. This, in addition to the increased 
presence of proinflammatory saturated FA, induces the classical activation of 
macrophages, which in turn also secrete proinflammatory cytokines and 
chemokines (Figure 1.6). Furthermore, macrophages can also induce inflammatory 
responses through activation of the inflammasome, the best-characterised being 
the NLRP3 (nucleotide-binding and oligomerisation domain-like receptor family 
pyrin domain-containing 3) inflammasome. This stimulates maturation and 
secretion of proinflammatory cytokines IL-1 and IL-18; thus activation of the 
inflammasome has been associated with obesity-related inflammation, insulin 
resistance and Type 2 diabetes (Vandanmagsar et al. 2011). This positive feedback 
loop therefore further exacerbates the inflammatory state of the tissue.  In 
contrast, adipocytes in lean adipose tissue secrete anti-inflammatory factors, 
including IL-4, IL-10 and IL-13, and anti-inflammatory FA (Olefsky and Glass 2010, 
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Solinas et al. 2007, Fujisaka et al. 2009), which promote the alternative activation 
of macrophages (Figure 1.6). These M2-activated macrophages secrete IL-10, 
which not only acts on adipocytes to maintain an insulin-sensitive state, but also 
elicits a protective effect by inhibiting secretion of proinflammatory mediators 
(Lumeng, Bodzin, and Saltiel 2007). 
 
 
Figure 1-6: Regulation of macrophage activation states 
Obesity is associated with hypertrophic adipocytes which secrete 
proinflammatory cytokines and chemokines, stimulating macrophage recruitment 
and M1 activation, leading to further production of proinflammatory mediators 
and insulin resistance in metabolic tissues. Lean adipocytes secrete anti-
inflammatory cytokines such as IL-4 and IL-13 which induces macrophage M2 
polarisation; M2 macrophages secrete anti-inflammatory cytokines such as IL-10 
and contribute toward an insulin sensitive phenotype. 
 
Proinflammatory T-cells have been reported to be present in VAT of mice with 
HFD-induced obesity, and their accumulation has been proposed to stimulate 
macrophage infiltration and M1 activation (Nishimura et al. 2009, Kintscher et al. 
2008, Wu et al. 2007). Indeed, adipocyte production of the chemokine IP-10 
(interferon-γ-induced protein 10 kDa) has been reported to induce T-cell 
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migration, which was ablated following NFB blockade in adipocytes (Krinninger 
et al. 2011). Furthermore, levels of protective, anti-inflammatory regulatory T-
cells have been found to be diminished in adipose tissue of mice with HFD-induced 
obesity (Nishimura et al. 2009, Feuerer et al. 2009), further enhancing the 
proinflammatory environment. 
1.2.4  Role of inflammation in the development of insulin 
resistance 
Inflammation is a key factor in the development of obesity-related insulin 
resistance, with a plethora of evidence suggesting that inhibition of 
proinflammatory signalling either via genetic or pharmacological means ablates 
diet-induced insulin resistance and subsequent Type 2 diabetes. Insulin sensitivity 
is reduced in response to elevated serum FA and increased production of 
proinflammatory cytokines by adipocytes and M1 activated macrophages in obese 
WAT (Figure 1.7). Macrophages contribute the most significant proportion of 
inflammatory mediators within obese WAT; consistent with this, genetic ablation 
of the MCP-1 receptor CCR2 is associated with a reduction in adipose tissue 
macrophage infiltration and an improvement in insulin sensitivity in HFD-fed mice 
(Weisberg et al. 2006). Furthermore, mice with macrophage-specific deletion of 
JNK or IKK were reported to exhibit a reduction in proinflammatory gene 
expression and adipose tissue macrophage infiltration, with a concomitant 
increase in insulin sensitivity (Arkan et al. 2005, Solinas et al. 2007). The 
molecular mechanism by which proinflammatory cytokines such as TNF-, IL-1 
and IL-6 have been reported to negatively regulate the insulin signalling pathway 
in target tissues is outlined in Figure 1.7. 
1.2.4.1 TNF-/IL-1 signalling induces insulin resistance 
TNF- was the first cytokine to be linked to obesity-related insulin resistance, 
with studies carried out by Hotamisligil and co-workers using animal models of 
obesity and diabetes demonstrating that neutralisation of TNF- could improve 
glucose metabolism (Hotamisligil, Shargill, and Spiegelman 1993). An abundance 
of studies followed, all supporting a key role for TNF- in obesity-related insulin 
resistance. 
  
Figure 1-7: Inflammation-mediated inhibition of insulin signalling  
A positive energy balance causes an increase in adipocyte size due to increased TG storage. Dysfunctional hypertrophic adipocytes secrete 
proinflammatory cytokines and chemokines, which stimulate the recruitment and M1 activation of macrophages, further exacerbating 
the inflammatory environment within the tissue. Proinflammatory cytokines can stimulate an increase serum FA, promote ectopic lipid 
deposition and induce insulin resistance in the metabolic tissues. 
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Dietary and genetic (ob/ob) mouse models of obesity deficient in either TNF- or 
TNF-RI displayed improved insulin sensitivity (Uysal et al. 1997), while there was 
found to be elevated expression of TNF- in adipose tissue of obese humans which 
was reduced upon weight loss (Kern et al. 1995, Dandona et al. 1998). Several 
studies sought to determine the mechanism by which TNF- signalling induced 
insulin resistance, with early studies suggesting the JNK1–mediated inhibitory 
phosphorylation of Ser307 (equivalent to Ser312 in human) of IRS-1 (Aguirre et al. 
2000, Hotamisligil et al. 1996) (Figure 1.8). Increased insulin resistance was 
reported following activation or overexpression of IKK in Zucker fa/fa and ob/ob 
mice, while conversely, a reduction in IKK activity or expression led to an 
improvement in insulin sensitivity (Yuan et al. 2001). IRS-1 Ser307 was later 
proposed to also be a substrate for IKK as interactions were observed using a co-
immunoprecipitation approach and the TNF--induced Ser307 phosphorylation of 
IRS-1 was diminished following IKK inhibition (Figure 1.8). Cells derived from IKK-
deficient mice supported this finding (Gao et al. 2002). 
Following the plethora of in vitro and animal studies conducted on the importance 
of TNF- in obesity-related insulin resistance, further studies were carried out to 
assess the clinical relevance of TNF- in humans. Infliximab (a TNF- neutralising 
monoclonal antibody) is widely used in the treatment of chronic inflammatory 
conditions, such as rheumatoid arthritis (RA). A small study conducted in patients 
with RA taking Infliximab demonstrated a significant reduction in insulin 
resistance (Gonzalez-Gay et al. 2006). Other studies, however, showed no 
improvement in insulin sensitivity with TNF--neutralising antibodies or inhibitors, 
despite improvements in inflammatory status (Ofei et al. 1996, Wascher et al. 
2011, Ferraz-Amaro et al. 2011). Taken together, these studies indicate that while 
chronic low-grade inflammation plays a key role in the development of obesity-
related insulin resistance, it is likely that proinflammatory cytokines other than 
TNF- alone may play a more prominent role. 
Recent evidence suggests IL-1 may be important in the development of insulin 
resistance, with IL-1 expression found to be elevated in serum and WAT of obese 
patients and positively correlated with body mass index and insulin resistance. 
Conversely, IL-1 levels are reduced upon weight loss (Moschen et al. 2011, Meier 
et al. 2002).  IL-1 expression was found to be upregulated in adipose tissue of 
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obese and insulin resistant mouse models (diet-induced and ob/ob), while 
phosphorylation of insulin signalling pathway components including IRS-1 and PKB 
were inhibited in 3T3-L1 and human adipocytes treated with IL-1 (Lagathu et al. 
2006) (Figure 1.8). It has also been proposed that prolonged treatment of IL-1 in 
3T3-L1 adipocytes downregulates mRNA expression of IRS-1 in an ERK-dependent 
manner (Jager et al. 2007).  
An interesting study conducted by Larsen and co-workers found that neutralisation 
of IL-1 with anakinra (a recombinant IL-1R antagonist) over 13 weeks improved 
hyperglycaemia and reduced markers of systemic inflammation in human subjects. 
Furthermore, these effects were maintained 39 weeks following withdrawal of 
treatment (Larsen et al. 2007, Larsen et al. 2009). 
Taken together, NFB and MAPK signalling plays a key role in the development of 
chronic inflammatory disorders, particularly obesity-related insulin resistance 
(Figure 1.8). Clinical studies indicate IL-1 may be a more important activator of 
these pathways than TNF- in terms of insulin resistance in humans. 
1.2.4.2 IL-6 signalling induces insulin resistance 
There is conflicting evidence regarding the role of IL-6 in the development of 
insulin resistance in different tissues. IL-6 has been reported to induce insulin 
resistance in both adipose and liver (Rotter, Nagaev, and Smith 2003, Senn et al. 
2002, Klover et al. 2003), while locally stimulating glucose uptake in muscle (Carey 
et al. 2006). While it would seem paradoxical that exercise, which has been well 
established to enhance insulin action, would stimulate the release of a factor from 
muscle that inhibits insulin signalling, there are a number of in vitro and in vivo 
studies demonstrating the proinflammatory nature of IL-6 in liver and adipose. It 
is thought that these pro- and anti-inflammatory effects of IL-6 are context-
dependent, with many different cells producing IL-6 under varying physiological 
conditions. Adipose tissue has been proposed to release 10-35 % of circulating IL-
6 levels in healthy individuals (Mohamed-Ali et al. 1997), with macrophages within 
the adipose being the primary site of production. The number of macrophages 
present in adipose tissue is positively correlated with obesity (Weisberg et al. 
2003); therefore an increase in macrophages is associated with an increase in 
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production of proinflammatory mediators. Furthermore, hypertrophic adipocytes 
in obese adipose tissue have also been found to produce IL-6 (Gustafson 2010, 
Sopasakis et al. 2004). As previously described, obesity is characterised as a state 
of sustained, low-grade inflammation, with a 2-3 fold increase in secretion of 
proinflammatory mediators from adipose tissue (Weisberg et al. 2003, Kern et al. 
2001) (Figure 1.7). In direct contrast, exercise has been suggested to induce an 
acute, but transient, increase in IL-6 (but not other inflammatory markers such as 
TNF-) production in skeletal muscle (Brandt and Pedersen 2010, Jonsdottir et al. 
2000), found to be approximately 100 fold, depending on the duration and 
intensity of the exercise (Jonsdottir et al. 2000). Moreover, the acute increase in 
IL-6 levels in muscle in response to exercise has been proposed to be independent 
of macrophage activation (Moldoveanu, Shephard, and Shek 2000). Therefore the 
source and duration of IL-6 production is likely to determine whether IL-6 has 
beneficial anti-inflammatory effects, or whether it is a key player in the 
development of a chronic, proinflammatory, insulin resistant phenotype in 
obesity. 
While the effect of TNF- on inhibition of insulin signalling has been thoroughly 
examined, comparatively fewer studies have been undertaken concerning the 
mechanism by which IL-6 may inhibit insulin signalling (Figure 1.8). Mooney and 
co-workers found that IL-6 inhibited insulin signalling and action in vitro in 
isolated hepatocytes and hepatoma cell lines (Senn et al. 2002), and in vivo in 
livers of mice chronically administered IL-6 at levels physiologically similar to 
those found in obesity (Klover et al. 2003). Conversely, neutralisation with an anti-
IL-6 antibody was found to improve hepatic insulin sensitivity in DIO (diet-induced 
obesity) and ob/ob mouse models of obesity (Klover, Clementi, and Mooney 2005). 
It was found that IL-6 transiently increased expression of the negative regulator 
of IL-6 signalling, SOCS3 (suppressor of cytokine signalling 3), in HepG2 and rat 
liver cells which was associated with an inhibition of insulin-stimulated IRS-1 
tyrosine phosphorylation, p85 binding, and subsequent PKB phosphorylation (Senn 
et al. 2003). Similarly in adipocytes, Rotter and co-workers found that chronic 
exposure of 3T3-L1 adipocytes with IL-6 induced insulin resistance via inhibition 
of IRS-1 and GLUT4 protein expression, while short term incubation with IL-6 had 
no effect on insulin sensitivity (Rotter, Nagaev, and Smith 2003). Importantly, this 
Sarah Mancini, 2014   Chapter 1, 42 
was not found to be due to an increase in TNF-, as IL-6 was not found to stimulate 
TNF- expression in this study (Rotter, Nagaev, and Smith 2003). 
 
Figure 1-8: Inflammation-mediated inhibition of insulin signalling  
Insulin signalling has been reported to be inhibited at the level of IRS, via 
downregulation, IKK/JNK-mediated serine phosphorylation or inhibition of 
tyrosine phosphorylation by proinflammatory cytokines and FFA/activated lipid 
intermediates. Inhibition of insulin signalling results in a reduction in GLUT4-
mediated glucose uptake in adipose tissue and skeletal muscle. Abbreviations: 
IRS, insulin receptor substrate; PI3K, phosphatidylinositol 3-kinase; PIP2, 
phosphatidylinositol 4,5 bisphosphate; PIP3, (phosphatidylinositol 3,4,5-
trisphosphate); PKB, protein kinase B; AS160, Akt substrate of 160 kDa; GSV, 
GLUT4 storage vesicle; PKC, protein kinase C. 
 
Consistent with a role for IL-6 in reducing insulin sensitivity, it has been reported 
that adipose tissue IL-6 content correlated with insulin resistance both in vitro 
and in vivo (Bastard et al. 2002). Moreover, neutralisation with an anti-IL-6 
antibody improved hepatic insulin sensitivity in DIO and ob/ob mouse models of 
obesity (Klover, Clementi, and Mooney 2005). Furthermore, clinical trials for 
tocilizumab (a monoclonal antibody against the IL-6 receptor) demonstrated an 
improvement in insulin sensitivity in RA patients upon inhibition of IL-6 signalling 
(Schultz et al. 2010). Taken together, these studies indicate that while chronic 
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low-grade inflammation plays a key role in the development of obesity-related 
insulin resistance, further studies are required to delineate the pro- and anti-
inflammatory effects of IL-6 in different tissues. 
1.2.4.3 Serum FA induces insulin resistance 
Cytokines such as TNF- cause an increase in circulating FA by stimulating lipolysis 
and impairing storage of FA as TG in adipocytes (Figure 1.7). Elevated circulating 
FA can contribute to the development of obesity-related insulin resistance; FAs 
can stimulate TLR4 on adipocytes and macrophages, activating proinflammatory 
signalling pathways and further enhancing the inflammatory environment (Shi, 
Kokoeva, et al. 2006). Moreover, TLR4 is reported to be essential for FA-induced 
insulin resistance in myotubes and adipocytes (Senn 2006, Suganami et al. 2007), 
while TLR4-/- mice have been reported to be protected from obesity-induced 
inflammation and insulin resistance (Shi, Kokoeva, et al. 2006). Furthermore, an 
increase in circulating FA leads to an accumulation of TG and activated lipids in 
the form of long-chain fatty-acyl CoA (LCACoA) esters in tissues other than 
adipose, namely liver and skeletal muscle (Figure 1.7), as well as pancreatic -
cells (Guilherme et al. 2008). This ectopic deposition of FA and their derivatives 
has been shown to induce insulin resistance via disruption of the insulin signalling 
pathway (Kraegen et al. 2001). FA and their derivatives can directly activate PKC 
(protein kinase C), which in turn activates JNK and IKK leading to the subsequent 
serine phosphorylation of IRS-1 (Gao et al. 2004, Yu et al. 2002). Interestingly, 
while it is the TG content of the liver and skeletal muscle that is used as a marker 
for abnormal lipid accumulation, it has been suggested that it is in fact the lipid 
intermediates, primarily diacylglycerol (DAG), ceramide and LCACoA that have a 
negative impact upon insulin sensitivity (Kraegen and Cooney 2008, Timmers, 
Schrauwen, and de Vogel 2008). 
1.3 AMPK 
1.3.1  Overview of AMPK 
In the 1970’s two separate groups discovered that incubating acetyl CoA 
carboxylase (ACC) or HMG-CoA reductase (HMGR) (Timmers, Schrauwen, and de 
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Vogel 2008, Beg, Stonik, and Brewer 1978), with ATP resulted in their inactivation, 
however it was not until later that a third group provided evidence suggesting it 
was the same protein kinase which was responsible for the phosphorylation and 
inactivation of both these enzymes (Carling, Zammit, and Hardie 1987). This group 
subsequently named this kinase AMP-activated protein kinase (AMPK) after its 
allosteric activator 5’-AMP (Munday et al. 1988). 
AMPK is the downstream component of a protein kinase cascade that plays a key 
role in the regulation of energy balance at both the cellular and whole-body level. 
AMPK is sensitive to cellular energy levels and is activated in response to a 
decrease in cellular energy, and functions to stimulate catabolic ATP-producing 
pathways while suppressing anabolic ATP-consuming pathways in order to restore 
the energy balance. 
1.3.2  AMPK structure and regulation 
AMPK exists as a heterotrimeric complex consisting of a catalytic  subunit and 
regulatory  and  subunits, as shown in Figure 1.9. Isoforms of each AMPK subunit 
(1, 2, 1, 2, 1, 2, 3) are encoded by seven genes in mammals, thus 12 
heterotrimeric complexes are theoretically possible (Kahn et al. 2005). Expression 
levels of the different subunit isoforms vary between tissues and may dictate the 
subcellular localisation of the AMPK complex; the 1, 1 and 1 isoforms are 
ubiquitously expressed, while the 2 and 2 isoforms are predominantly expressed 
in striated muscle (Thornton, Snowden, and Carling 1998, Verhoeven et al. 1995). 
The 2 and 3 isoforms are expressed in several different tissues (Cheung et al. 
2000). These can also be subject to alternative splicing, thereby further increasing 
the diversity of the complexes. Homologues have been found to be highly 
conserved in a wide range of species, from mammals to yeast to primitive 
protozoa, indicating the importance of the system in various species (Hardie et al. 
2003). 
Figure 1.9 outlines the domain structures of the AMPK subunits. The catalytic  
subunit consists of a serine/threonine kinase domain at the N-terminus which 
contains a conserved threonine residue at position 172, phosphorylation of which 
is essential for AMPK activity (Woods et al. 1994). The last 150 amino acids of the 
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C-terminus are responsible for interaction with  and  subunits and subsequent 
complex formation (Crute et al. 1998). The  subunit stabilises the interaction 
between the  and  subunits via its C-terminus (Hudson et al. 2003). The  subunit 
also contains a carbohydrate-binding module (CBM) (Hudson et al. 2003, Polekhina 
et al. 2003) to which oligosaccharide components of glycogen can bind and inhibit 
AMPK (McBride et al. 2009). The  subunits are characterised by the presence of 
four CBS (cystathione--synthase) motifs, which occur as tandem pairs, known as 
Bateman domains (Bateman 1997, Kemp 2004), with a deep binding cleft 
separating them and are found in a small number of proteins which tend to bind 
adenosine-containing ligands (Scott et al. 2004). The Bateman domains of the 
AMPK  subunit bind adenine nucleotides; crystallisation of the regulatory core of 
mammalian AMPK revealed that three of the four CBS motifs contained nucleotide 
binding sites (Xiao et al. 2007). Two of these sites can bind AMP, ADP or ATP with 
approximately equal affinity in a competitive manner, while the remaining site 
contains a tightly-bound, non-exchangable molecule of AMP (Xiao et al. 2007). 
 
Figure 1-9: Domain structure of AMPK subunit isoforms  
Binding of AMP or ADP to the  subunit regulates AMPK activity, as it promotes 
allosteric activation of the enzyme and phosphorylation of the catalytic  subunit 
at Thr172 by upstream kinases. In contrast, binding of ATP to the  subunit 
competitively antagonises the AMP or ADP-mediated allosteric activation and 
Thr172 phosphorylation (Carling et al. 2012, Hardie, Ross, and Hawley 2012b); 
therefore an increase in the AMP/ATP or ADP/ATP ratio allosterically activates 
AMPK and further promotes activity as a result of increased Thr172 
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phosphorylation (Figure 1.10). Furthermore, AMP/ADP binding to the  subunit 
renders AMPK a poor substrate for protein phosphatases such as PP2C; therefore 
Thr172 phosphorylation is maintained (Davies et al. 1995). Interestingly, the 
different  subunit isoforms exhibit differential adenine nucleotide sensitivity, 
therefore potentially allowing for tissue-specific regulation of AMPK (Hardie, Ross, 
and Hawley 2012b, Carling et al. 2012, Cheung et al. 2000). It has recently been 
suggested that ADP may be the principal nucleotide to allosterically activate 
AMPK, not AMP as previously thought. While the exchangable nucleotide binding 
sites on the  subunit exhibit similar binding affinity for AMP, ADP and ATP, the 
cellular concentrations of ADP and ATP far exceed that of AMP; thus the ADP/ATP 
ratio has been proposed to be a more physiologically relevant stimulus for AMPK 
and the extent to which AMPK is activated allosterically in vivo may be modest 
compared to the effect of phosphorylation at Thr172 (Carling et al. 2012). On the 
contrary, a recent study suggests that the allosteric regulation of AMPK by AMP 
may be at least as important as the effect of Thr172 phosphorylation in the 
activation of AMPK in intact cells, if not more so. Gowans and co-workers reported 
that AMP is a more potent inhibitor of Thr172 dephosphorylation than ADP; 
furthermore, AMP stimulated an increase in downstream substrate ACC 
phosphorylation without Thr172 phosphorylation; thus entirely by allosteric 
activation of AMPK (Gowans et al. 2013).  
The AMPK phosphorylation site Thr172 lies within the activation loop of the 
catalytic  subunit (Hawley et al. 1996). Two upstream kinases have been 
identified which mediate this phosphorylation: LKB1 (liver kinase B1) and CaMKK 
(Ca2+/calmodulin-dependent protein kinase kinase ) (Figure 1.10). While LKB1 is 
ubiquitously expressed, CaMKK expression appears to be restricted to primarily 
neuronal cells (Anderson et al. 1998). 
LKB1 was originally identified as a tumour suppressor which is mutated in Peutz-
Jeghers Syndrome (PJS) (Anderson et al. 1998). LKB1 exists in complex with two 
accessory subunits, STRAD and MO25 (Woods et al. 2003, Hawley et al. 2003). 
MO25 is thought to stabilise the LKB1-STRAD complex (Milburn et al. 2004), while 
STRAD is essential for the phosphorylation of AMPK on Thr172 by the complex 
(Hawley et al. 2003). Indeed, cells deficient in LKB1 were demonstrated to exhibit 
reduced AMPK activity, and AMPK was found not to be activated in response to 
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stimuli which would normally activate it (Shaw et al. 2004, Hawley et al. 2003, 
Woods et al. 2003); thereby highlighting LKB1 as an AMPK kinase. Furthermore, 
LKB1 itself was not found to be regulated by AMP (Hawley et al. 2003, Woods et 
al. 2003), or other stimuli which activate AMPK in cells (Woods et al. 2003, Lizcano 
et al. 2004), or skeletal muscle (Sakamoto et al. 2004). These findings suggested 
LKB1 was constitutively active, and that AMPK activation was regulated directly 
by binding of AMP to  subunits. 
Hawley and co-workers first reported that CaMKK could phosphorylate and 
activate AMPK in cell-free assays (Hawley et al. 1995); however the major AMPK 
kinase purified from rat liver was not found to be calmodulin dependent (Hawley 
et al. 1996), and was later identified as LKB1 (Hawley et al. 2003, Shaw et al. 
2004). Interestingly, Hawley and co-workers found there to be significant basal 
AMPK activity in LKB1-deficient cells, indicating the existence of an alternative 
AMPK kinase which was demonstrated to be CaMKK (Hawley et al. 2005). 
Although the LKB1 complex is the predominant upstream kinase of AMPK in most 
cells, this alternative pathway for AMPK activation is AMP-independent and is 
triggered by an increase in cytoplasmic Ca2+, which activates CaMKK (Hawley et 
al. 2005, Woods et al. 2005, Hurley et al. 2005). AMPK was demonstrated to be 
rapidly phosphorylated in HeLa cells (which lack LKB1) in response to the Ca2+ 
ionophore A23187 (Hawley et al. 2005). Furthermore, AMPK activation was ablated 
by addition of the CaMKK inhibitor STO-609 or siRNA-mediated knockdown of the 
CaMKK gene (Hawley et al. 2005). 
1.3.3  AMPK activation and physiological role 
AMPK is activated under conditions upon which the energy demands within the 
cell are increased and thus ATP consumption rises, or fuel availability is reduced, 
such that ATP synthesis falls; i.e. there is a reduction in the ATP/AMP ratio. As a 
consequence, activated AMPK phosphorylates key target proteins in order to 
stimulate FA oxidation, muscle glucose transport, mitochondrial biogenesis and 
caloric intake; thereby increasing ATP production. Concurrently, AMPK activation 
suppresses ATP-consuming anabolic pathways, including FA synthesis, cholesterol 
and isoprenoid synthesis, hepatic gluconeogenesis and mTOR (mammalian target 
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of rapamycin)-mediated protein translation. Thus, AMPK activation regulates the 
energy balance at a cellular and whole-body level. Physiological stimuli which 
activate AMPK include metabolic stresses such as hypoxia, ischaemia, glucose 
deprivation and heat shock; all of which inhibit ATP production, while exercise 
stimulates AMPK activation in muscle as it increases ATP consumption.  
1.3.3.1 AMPK activation by adipocytokines 
Leptin can activate AMPK in skeletal muscle, leading to an increase in glucose 
uptake and FA oxidation (Minokoshi et al. 2002). Minokoshi and co-workers 
observed that leptin acts directly on muscle to activate AMPK by acutely triggering 
an increase in the cellular AMP/ATP ratio, while prolonged treatment with leptin 
activates AMPK indirectly via the hypothalamic-sympathetic nervous system axis 
and is independent of nucleotides (Minokoshi et al. 2002). Furthermore, chronic 
leptin treatment in skeletal muscle is associated with increased expression of the 
2 and 2 subunits and sustained AMPK activation in the tissue, with subsequent 
increased rates of fatty acid oxidation being observed (Steinberg, Rush, and Dyck 
2003). In addition to skeletal muscle, leptin has also been found to activate AMPK 
in adipocytes, stimulating fatty acid oxidation and mitochondrial biosynthesis 
(Wang et al. 2005). In contrast, the anorexigenic action of leptin previously 
mentioned is mediated by inhibition of AMPK activity in the arcuate and 
paraventricular hypothalamus (Minokoshi et al. 2004). The mechanism by which 
AMPK is inhibited by leptin in the hypothalamus has not been characterised. 
Reduced AMPK activity in the arcuate nucleus suppresses the actions of orexigenic 
peptides NPY/AgRP, while the anorexigenic MC4Rs appear to be required for 
regulation of AMPK in the hypothalamus, as a MC4R agonist was found to suppress 
AMPK activity in the paraventricular nucleus. Moreover, MC4R-deficient mice have 
a hyperphagic and obese phenotype, and are unable to suppress AMPK activity in 
response to feeding or leptin (Minokoshi et al. 2004). 
Adiponectin has been reported to acutely stimulate AMPK in muscle and liver, with 
a concomitant increase in FA oxidation and glucose uptake in myocytes, reduction 
in gluconeogenic enzymes in the liver, and a reduction in overall glucose levels in 
vivo (Yamauchi et al. 2002). These effects of adiponectin were abolished with the 
use of a dominant-negative AMPK mutant, indicating the AMPK-dependence of 
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these effects by adiponectin (Yamauchi et al. 2002). Furthermore, adiponectin 
has been demonstrated to activate AMPK in adipocytes (Wu et al. 2003, Liu et al. 
2010), pancreatic -cells (Huypens, Moens, et al. 2005) and endothelial cells, 
resulting in increased eNOS (endothelial nitric oxide (NO) synthase) 
phosphorylation and subsequent NO production (Hattori et al. 2008). The 
mechanism by which adiponectin stimulates AMPK activation is unclear. One 
hypothesis is that the interaction of an adaptor protein APPL1 with the 
adiponectin receptor induces LKB1 translocation from the nucleus to the cytosol 
in muscle, thus enhancing AMPK Thr172 phosphorylation (Zhou, Deepa, et al. 2009, 
Dadson et al. 2014). A separate study suggested that activation of the adiponectin 
receptor is coupled to acyl-CoA synthetase activity, and the 5’AMP released during 
the attachment of FA to CoA activates AMPK in adipocytes (Liu et al. 2010). 
There is conflicting evidence surrounding whether or not levels of 
proinflammatory cytokines such as IL-6 and TNF-α have any effect on activation 
of AMPK. TNF- has been reported to rapidly activate AMPK in endothelial and 
kidney cell lines (Tang et al. 2010), while in contrast, chronic exposure to TNF- 
has been reported to attenuate AMPK activity in myotubes and muscle, thought to 
be the result of dephosphorylation of Thr172 via upregulation of PP2C 
transcription (Steinberg et al. 2006). Similarly, LPS treatment was found to inhibit 
AMPK activation in macrophages in vitro (Sag et al. 2008), and attenuate AMPK 
expression in leukocytes and liver in vivo (Zhang et al. 2010). Exercise induced an 
increase in plasma IL-6, which was associated with an increase in AMPK2 activity 
in rat muscle and epididymal adipose tissue (Ruderman et al. 2006). IL-6 
treatment was reported to acutely stimulate AMPK activation in L6 myotubes 
(Carey et al. 2006) and cultured F422A adipocytes (Kelly et al. 2004). 
Furthermore, Kelly and co-workers found AMPK activation to be diminished in 
skeletal muscle and adipose of IL-6-/- mice compared to control mice (Kelly et al. 
2004). In contrast, Nerstedt and co-workers found that IL-6 did not have any 
significant effect on AMPK activation in hepatocytes (Nerstedt et al. 2010), 
suggesting that activation of AMPK by IL-6 could be cell type-specific. 
1.3.3.2 Pharmacological AMPK activation 
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AMPK is a central regulator of energy balance not only at a cellular level, but also 
at the level of the whole organism; AMPK activation results in many changes 
including regulation of glucose uptake and metabolism by muscle and other 
tissues, reduced glucose production in the liver and reduced synthesis and 
increased oxidation of FA. These are all effects which would be beneficial to 
individuals with Type 2 diabetes and the metabolic syndrome, thus making 
activation of AMPK in the metabolic tissues an attractive therapeutic target. In 
support of this, two widely used classes of insulin-sensitising drugs, the 
thiazolidinediones (TZDs) and the biguanide metformin have been reported to 
stimulate AMPK (Figure 1.10); however the extent to which AMPK activation 
mediates their clinical effects is still unclear. TZDs such as rosiglitazone are 
adipocyte PPAR agonists (Lehmann et al. 1995); while the insulin-sensitising 
effects of TZDs are largely due to regulation of gene transcription by PPAR, it has 
been suggested that the more acute effects of TZDs may be mediated by their 
ability to stimulate adiponectin production in adipocytes, which in turn activates 
AMPK, thereby reducing gluconeogenesis and stimulating FA oxidation (Kubota et 
al. 2006). Metformin is an antihyperglycaemic agent, with its main function being 
to suppress hepatic glucose production. It was discovered that metformin 
activates AMPK in hepatocytes (Zhou et al. 2001) in an AMP-dependent manner 
(Shaw et al. 2005) via inhibition of NADH dehydrogenase (Complex I) of the 
mitochondrial respiratory chain, which blocks ATP production and therefore 
increases the cellular AMP/ATP ratio (Brunmair et al. 2004), thus activating AMPK. 
Metformin has also been demonstrated to activate AMPK in WAT from mice and 
individuals with Type 2 diabetes in addition to cultured 3T3-L1 adipocytes (Boyle 
et al. 2011, Caton et al. 2011). Several plant-derived compounds including 
berberine, resveratrol and galgeine have also been reported to activate AMPK by 
altering adenine nucleotide ratios (Hawley et al. 2010) (Figure 1.10). 
Several other compounds have been used experimentally activate AMPK. A widely 
used compound is AICAR (5’-aminoimidazole-4-carboxamide ribonucleoside), an 
adenosine analogue which enters cells via adenosine transporters. It is 
phosphorylated to the AMP mimetic ZMP by adenosine kinase (Vincent et al. 1991), 
thereby activating AMPK without altering adenine nucleotide ratios (Figure 1.10). 
AICAR has been widely used to activate AMPK in intact cells, tissues and animals. 
Actions of AICAR are not completely specific to AMPK, however, as ZMP has the 
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ability to regulate any enzyme which is sensitive to cellular AMP; though it is not 
known to activate any other kinases, AICAR has been demonstrated to inhibit 
fructose-1,6-bisphosphate in isolated rat hepatocytes (Vincent et al. 1991) and 
stimulate glycogen phosphorylase in rat muscle preparations in vitro (Longnus et 
al. 2003). 
A769662 is a member of the thienopyridine family and can directly activate AMPK 
(Cool et al. 2006) in a similar manner to AMP, in that it triggers allosteric 
activation of the enzyme and inhibits dephosphorylation of Thr172 by protein 
phosphatases; however A769662 activates AMPK independently of AMP (Figure 
1.10). Scott and co-workers reported that A769662 selectively activates AMPK 
complexes containing the 1, but not 2, regulatory subunit, and activation 
involves the CBM of the 1 subunit interacting with  subunit residues distinct from 
those involved in AMP binding (Scott et al. 2008). Mutation of Ser108 within the 
CBM was reported to reduce A769662-mediated AMPK activation (Sanders et al. 
2007), suggesting this site is critical for the action of A769662. Furthermore, 
mutagenesis studies revealed a cluster of hydrophobic amino acids proximal to the 
carbohydrate-binding loop of the CBM of 1 were important for the allosteric 
activation and phosphorylation of Thr172, and therefore activation of the enzyme 
(Scott et al. 2008). The development of this compound demonstrates that 
selective manipulation of AMPK complexes containing specific subunit isoforms is 
possible. A recent study by Ducommum and co-workers proposed that 
simultaneous administration of AICAR and A769662 in primary hepatocytes 
resulted in a synergistic effect of AMPK activation and subsequent downstream 
events, compared to treatment with a single compound (Ducommun et al. 2014). 
As AICAR and A769662 act on different sites of the AMPK protein, co-treatment is 
attractive from a therapeutic point of view as it would mean lower doses by 
promoting sensitivity via dual treatment. 
Salicylate, a derivative of aspirin, has recently been demonstrated to stimulate 
AMPK activation (Hawley et al. 2012) (Figure 1.10). It was found to bind at the 
same AMPK site as A769662 and, similarly to A769662, salicylate caused allosteric 
activation and inhibition of Thr172 dephosphorylation independently of alterations 
in adenine nucleotide concentrations (Hawley et al. 2012). Moreover, salicylate-
stimulated FA oxidation was ameliorated in AMPK1-/- mice, thus indicating the 
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effects of salicylate on lipid metabolism in vivo are mediated by AMPK (Hawley et 
al. 2012). 
 
Figure 1-10: Regulation of AMPK  
AMPK is activated by phosphorylation of the catalytic  subunit at Thr172 by LKB1 
(liver kinase B1) or CaMKK (Ca2+/calmodulin-dependent protein kinase kinase ) 
independently of adenine nucleotides. Increased AMP or ADP concentrations can 
allosterically activate AMPK and inhibit Thr172 dephosphorylation by protein 
phosphatases (PPase). A number of stimuli including xenobiotics and anti-diabetic 
agents activate AMPK via an increase in AMP/ATP or ADP/ADP concentrations. 
AICAR is phosphorylated to the AMP mimetic ZMP, thereby activating AMPK, 
whereas A769662 and salicylate are reported to active AMPK complexes 
containing the 1 regulatory subunit directly. 
 
1.3.4  AMPK targets 
AMPK regulates a wide range of different pathways in a variety of tissues via rapid 
phosphorylation of target proteins and longer-term effects on gene expression. 
Effects of AMPK are pleiotropic and can be observed in several tissues, such as 
adipose, liver, skeletal muscle, heart, brain and pancreas. Figure 1.11 below 
summarises many of the well-established downstream targets and effects of 
AMPK: 
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Figure 1-11: Targets for AMPK  
AMPK regulates many target proteins and processes, including glucose 
metabolism (blue), lipid metabolism (red), mitochondrial biogenesis and 
autophagy (black) and protein metabolism (green). Abbreviations: AS160, Akt 
substrate of 160 kDa; G6Pase, glucose-6-phosphatase; GPAT, glycerol phosphate 
acyltransferase; GS, glycogen synthase; HMGR, 3-hydroxy-3-methyl-CoA 
reductase; IRS1, insulin resceptor substrate 1; mTOR, mammalian target of 
rapamycin; PEPCK, phosphoenolpyruvate carboxykinase; PGC1, peroxisome 
proliferator-activated receptor- co-activator 1; PI3K, phosphatidylinositol 3-
kinase; SIRT1, sirtuin 1; TIF-1A, transcription initiation factor-1A; TSC2, tuberous 
sclerosis 2; ULK1/2, unc-51-like kinase. 
 
1.3.5  Regulation of glucose homeostasis by AMPK 
AMPK plays an important role in the regulation of glycogen synthesis, 
gluconeogenesis, glycolysis and glucose transport. AMPK has been reported to 
directly phosphorylate and inhibit muscle and liver GS (glycogen synthase), the 
key enzyme in the anabolic process of glycogen synthesis (Carling and Hardie 1989, 
Bultot et al. 2012). Interestingly, chronic activation of AMPK has been reported to 
increase glycogen storage in skeletal (Holmes, Kurth-Kraczek, and Winder 1999, 
Ojuka, Nolte, and Holloszy 2000) and cardiac (Arad, Seidman, and Seidman 2007) 
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muscle, suggested to be the result of allosteric activation of GS via increased 
glucose uptake and the subsequent rise in intracellular G6P (glucose-6-phosphate) 
concentrations (Hunter et al. 2011). 
AMPK activators AICAR (Lochhead et al. 2000), metformin (Kim et al. 2008, Zhou 
et al. 2001), and adiponectin (Yamauchi et al. 2002) have all been reported to 
suppress hepatic gluconeogenesis via downregulation of gluconeogenic enzymes 
PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase) 
in an AMPK-dependent manner. In contrast, a recent study by Foretz and co-
workers reported that mice with a liver-specific AMPK1/2 double knockout still 
exhibited normal blood glucose and insulin, and metformin still suppressed glucose 
output and G6Pase expression (Foretz et al. 2010). Furthermore, AICAR was still 
able to inhibit expression of both PEPCK and G6Pase in isolated hepatocytes 
derived from these mice; thus indicating the possibility for metformin and AICAR 
to reduce expression of gluconeogenic enzymes via AMPK-independent 
mechanisms (Foretz et al. 2010). 
PFK-2 (phosphofrucokinase-2) controls the synthesis and degradation of fructose 
2,6-bisphosphate, which itself stimulates PFK-1, a key glycolytic enzyme. AMPK 
has been reported to phosphorylate and activate PFK-2 in ischaemic cardiac 
muscle, thereby stimulating glycolysis (Marsin et al. 2000). 
Insulin-stimulated glucose uptake in striated muscle and adipocytes is mediated 
by the translocation of vesicles containing GLUT4 to the plasma membrane, with 
the resultant influx of glucose providing a substrate for glycogen synthesis in 
skeletal muscle and TG synthesis in adipocytes. AMPK activation in skeletal muscle 
has been demonstrated to increase both basal and insulin-stimulated glucose 
uptake by promoting GLUT4 translocation to the cell surface (Buhl et al. 2001, 
Koistinen et al. 2003, Fazakerley et al. 2010), and GLUT4 gene expression (Ojuka, 
Nolte, and Holloszy 2000, Holmes, Kurth-Kraczek, and Winder 1999). Interestingly, 
AMPK appears to have opposing effects in adipocytes, whereby it inhibits insulin-
stimulated glucose uptake as will be described in more detail in 1.4.3. 
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1.3.6  Regulation of lipid metabolism by AMPK 
A key metabolic target of AMPK is ACC, which is the rate-limiting enzyme in the 
conversion of acetyl CoA to malonyl CoA (Tong 2005). Malonyl CoA itself is both a 
precursor for the biosynthesis of FA as it provides acetyl groups (Wakil, Stoops, 
and Joshi 1983) and an inhibitor of FA oxidation via the allosteric inhibition of 
CPT1 (carnitine palmitoyl transferase 1) and the subsequent transport of long-
chain FA into the mitochondrial matrix (McGarry 1995). Thus, phosphorylation and 
inhibition of ACC by AMPK suppresses the synthesis of malonyl CoA, reducing FA 
synthesis and relieving inhibition of CPT1, thereby facilitating the oxidation of FA 
to yield ATP (Figure 1.12). Furthermore, AMPK has been proposed to activate 
malonyl CoA decarboxylase, which catalyses the conversion of malonyl CoA to 
acetyl CoA, thus further propagating these effects (Assifi et al. 2005). There are 
two isoforms of ACC in mammals; ACC1 (265 kDa) is predominantly expressed in 
lipogenic tissues including liver, adipose tissue and lactating mammary gland (Ha 
et al. 1996, Abu-Elheiga et al. 2005), and as such is proposed to primarily regulate 
FA synthesis (Ruderman et al. 2003). ACC2 (280 kDa) is predominantly expressed 
in cardiac and skeletal muscle (Ha et al. 1996, Abu-Elheiga et al. 2005), and is 
proposed to be primarily involved in the regulation of FA oxidation (Merrill et al. 
1997). Furthermore, long-term AMPK activation has been reported to reduce gene 
expression of ACC and FAS (Hardie 2008), thereby further increasing FA oxidation 
and reducing FA synthesis. The effect of AMPK activation on lipid metabolism in 
adipose tissue will be discussed in more detail in 1.4.4. 
Finally, another anabolic process inhibited by AMPK activation is the biosynthesis 
of cholesterol and isoprenoids; AMPK can phosphorylate and inhibit HMGR (HMG-
CoA reductase), the rate-limiting enzyme in this process (Beg, Stonik, and Brewer 
1978). 
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Figure 1-12: AMPK regulation of fatty acid oxidation  
AMPK stimulates FA oxidation by phosphorylating and inactivating ACC, thus 
inhibiting the conversion of acetyl CoA to malonyl CoA and relieving the 
inhibitory effect of malonyl CoA on CPT (carnitine palmitoyl transferase). FA 
thereby enter into the mitochondrial matrix where they are oxidised to yield 
ATP.  
 
1.3.7 Regulation of mitochondrial biogenesis and autophagy by 
AMPK 
Mitochondrial biogenesis is the de novo formation of mitochondria, ultimately 
increasing the capacity for the oxidative catabolism of glucose and FA within the 
cell. AMPK activates PGC-1 (peroxisome proliferator-activated receptor- co-
activator 1), a co-activator which enhances the activity of several transcription 
factors leading to the increased transcription of mitochondrial genes (Lin, 
Handschin, and Spiegelman 2005). Indeed, rats treated with AICAR exhibited 
elevated expression of mitochondrial genes in muscle (Winder et al. 2000). 
Autophagy is a catabolic process by which cellular components are degraded in 
order to maintain essential activity and cellular viability in response to energy 
depletion; thus, autophagy is promoted by AMPK activation. AMPK has been 
reported to directly phosphorylate and activate the mammalian autophagy-
initiating kinase Ulk1 under conditions of glucose starvation (Kim et al. 2011). 
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1.3.8  Regulation of protein metabolism by AMPK 
mTOR is a highly conserved Ser/Thr protein kinase that is ubiquitously expressed 
and exists as two complexes: mTORC1, in which mTOR associates with Raptor  and 
mLST8; and mTORC2, in which mTOR associates with Rictor, mSIN1 and mLST8. 
Importantly, mTORC1 is sensitive to rapamycin, while mTORC2 is not; thus 
providing a way of distinguishing mTORC1 and mTORC2 functions. The two 
complexes differentially regulate protein targets; mTORC1 is by far the best 
characterised and is generally thought to promote protein synthesis via 
phosphoryalation of S6K1 (ribosomal protein S6 kinase) and 4E-BP1 (elongation 
factor-4E binding protein 1) (Inoki, Zhu, and Guan 2003), while mTORC2 has been 
suggested to regulate cell survival, metabolism and cytoskeletal organisation via 
phosphorylation of PKB, SGK1 (serum/glucocorticoid regulated kinase 1) and PKC 
(protein kinase C) (Weber and Gutmann 2012). 
AMPK activation has been shown to inhibit the mTORC1 pathway via 
phosphorylation and activation of the upstream TSC1/2 (tuberous sclerosis 
complex 1/2) (Inoki et al. 2006). Consistent with this, AICAR-mediated mTOR 
inhibition is attenuated in TSC1 or TSC2-deficient cells (Wolff et al. 2011). In 
addition, AMPK-mediated phosphorylation of Raptor may also negatively regulate 
mTORC1 activity; AICAR-induced mTOR inhibition was reported to be suppressed 
in cells with a phospho-defective Raptor mutant (Gwinn et al. 2008). 
AMPK has been reported to suppress rRNA (ribosomal RNA) synthesis via 
phosphorylation of the RNA polymerase I (Pol I)-associated transcription factor 
TIF-IA, thereby inhibiting the formation of a functional transcription initiation 
complex (Hoppe et al. 2009). 
Recent studies utilising AICAR or metformin in intact cells have suggested that 
AMPK may inhibit the anabolic process of cell proliferation via inhibition of mTOR 
(Grimaldi et al. 2012, Carling et al. 2012). In contrast, treatment with AICAR, 
A769662 or infection with viruses expressing a constitutively active AMPK mutant 
were revealed to inhibit endothelial cell proliferation via increased p21 and p27 
expression (Peyton et al. 2012), while AICAR was reported to inhibit growth of a 
HepG2 cell line via phosphorylation of p53 (Imamura et al. 2001), all leading to 
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cell cycle arrest. Taken together, AMPK suppresses the anabolic processes of 
protein synthesis, cell growth and proliferation when cellular energy is depleted. 
1.4 Role of AMPK in adipose tissue and obesity 
1.4.1  Expression and activation of AMPK in adipose tissue 
AMPK1 has been reported to be the principal catalytic isoform expressed in 
cultured 3T3-L1 adipocytes (Salt, Connell, and Gould 2000), isolated epididymal 
rat adipocytes (Daval et al. 2005), human SCAT (Lihn et al. 2004) and mouse BAT 
(Mulligan et al. 2007), as assessed in immunoprecipitates using isoform-specific 
anti-AMPK subunit antibodies which measure total cellular/tissue activity. 
AMPK2 is only a minor isoform in adipocytes; however it is possible that 
complexes containing the 2 subunit isoform could play a role in specific 
subcellular compartments as has been proposed in endothelial cells, in which 
ablation of the 2 subunit isoform was associated with a marked increase in 
oxidative stress despite AMPK1 being the major isoform (Wang, Zhang, et al. 
2010). The AMPK1-specific pharmacological activators A769662 and salicylate 
have been reported to stimulate AMPK activity in 3T3-L1 adipocytes and mouse 
WAT, thus indicating adipocytes contain the 1 subunit isoform (Zhou, Wang, et 
al. 2009, Hawley et al. 2012). Furthermore, a modest reduction in AMPK Thr172 
phosphorylation and activity was observed in adipose tissue of AMPK1-/- mice 
(Dzamko et al. 2010). As the reduction in AMPK activity was not substantial, this 
could imply that 2 could represent the significant  isoform in adipose; however 
WAT from mice lacking the 2 subunit displayed no reduction in AMPK activity 
(Steinberg et al. 2010), thus 1 is likely to be the dominant  isoform in WAT. 
While there is a lack of published data describing the principal AMPK subunits in 
other cells which constitute adipose tissue, AMPK1 is reported to be the 
dominant catalytic subunit expressed in human endothelial cells (Wang, Zhang, et 
al. 2010) and mouse macrophages (Yang et al. 2010). Furthermore, these cells also 
express 1 (Reihill, Ewart, and Salt 2011, Galic et al. 2011). 
A number of stimuli have been reported to regulate adipose tissue AMPK activation 
under physiological and pathophysiological conditions. Caloric restriction 
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stimulates AMPK activation in rodent WAT (Daval et al. 2005, Sponarova et al. 
2005), as does exercise (potentially via adrenergic stimulation) in human SCAT and 
rat epididymal adipose tissue (Watt et al. 2006, Park et al. 2002). Cold exposure 
has also been reported to activate AMPK in rodent WAT (Mulligan et al. 2007) and 
BAT (Mulligan et al. 2007, Vucetic et al. 2011). As previously mentioned, the 
adipocytokines adiponectin and leptin have been reported to activate adipocyte 
AMPK (Wu et al. 2003, Liu et al. 2010, Wang et al. 2005), thus highlighting the 
potential autocrine regulation of AMPK activity. 
1.4.2  Role of AMPK in adipogenesis 
Differentiation of preadipocytes involves a highly regulated transcriptional 
cascade induced by hormones, including insulin and glucocorticoids, and is 
characterised by expression of FAS and aP2 (adipocyte-specific FA-binding protein) 
in addition to increased expression of the PPAR and C/EBP (CCAAT/enhancer-
binding protein) transcription factors (MacDougald and Lane 1995). The initial 
phase is known as mitotic clonal expansion (MCE), and involves re-entry of growth-
arrested pre-adipocytes into the cell cycle where they undergo several rounds of 
mitosis. This is accompanied by the transient expression of C/EBP and C/EBP. 
These transcription factors subsequently stimulate transcription of PPAR, which 
can in turn active C/EBP (Figure 1.13). PPAR and C/EBP exist in a positive-
feedback loop to propagate differentiation and induction of late adipogenic genes, 
including aP2 and FAS, in the terminal differentiation phase (Rosen et al. 2000). 
 Adipogenesis is an anabolic process, and AMPK has been suggested to inhibit it in 
the MCE phase. AMPK activation in adipocytes has been reported to reduce 
expression of C/EBP (which is essential for initiation of the adipogenic 
transcriptional cascade), and subsequent inhibition of PPAR, C/EBP and late 
adipogenic markers (Habinowski and Witters 2001, Zhou, Wang, et al. 2009, Giri 
et al. 2006). A769662 was reported to reduce the expression of C/EBP, PPAR 
and C/EBP, with a concomitant suppression of lipid droplet accumulation in 3T3-
L1 adipocytes (Zhou, Wang, et al. 2009). AICAR was also reported to suppress 
adipogenesis, reducing expression of C/EBP, PPAR, SREBP-1c and aP2 
(Habinowski and Witters 2001, Giri et al. 2006). Furthermore, a recently 
discovered novel synthetic compound structurally and functionally similar to 
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resveratrol has also been suggested to inhibit adipogenesis via AMPK activation, 
suppressing expression of C/EBP, PPAR, FAS and aP2 (Vingtdeux et al. 2011). 
While these studies all indicate that AMPK acts at the early proliferation phase to 
inhibit adipogenesis, the exact mechanism by which AMPK elicits these effects is 
still unclear. 
 
Figure 1-13: Temporal expression of key adipogenic genes  
Upon induction of differentiation, growth-arrested adipocytes undergo several 
rounds of mitosis, known as the mitotic clonal expansion (MCE) phase, which is 
accompanied by the transient expression of C/EBP and C/EBP. C/EBP and 
C/EBP induce transcription of PPAR, which in turn activates C/EBP. PPAR and 
C/EBP exist in a positive feedback loop to propagate differentiation and 
induction of adipogenic genes in the terminal differentiation phase. D, number 
of days post-induction of differentiation. 
 
1.4.3 Effect of AMPK on adipocyte cell size 
An increase in adipose tissue mass during obesity can be the result of an increase 
in adipocyte number (hyperplasia), an increase in adipocyte cell size 
(hypertrophy), or both. The role of AMPK in altered adipose tissue mass has been 
previously examined utilising mice deficient in the alpha2 catalytic subunit 
isoform; HFD-fed AMPK2-/- mice displayed an increased adipose tissue mass 
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compared with wild-type littermates (Villena et al. 2004). This was reported to 
be exclusively due to adipocyte hypertrophy, with no change in cell number or 
adipogenic marker expression observed (Villena et al. 2004). In contrast, Daval 
and co-workers reported a reduction in adipocyte size in AMPK1-/- mice; however 
it is important to note these mice were fed a chow diet and were not obese (Daval 
et al. 2005). 
1.4.4 Effect of AMPK on adipocyte carbohydrate metabolism 
AMPK has been shown to stimulate glucose uptake into muscle via upregulation of 
GLUT4 translocation as described in section 1.3.5; however the effect of AMPK 
activation on glucose uptake in adipocytes is less clear. Studies in 3T3-L1 
adipocytes showed that AICAR increased basal (Salt, Connell, and Gould 2000, 
Sakoda et al. 2002) and inhibited insulin-stimulated glucose uptake (Salt, Connell, 
and Gould 2000, Boyle et al. 2011), while AICAR was reported to inhibit both basal 
and insulin-stimulated glucose uptake in isolated rat adipocytes (Gaidhu, Fediuc, 
and Ceddia 2006, Gaidhu et al. 2010). Although in direct contrast to its effects in 
muscle, multiple lines of evidence supports inhibition of insulin-stimulated 
glucose uptake by AMPK in adipocytes. Furthermore, this is proposed to be 
independent of any effects on the early steps in the insulin signalling pathway, 
including tyrosine phosphorylation of IRS-1 (Wu et al. 2003, Salt, Connell, and 
Gould 2000), PI3K recruitment to IRS-1 (Salt, Connell, and Gould 2000) or PKB 
activity/phosphorylation (Wu et al. 2003, Salt, Connell, and Gould 2000, Boyle et 
al. 2011, Gaidhu et al. 2010). The mechanism by which AMPK suppresses insulin-
stimulated glucose transport is not yet fully understood; however it is thought to 
reduce the insulin-stimulated inhibitory phosphorylation of AS160 by PKB via a 
currently unknown mechanism (Gaidhu et al. 2010). Less is known about the long 
term effects of AMPK on glucose transport. 3T3-L1 adipocytes incubated with 
metformin for 24-48 h exhibited a reduction in the fold increase in insulin-
stimulated glucose transport as a result of higher basal glucose uptake (Boyle et 
al. 2011). Interestingly, increased basal glucose uptake was also observed in 
human SCAT and VAT preadipocyte-derived adipocytes incubated for 24 h with 
metformin (Fischer et al. 2010). Furthermore, metformin was found to further 
enhance insulin-stimulated glucose uptake in human SCAT preadipocyte-derived 
adipocytes (Fischer et al. 2010). While it has been reported that AMPK activation 
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increases GLUT4 expression in muscle (Ojuka, Nolte, and Holloszy 2000, Holmes, 
Kurth-Kraczek, and Winder 1999), GLUT4 protein levels were unaffected following 
chronic AICAR or metformin treatment in 3T3-L1 adipocytes or in adipose biopsies 
from volunteers with Type 2 diabetes treated with metformin for 10 weeks (Boyle 
et al. 2011). Overall, AMPK activation in adipocytes appears to suppress insulin-
stimulated glucose uptake; however further studies are necessary to fully 
understand the molecular mechanisms behind this. 
1.4.5  Effect of AMPK on adipose lipid metabolism 
1.4.5.1 Fatty acid oxidation 
AMPK-mediated phosphorylation and inactivation of ACC promotes FA oxidation to 
yield ATP via a reduction in malonyl CoA concentrations as described in 1.3.6. 
Chronic activation of AMPK in adipocytes was associated with an increase in FA 
oxidation (Gaidhu et al. 2009, Luo et al. 2007) and mitochondrial content (Orci et 
al. 2004, Gaidhu et al. 2011). Moreover, sustained AICAR treatment increased WAT 
expression of PPAR, PPAR and PGC-1; these all influence expression of 
enzymes involved in FA oxidation and mitochondrial biogenesis (Gaidhu et al. 
2009, Ahmadian et al. 2011).  In contrast, acute stimulation with AICAR was 
reported to inhibit FA oxidation in isolated rat adipocytes (Gaidhu, Fediuc, and 
Ceddia 2006). Gaidhu and co-workers hypothesised that suppression of FA 
oxidation in adipocytes may spare FA for oxidation by other tissues in which local 
ATP production is more crucial (Gaidhu, Fediuc, and Ceddia 2006). Thus, the role 
of AMPK in the regulation of FA oxidation in WAT may be dependent upon the 
duration of AMPK stimulation, such that acute AMPK activation may inhibit FA 
oxidation, while sustained AMPK activation appears to stimulate FA oxidation. 
1.4.5.2 Lipolysis 
Lipolysis is the process by which TG are hydrolysed to glycerol and FA in response 
to adrenergic stimulation of PKA and the subsequent phosphorylation of HSL and 
perilipins in the fasted state, and is suppressed by insulin-mediated PKB 
phosphorylation and subsequent activation of PDE3B in the fed state as described 
in more detail in 1.1.3. AICAR-mediated AMPK activation was reported to 
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antagonise lipolysis via phosphorylation of HSL on Ser565, thus preventing PKA-
stimulated phosphorylation and activation of HSL (Daval et al. 2005, Anthony, 
Gaidhu, and Ceddia 2009, Sullivan et al. 1994, Corton et al. 1995). Furthermore, 
an increase in lipolysis was found to activate AMPK (Gauthier et al. 2008). When 
the rate at which FA are liberated during lipolysis exceeds the rate at which they 
are being exported from the cells, they become re-esterified back into TG in an 
ATP-dependent manner. Therefore, it has been suggested that activation of AMPK 
and AMPK-mediated inhibition of lipolysis would prevent a futile cycling and 
depletion of ATP (Gauthier et al. 2008, Hardie, Ross, and Hawley 2012a). 
In contrast to these reports suggesting an anti-lipolytic role for AMPK, other 
studies have proposed that AMPK may stimulate lipolysis. Adrenergic stimulation 
has been reported to activate AMPK which results in the stimulation of lipolysis in 
3T3-L1 adipocytes (Yin, Mu, and Birnbaum 2003) and isolated rat adipocytes (Koh 
et al. 2007). Furthermore, the AMPK inhibitor Compound C was found to 
ameliorate -adrenergic-stimulated lipolysis in rat adipocytes (Koh et al. 2007), 
suggesting that AMPK is necessary for adrenaline-induced lipolysis. Interestingly, 
AICAR has been reported to initially suppress lipolysis in isolated rat adipocytes 
and in rats in vivo as assessed by a reduction in serum FA, yet chronic AICAR 
treatment was found to stimulate lipolysis (Gaidhu et al. 2009). Thus, as with FA 
oxidation, the role of AMPK in the regulation of lipolysis may depend on the 
duration and mode of AMPK activation; however the overall effect of AMPK on 
lipolysis remains controversial. 
1.4.5.3 Lipogenesis 
Chronic activation of AMPK by AICAR in isolated rat adipocytes (Gaidhu, Fediuc, 
and Ceddia 2006, Gaidhu et al. 2009, Sullivan et al. 1994) and metformin in human 
adipose tissue (Boyle et al. 2011) markedly increased ACC phosphorylation and 
suppressed lipogenic gene expression. Furthermore, Sullivan and co-workers 
observed a decrease in the lipogenic rate concomitant with ACC phosphorylation 
(Sullivan et al. 1994). Conversely, adipocytes from AMPK1-/- mice displayed an 
increase in lipogenesis in adipose explants (Dzamko et al. 2010). It has been 
suggested that the AMPK-mediated inhibition of lipogenesis would conserve ATP 
under conditions of cellular stress (Gaidhu, Fediuc, and Ceddia 2006). 
Sarah Mancini, 2014   Chapter 1, 64 
1.4.6  AMPK and brown adipose 
Brown adipocytes have a high mitochondrial content and characteristically express 
UCP-1, allowing for thermogenesis as described in 1.1.1.2. The role of brown 
adipose and the involvement of AMPK in its regulation are currently poorly 
characterised. AMPK has been reported to be activated in mice and rat BAT 
following prolonged exposure to cold (Mulligan et al. 2007, Vucetic et al. 2011), 
while studies in cultured mouse brown adipocytes revealed an increase in AMPK 
activation and glucose transport following AICAR (Sakaue et al. 2003) or -
adrenergic (Hutchinson et al. 2005) stimulation. Furthermore, in mouse BAT, 
acute adrenergic signalling has been proposed to stimulate AMPK activation via an 
increase in Thr172 phosphorylation, while chronic adrenergic stimulation 
increases AMPK  subunit protein levels (Pulinilkunnil et al. 2011). Metformin has 
recently been reported to increase AMPK1 expression and AMPK activity in both 
mouse BAT and cultured brown adipocytes (Geerling et al. 2013). Intriguingly, 
AMPK activity was found to be increased during differentiation in brown 
adipocytes; conversely siRNA-mediated knockdown of AMPK suppressed 
differentiation of brown adipocytes, indicating AMPK may promote differentiation 
in thermogenic BAT (Vila-Bedmar, Lorenzo, and Fernández-Veledo 2010). This is 
in direct contrast to the anti-adipogenic affect AMPK has in white adipocytes; the 
differential role of AMPK in white and brown adipocytes could be due to the fact 
that BAT specialises in lipid catabolism as opposed to energy storage. 
Interestingly, sustained AICAR treatment in mice was shown to increase the 
proportion of beige adipocytes within WAT deposits (Vila-Bedmar, Lorenzo, and 
Fernández-Veledo 2010), indicating AMPK activation may play a role in the 
remodelling of adipocyte metabolism by stimulating energy dissipation in WAT 
rather than lipid storage. 
1.4.7  AMPK and Inflammation 
1.4.7.1 Adipocytokines regulated by AMPK 
Prior to this study, AMPK had been proposed to exert anti-inflammatory effects in 
different tissues and cell types, including endothelial cells (Ewart, Kohlhaas, and 
Salt 2008) and macrophages (Sag et al. 2008); however the effects of AMPK 
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activation on inflammatory pathways in adipocytes were not well understood. The 
first study to suggest an anti-inflammatory role for AMPK showed that AICAR 
inhibited both the protein and mRNA expression of LPS-induced TNF-, IL-1 and 
IL-6 in rat primary astrocytes, microglia and macrophages (Giri et al. 2004). Other 
studies followed, providing further evidence that AMPK activation attenuates 
synthesis of proinflammatory cytokines TNF-, IL-1 and IL-6 in macrophages 
(Yang et al. 2010, Jeong et al. 2009, Sag et al. 2008), and IL-6 and IL-8 in 
adipocytes (Lihn et al. 2008). Berberine was reported to reduce proinflammatory 
cytokine expression in adipose tissue of db/db mice (Jeong et al. 2009), while 
AICAR was demonstrated to inhibit secretion of TNF- and IL-6 in human SCAT 
cultured ex-vivo (Lihn et al. 2004). A study utilising expression of a constitutively 
active AMPK in macrophages demonstrated a reduction in LPS-induced TNF- 
synthesis together with a concomitant increase in the anti-inflammatory cytokine 
IL-10 (Sag et al. 2008). Conversely, downregulation of AMPK via either antisense 
oligonucleotides or expression of a dominant negative mutant AMPK led to an 
increase in both mRNA and protein expression of TNF- and a reduction in IL-10 
production (Sag et al. 2008). Furthermore, AICAR-mediated AMPK activation has 
been found to diminish immune responses in a range of in vivo models of 
inflammation, including a murine model of acute and chronic colitis (Bai et al. 
2010), rat model of autoimmune encephalomyelitis (Prasad et al. 2006), and a 
murine lung injury model (Zhao et al. 2008). 
While it is well established that adiponectin stimulates AMPK activation as 
described in 1.3.3.1, AMPK may also regulate adiponectin expression. AICAR 
reportedly stimulated an increase in adiponectin gene expression in human SCAT 
cultured ex vivo (Lihn et al. 2004). In contrast, however, adiponectin expression 
was found to be suppressed in 3T3-L1 adipocytes following AICAR or metformin 
treatment (Huypens, Quartier, et al. 2005); thus indicating the effect of AMPK on 
adiponectin expression is still unclear. 
1.4.7.2 Inhibition of inflammation by AMPK 
Prior to the beginning of this study, few groups had attempted to elucidate the 
molecular mechanisms by which AMPK may inhibit proinflammatory signalling in a 
variety of cell types; and the regulation of adipocyte inflammation by AMPK was 
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poorly characterised. Early studies found that activation of AMPK was associated 
with a decrease in NFB reporter gene activity (Giri et al. 2004, Cacicedo et al. 
2004). Several studies followed which supported this observation and found that 
AMPK activation attenuated cytokine-stimulated NFB in multiple cell types, 
including cultured endothelial cells (Cacicedo et al. 2004), macrophages (Yang et 
al. 2010), neutrophils (Zhao et al. 2008), microglial cells, astrocytes (Giri et al. 
2004) and hepatic stellate cells (Caligiuri et al. 2008). Furthermore, constitutively 
active AMPK suppresses LPS-stimulated degradation of IB and subsequent 
binding of NFB p65 to the IL-6 promoter in macrophages (Yang et al. 2010, Sag 
et al. 2008) while conversely downregulation of AMPK with RNA interference 
reduces the ability of AICAR to inhibit binding of p65 to the IL-6 promoter (Yang 
et al. 2010). Finally, it has been suggested that AMPK may inhibit the NFB 
signalling pathway at the level of IKK, as metformin has been reported to reduce 
TNF--stimulated IKK/ S180/181 phosphorylation in HUVECs (human umbilical 
vein endothelial cells) in an AMPK-dependent manner (Huang et al. 2009). 
Inhibition of cytokine-stimulated MAPK phosphorylation by AMPK has previously 
been demonstrated in a small number of studies, however the mechanism had not 
been characterised. Berberine was found to inhibit LPS-stimulated 
phosphorylation of JNK, ERK1/2 and p38 MAPK in macrophages in an AMPK-
dependent manner (Jeong et al. 2009), while increased JNK phosphorylation was 
observed not only in HUVECs following siRNA-mediated downregulation of either 
AMPK1 or AMPK2, but also in aortic endothelial cells isolated from AMPK2-/- 
mice (Dong et al. 2010). AICAR and metformin were also reported to inhibit JNK 
activation in HUVECs in response to TNF- or H2O2 (Schulz et al. 2008).  
Before this study began, little was known about the effect of AMPK on IL-6 
stimulated proinflammatory signalling. Handy and co-workers suggested AMPK 
activation triggered suppression of leptin-mediated STAT3 phosphorylation and 
SOCS-3 induction in hepatic stellate cells (Handy et al. 2010); however, to our 
knowledge the current study is the first to investigate the effect of AMPK on IL-6 
signalling in adipocytes.  
Sag and co-workers reported that transfection of a constitutively active mutant 
AMPK promoted polarisation of macrophages towards an M2 phenotype (Sag et al. 
2008). Furthermore, inhibition of AMPK expression with RNA interference or 
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transfection with a dominant negative mutant AMPK elevated mRNA and protein 
expression of proinflammatory cytokines TNF- and IL-6; therefore macrophages 
displayed an M1 phenotype in the absence of AMPK (Sag et al. 2008). Adiponectin 
was also reported to prime human monocytes towards an M2 phenotype, as 
demonstrated by an inhibition of proinflammatory factors (Lovren et al. 2010). It 
should be noted that neither of these studies investigated whether AMPK 
activation had any effect on macrophages which were already of a 
proinflammatory, M1 phenotype (Sag et al. 2008, Lovren et al. 2010). 
1.5 Aims 
The overall aim of this study was to determine the functional consequences of 
AMPK activation in adipocytes subjected to proinflammatory stimuli and 
characterise the mechanisms by which AMPK exerts its actions. Although AMPK 
activation has been previously reported to inhibit inflammatory responses in 
endothelial cells and macrophages, an investigation into the consequences of 
AMPK activation on inflammatory signalling in adipocytes has yet to be 
undertaken. Elevated levels of proinflammatory cytokines are strongly associated 
with obesity, insulin resistance and Type 2 diabetes, and ablation of 
proinflammatory signalling has been demonstrated to improve insulin sensitivity. 
The initial aim of this study was to investigate the temporal parameters of 
inhibition of intermediates of the cytokine-stimulated MAPK, NFB and JAK/STAT 
signalling pathways by AMPK activation in 3T3-L1 adipocytes by immunoblotting 
and immunofluorescence. Furthermore, the mechanisms by which AMPK inhibits 
these proinflammatory signalling pathways was investigated by pharmacological 
and genetic manipulation of the signalling pathways. The proinflammatory profile 
of adipose tissue from AMPK1-/- mice compared to litter-matched wild-type mice 
was also examined. 
Functional consequences of AMPK activation in 3T3-L1 adipocytes and RAW 264.7 
macrophages were investigated in this study as macrophages also contribute to 
the proinflammatory profile of adipose tissue. The effect of AMPK activation on 
cytokine and chemokine secretion from 3T3-L1 adipocytes and RAW 264.7 
macrophages in response to proinflammatory stimuli was assessed in culture 
Sarah Mancini, 2014   Chapter 1, 68 
medium using a mouse multiplex bead immunoassay kit and Luminex detection 
system. Furthermore, the effect of individual proinflammatory cytokines or 
conditioned medium from activated macrophages on insulin-stimulated glucose 
uptake in 3T3-L1 adipocytes was determined using 2-[3H] deoxy-D-glucose.   
Downstream effects of AMPK activation on proinflammatory cytokine-stimulated 
gene expression of the chemokine MCP-1 was assessed using semi-quantitative 
PCR. 
Finally, the effect of AMPK activation on 3T3-L1 adipocyte differentiation was 
investigated by immunoblotting and lipid staining with Oil red O. In addition, 
adipocyte cell size was examined in AMPK1-/- mice by hematoxylin and eosin 
staining.
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 Chapter 2 - Materials and Methods 
2.1 Materials 
2.1.1  List of materials and suppliers 
Abcam, Cambridge, UK 
A769662 (6,7-Dihydro-4-hydroxy-3-(2'-hydroxy[1,1'-biphenyl]-4-yl)-6-oxo-
thieno[2,3-b]pyridine-5-carbonitrile) 
BBC Biochemical, Mt Vernon, WA, USA 
Zinc formalin 
Cambridge Biosciance Ltd, Cambridge, UK 
Quick Titer™ Adenovirus Titer Immunoassay kit 
Cayman Chemicals, Ann Arbor, MI, USA 
PP242 
Cell signalling Technology Inc, Danvers, MA, USA 
Interleukin-1β (IL-1β) 
BDH Laboratory Supplies, Poole, UK 
Coomassie brilliant blue G-250 
Tetrasodium pyrophosphate (Na4PPi) 
Bio-rad Laboratories Ltd, Hertfordshire, UK 
Mini-PROTEAN® TGX™ precast gels 
Eastman Kodak Company, Rochester, NY, USA 
Kodak medical X-ray film 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK 
Ammonium persulphate (APS) 
Corning tissue culture T75/T150 flasks, 10 cm diameter dishes and 6 well plates 
Ethidium bromide 
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Tris base (tris(hydroxymethyl)aminoethane) 
Formendium, Hunstanton, Norfolk, UK 
Bacterial Agar 
Tryptone 
Yeast extract powder 
GE Healthcare, Little Chalfont, Buckinghamshire, UK 
Protein G sepharose beads 
Protein A sepharose beads 
Invitrogen (Life Technologies Ltd), Paisley, UK 
dNTPs (dATP, dCTP, dGTP, dTTP) 
Lipofectamine 2000 
Mouse cytokine 20-plex panel for Luminex® platform 
S.O.C. medium 
Taq PCRx® DNA Polymerase 
One Shot chemically competent TOP10 E.coli 
Invitrogen (GIBCO Life Technologies Ltd), Paisley, UK 
Dulbecco’s modified Eagles media (DMEM) 
Foetal calf serum (FCS) (USA origin) 
Foetal calf serum (FCS) (EU origin) 
L-glutamine 
Newborn calf serum (NCS) 
Opti-MEM® I Reduced Serum Media 
Penicillin/streptomycin 
Trypsin 
Melford Laboratories Ltd, Chelsworth, Ipswich, Suffolk, UK 
Dithiothreitol (DTT) 
 
Merck Chemicals Ltd, Nottingham, UK 
Compound C 
MG132 
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National Diagnostics (UK) Ltd, Hessle, East Riding of Yorkshire, UK 
Ecoscint A 
New England Biolabs, Ipswich, MA, USA 
Gel loading dye (6x) 
Low molecular weight DNA marker (100 bp) 
Prestained protein marker (broad range 6-175 kDa) 
PALL Life Sciences, Pensacola, FL, USA 
Nitrocellulose transfer membrane, 0.45 μM pore size 
Perkin Elmer, Beaconsfield, Buckinghamshire, UK 
2-[3H]-deoxy-D-glucose 
Pierce, Perbio Science, UK Ltd, Tettenhall, Cheshire, UK 
10,000 MWCO slide-a-lyzer 
Premier International Foods, Cheshire, UK 
Dried skimmed milk 
Promega, Madison, WI, USA 
ImProm-II™ Reverse Transcription System 
Wizard® Plus SV Minipreps Kit 
Qiagen Ltd, Crawley, West Sussex, UK 
RNeasy Mini Kit 
R & D Systems, Abingdon Science Park, Abingdon, Oxford, UK 
Interleukin-6 (IL-6) (murine/human) 
Soluble interleukin-6 receptor-α (sIL-6α) (murine/human) 
Roche Diagnostic Ltd, Burgess Hill, UK 
Agarose MP 
Severn Biotech Ltd, Kidderminster, Hereford, UK 
Acrylamide:Bisacrylamide (37.5:1; 30% (w/v) Acrylamide) 
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Sigma-Aldrich Ltd, Gillingham, Dorset, UK 
5-Amino-2,3-dihydro-1,4-phthalazinedione (luminol) 
Ampicillin 
Bovine serum albumin (BSA) 
Benzamidine 
p-Coumaric acid 
Cytochalasin B 
Dexamethasone 
D-mannitol 
DPX mountant 
Dulbecco’s modified Eagles media (DMEM) 
Eosin Y 
Ethylenediamine tetraacetic acid (EDTA) 
Ethylene glycol-bis (β-amino-ethylether)-N,N,N’,N’-tetraacetic acid (EGTA) 
Haematoxylin solution 
Hydrogen peroxide (H2O2) 
Isobutylmethylxanthine (IBMX) 
Lipopolysaccharide (LPS) 
β-mercaptoethanol 
MCP-1 mouse forward and reverse primers 
Nω-Nitro-D-arginine methyl ester hydrochloride (D-NAME) 
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) 
Oil red O 
Paraformaldehyde 
phenylmethylsulphonyl fluoride (PMSF) 
Ponceau stain 
Porcine Insulin 
18S forward and reverse primers 
Saponin 
Sodium deoxycholate 
Soyabean trypsin inhibitor (SBTI) 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) 
Triton X-100 
Tumour necrosis factor-α (TNF-α) 
Tween-20 
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Thermo Scientific, Waltham, MA, USA 
Immunomount 
Tocris Bioscience, Bristol, UK 
NSC-87877 (SHP-2 inhibitor) (Chen et al. 2006) 
Troglitazone 
Toronto Research Chemicals Inc, Ontario, Canada 
AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) 
VWR International Ltd., Lutterworth, Leicestershire, UK 
Falcon tissue culture 10 cm diameter dishes and 6/12/24 well plates 
HEPES (N-2-hydroxyethylpiperazine-N’ 2-ethane sulphonic acid) 
Worthington Biochemical Corporation, Lakewood, NJ, USA 
Collagenase Type I 
TC-PTP inhibitor was generously donated by Prof. Zhong-Yin Zhang (Department 
of Biochemistry and Molecular Biology, Indiana University School of Medicine, USA) 
(Zhang et al. 2009). 
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2.1.2  List of specialist equipment and suppliers 
Beckman Coulter™, High Wycombe, UK 
Optima™ XL-80K ultracentrifuge 
SW40 rotor 
Multi-Purpose scintillation counter LS 6500 
Allegra® X-12 centrifuge 
Bio-Rad Laboratories, Hemel Hempstead, UK 
Protein gel casting and Western blotting equipment (Mini Protean III) 
Agarose gel casting equipment (Mini-Sub/Wide Mini-Sub Cell GT gel system) 
Luminex® 100™ detection system for mouse cytokine multiplex bead 
immunoassay analysis 
Carl Ziess Ltd, Cambridge, UK  
LSM Exciter laser scanning microscope 
Axiovision light microscope 
Fisher Scientific, Loughborough, UK 
Polycarbonate freezing container 
Optika Microscopes, Ponteranica, Italy 
XDS-1B light microscope 
Techne, Bibby Scientific Ltd, Staffordshire, UK 
Progene FPR0G050  Thermocycler 
Thermo Scientific, Waltham, MA, USA 
Nanodrop spectrophotometer 
WPA, Cambridge, UK 
S2000 spectrophotometer 
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2.1.3  List of cells and suppliers 
American Type Culture Collection, Manassas, VI, USA 
3T3-L1 preadipocytes 
3T3-L1 CAR (3T3-L1 adipocytes overexpressing the coxsackie virus and adenovirus 
receptor) were a kind gift from Prof. David Orlicky, University of Colorado (CO, 
USA) (Ross et al. 2003). 
 
TC-PTP+/+ and TC-PTP-/- MEFs were kind gifts from Dr. M. Tremblay, McGill 
University (Montreal, Canada) (Ibarra-Sánchez et al. 2001). 
 
TSC2+/+p53-/- and TSC2-/-p53-/- MEFs were kind gifts from Dr. A. Tee, University of 
Cardiff (Cardiff, UK) (Kwiatkowski et al. 2002). 
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2.1.4  List of antibodies and conditions of use 
2.1.4.1  Primary antibodies for western blotting 
Table 2-1: Primary antibodies used for western blotting 
n/a: not applicable; OBB: Odyssey® blocking buffer. All blots were incubated 
overnight at 4°C. 
Epitope Clonality Host 
species 
Dilution Diluent 
ECL (w/v 
PBST) or 
LI-COR 
(v/v PBST 
Source 
ACC1 polyclonal sheep 2 g/ml 3% milk or 
50% OBB 
A generous gift 
from Prof. D.G. 
Hardie, University 
of Dundee, 
Dundee, UK. 
Raised against 
CQRDFTVASPAEFVT 
(C + residues 96-
109 of rat ACC1 
conjugated to 
KLH) 
ACC S79 polyclonal rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#3661) 
ACRP polyclonal rabbit 1 :1000 50% OBB Dr Mairi Clarke, 
University of 
Glasgow (Clarke et 
al. 2006) 
Sarah Mancini, 2014   Chapter 2, 77 
AMPK1 polyclonal sheep 1 g/ml 3% milk or 
50% OBB 
A generous gift 
from Prof. D.G. 
Hardie, University 
of Dundee, 
Dundee, UK. 
(Woods et al. 
1996) 
AMPK2 polyclonal sheep 1 g/ml 3% milk or 
50% OBB 
A generous gift 
from Prof. D.G. 
Hardie, University 
of Dundee, 
Dundee, UK. 
(Woods et al. 
1996) 
AMPK 
phospho-
T172 
polyclonal rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#2531) 
C/EBP polyclonal rabbit 1 :200 50% OBB Santa Cruz 
Biotechnology, CA, 
USA. (#SC-61) 
C/EBP polyclonal rabbit 1 :200 50% OBB Santa Cruz 
Biotechnology, CA, 
USA. (#SC-150) 
GAPDH monoclonal 
clone:6C5 
mouse 1 :80000 5% milk or 
50% OBB 
Ambion, 
Cambridgeshire, 
UK. (#4300) 
IB monoclonal 
clone:44D4 
rabbit 1 :1000 5% BSA 
or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#4812) 
Sarah Mancini, 2014   Chapter 2, 78 
IB (amino 
terminus) 
monoclonal 
clone:L35A5 
mouse 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#4814) 
IB 
phospho-
S32 
monoclonal 
clone:14D4 
rabbit 1 :1000 5% BSA 
or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#2859) 
IKK monoclonal 
clone:2C8 
rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#2370) 
IKK IP 
preferred 
monoclonal 
clone:L570 
rabbit 1 :50 
(IP) 
n/a New England 
Biolabs, 
Hertfordshire, UK. 
(#2678) 
IKK polyclonal rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#2682) 
IKK/ 
phospho-
S176/S177 
monoclonal 
clone:C84E1
1 
rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#2078) 
JAK1 monoclonal 
clone: 
73/JAK1 
mouse 1 :1000 50% OBB BD transduction 
laboratories, 
Oxford, UK. 
(#610232) 
JAK1 
phospho-
Y1022/1023 
polyclonal rabbit 1 :200 50% OBB Santa Cruz 
Biotechnology, CA, 
USA. (#SC-16773) 
JAK2 XP® monoclonal 
clone:D2E12 
rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#3230) 
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JAK2 
phospho-
Y1007/1008 
polyclonal rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#3771) 
JNK polyclonal rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#9252) 
JNK 
phospho-
T183/Y185 
polyclonal rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#9251) 
JNK 
phospho-
T183/Y185 
monoclonal 
clone:G9 
mouse 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#9255) 
p44/42 
MAPK 
(Erk1/2) 
polyclonal rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#9102) 
p44/42 
MAPK 
(Erk1/2) 
phospho-
T202/Y204 
monoclonal 
clone:E10 
mouse 1 :2000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#9106) 
NFB p65 
XP® 
monoclonal 
clone: 
D14E12 
rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#8242) 
NFB p65 
phospho-
S536 
monoclonal 
clone:93H1 
rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#3033) 
Sarah Mancini, 2014   Chapter 2, 80 
p38 MAPK polyclonal rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#9212) 
p38 MAPK 
phospho-
T180/Y182 
XP® 
monoclonal 
clone:D3F9 
rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#4511) 
p53 monoclonal 
clone:D0-1 
mouse 1 :200 50% OBB Santa Cruz 
Biotechnology, CA, 
USA. (#SC-126) 
p70 S6 
kinase 
monoclonal 
clone:49D7 
rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#2708) 
p70 S6 
kinase 
phospho-
S371 
polyclonal rabbit 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#9208) 
PPAR monoclonal 
clone:E-8 
mouse 1 :200 50% OBB Santa Cruz 
Biotechnology, CA, 
USA. (#SC-7273) 
phospho-
tyrosine 
monoclonal 
clone:4G10 
mouse 1 :1000 50% OBB; 
50% TBST 
Millipore 
Corporation, 
Billerica, MA, USA. 
(#05-321) 
SOCS-3 polyclonal goat 1 :200 50% OBB Santa Cruz 
Biotechnology, CA, 
USA. (#SC-7009) 
STAT3 monoclonal 
clone:79D7 
rabbit 1 :2000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#4904) 
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STAT3 
phospho-
Y705 
monoclonal 
clone:3E2 
mouse 1 :1000 5% BSA or 
50% OBB 
New England 
Biolabs, 
Hertfordshire, UK. 
(#9138) 
STAT3 
phospho-
S727 
monoclonal 
clone:6E4 
mouse 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#9136) 
STAT5 monoclonal 
clone:3H7 
rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#9358) 
STAT5 
phospho-
Y694 
monoclonal 
clone:14H2 
mouse 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#9356) 
TC-PTP monoclonal 
clone: 
252294 
mouse 1 :1000 5% milk R&D Systems, 
Abingdon, UK. 
(#MAB1930) 
Tuberin/ 
TSC2 
monoclonal 
clone:D57A9 
rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#3990) 
-Tubulin monoclonal 
clone:9F3 
rabbit 1 :1000 50% OBB New England 
Biolabs, 
Hertfordshire, UK. 
(#2128) 
 
2.1.4.2  Primary antibodies for immunofluorescence 
Table 2-2: Primary antibodies used for immunofluorescence 
All coverslips were incubated in permeabilisation media (2% (w/v) BSA, 0.1% (w/v) 
Saponin, 20 mM glycine, PBS) for 45 min at room temperature. 
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Epitope Clonality Host 
species 
Dilution Source 
c-myc monoclonal  clone : 
9E10 
mouse 1 :100 Santa Cruz Biotechnology, 
CA, USA. (#SC-40) 
NFB p65 
XP® 
monoclonal clone : 
D14E12 
rabbit 1 :50 New England Biolabs, 
Hertfordshire, UK. 
(#8242) 
 
2.1.4.3  Secondary detection agents for western blotting 
Table 2-3: Secondary detection agents for western blotting 
All blots were incubated for 1 h at room temperature. 
Linked 
molecule 
Epitope Host 
species 
Dilution Diluent 
(w/v or 
v/v in 
PBST) 
Source 
HRP mouse IgG sheep 1 :2000 5% milk GE Healthcare, 
Buckinghamshire, 
UK. (#NA931) 
HRP rabbit IgG donkey 1 :2000 5% milk GE Healthcare, 
Buckinghamshire, 
UK. (#NA934) 
HRP streptococcus 
sp. Protein G 
n/a 1 :2000 5% milk Sigma, St Louis, 
MO, USA. (#P8170) 
IRDye® 
800CW 
mouse IgG donkey 1 :5000 50% OBB LI-COR 
Biosciences, 
Lincoln, NE, USA. 
(#926-32210) 
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IRDye® 
800CW 
rabbit IgG donkey 1 :5000 50% OBB LI-COR 
Biosciences, 
Lincoln, NE, USA. 
(#926-32213) 
IRDye® 
680LT 
rabbit IgG donkey 1 :5000 50% OBB LI-COR 
Biosciences, 
Lincoln, NE, USA. 
(#926-68023) 
IRDye® 
680LT 
goat IgG donkey 1 :5000 50% OBB LI-COR 
Biosciences, 
Lincoln, NE, USA. 
(#926-68074) 
Alexa 
Fluor® 
680 (red) 
sheep IgG donkey 1 :5000 50% OBB Invitrogen, Life 
Technologies Ltd, 
Paisley, UK. 
(#A21102) 
 
2.1.4.4  Secondary detection agents for immunofluorescence 
Table 2-4: Secondary detection agents for immunofluorescence 
All coverslips were incubated for in permeabilisation media (2% (w/v) BSA, 0.1% 
(w/v) Saponin, 20 mM glycine, PBS) for 30 min at room temperature. 
Linked 
molecule 
Epitope Clonality Host 
species 
Dilution Source 
Alexa 
Fluor® 
488 
(green) 
rabbit 
IgG 
polyclonal goat 1 :100 Invitrogen, Life 
Technologies Ltd, 
Paisley, UK. (#A11008) 
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Alexa 
Fluor® 
565 (red) 
rabbit 
IgG 
polyclonal goat 1 :100 Invitrogen, Life 
Technologies Ltd, 
Paisley, UK. (#A11011) 
Alexa 
Fluor® 
568 (red) 
mouse 
IgG 
polyclonal goat 1 :100 Invitrogen, Life 
Technologies Ltd, 
Paisley, UK. (#A11004) 
 
2.1.5  Standard solutions 
Unless stated otherwise, all buffers and reagents were made up with distilled 
water. 
Bradford’s reagent 
35.0 mg/l coomassie brilliant blue 
5.0% (v/v) ethanol 
5.1% (v/v) orthophosphoric acid 
Bradford’s reagent was filtered and stored in the dark. 
Enhanced chemiluminescence (ECL) detection reagents 
Solution 1: 
0.1 mM Tris-HCl, pH 8.5 
450 mg/l luminol in 2% (v/v) DMSO 
130 mg/l coumaric acid in 1% (v/v) DMSO 
Solution 2: 
0.1 mM Tris-HCl, pH 8.5 
0.02% (v/v) H2O2 
Immunoprecipitation (IP) buffer 
50 mM Tris-HCl, pH 7.4 at 4°C 
150 mM NaCl 
50 mM NaF 
5 mM Na4P2O7 
1 mM EDTA 
1 mM EGTA 
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1% (v/v) Triton-X-100 
1% (v/v) glycerol 
1 mM DTT 
0.1 mM benzamidine 
0.1 mM PMSF 
5 μg/mL SBTI 
1 mM Na3 VO4 
Krebs-Ringer HEPES (KRH) buffer 
119.0 mM NaCl 
20.0 mM HEPES-NaOH, pH 7.4 
5.0 mM NaHCO3 
10.0 mM glucose 
4.8 mM KCl 
2.5 mM CaCl2 
1.2 mM MgSO4 
1.2 mM NaH2PO4 
Krebs-Ringer phosphate (KRP) buffer 
130 mM NaCl 
4.8 mM KCl 
5 mM NaH2PO4, pH 7.4 
1.25 mM MgSO4 
1.25 mM CaCl2 
 
 
 
 
Lysis Buffer 
50 mM Tris-HCl, pH 7.4 at 4°C 
50 mM NaF 
1 mM Na4P2O7 
1 mM EDTA 
1 mM EGTA 
1% (v/v) Triton-X-100 
added on day of use 
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250 mM mannitol 
1 mM DTT 
1 mM Na3 VO4 
0.1 mM benzamidine 
0.1 mM PMSF 
5 μg/mL SBTI 
Phosphate-buffered saline (PBS) (pH 7.2) 
85 mM NaCl 
1.7 mM KCl 
5 mM Na2HPO4 
0.9 mM KH2PO4 
Phosphate-buffered saline + Tween 20 (PBST) 
85 mM NaCl 
1.7 mM KCl 
5 mM Na2HPO4 
0.9 mM KH2PO4 
0.1% (v/v) Tween 20 
Ponceau S stain 
0.2% (w/v) ponceau S 
1% (v/v) acetic acid 
Scott’s tap water substitute 
42 mM NaHCO3 
167 mM MgSO4 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) Running buffer 
190 mM glycine 
62 mM Tris base 
0.1% (w/v) SDS 
4 X SDS-PAGE sample buffer 
added on day of use 
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200 mM Tris-HCl, pH 6.8 
8% (w/v) SDS 
40% (v/v) glycerol 
0.4% (w/v) bromophenol blue 
200 mM DTT 
TAE buffer (pH 8.2) 
40 mM Tris acetate 
1 mM EDTA 
Transfer buffer 
25 mM Tris base 
192 mM glycine 
20% (v/v) ethanol 
Tris-buffered saline (TBS) 
20 mM Tris-HCl, pH 7.5 
137 mM NaCl 
Tris-buffered saline + Tween 20 (TBST) 
20 mM Tris-HCl, pH 7.5 
137 mM NaCl 
0.1% (v/v) Tween 20 
2 YT medium 
1.6% (w/v) Tryptone 
1% (w/v) Yeast extract 
0.5% (w/v) NaCl 
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2.2 Methods 
2.2.1  Cell Culture Procedures 
2.2.1.1  Cell culture plastic ware 
3T3-L1 and 3T3-L1 CAR (3T3-L1 adipocytes overexpressing the coxsackie virus and 
adenovirus receptor) cells were cultured in Corning T75 flasks and Falcon 10 cm 
diameter dishes, 6 well, 12 well and 24 well plates. Human embryonic kidney 
(HEK) 293 cells, mouse embryonic fibroblasts (MEFs) and HeLa cells were cultured 
in Corning T75 flasks and 6 well plates. RAW 264.7 macrophages were cultured in 
Corning T150 flasks and 10 cm diameter dishes. 
2.2.1.2  Cell culture growth media for 3T3-L1 preadipocytes 
Preadipocytes were maintained as fibroblasts (passage 2-12) in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) newborn calf 
serum (NCS) and 100 U/ml (v/v) penicillin and streptomycin. Cells were cultured 
at 37°C in a humidified atmosphere of 10% (v/v) CO2 in media replaced every 48 
h. 
2.2.1.3  Cell culture growth media for 3T3-L1 CAR preadipocytes 
Preadipocytes were maintained as fibroblasts (passage 15-30) in DMEM 
supplemented with 10% (v/v) foetal calf serum (FCS) and 100 U/ml (v/v) penicillin 
and streptomycin. Cells were cultured at 37°C in a humidified atmosphere of 10% 
(v/v) CO2 in media replaced every 48 h. 
2.2.1.4  Cell culture growth media for HEK 293 and HeLa cells 
HEK 293 cells and HeLa cells were each maintained in DMEM supplemented with 
10% (v/v) FCS and 2 mM glutamine. Cells were cultured at 37°C in a humidified 
atmosphere of 5% (v/v) CO2 in media replaced every 48 h. 
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2.2.1.5  Cell culture growth media for MEFs 
MEFs were maintained in DMEM supplemented with 10% (v/v) FCS, 100 U/ml (v/v) 
penicillin and streptomycin and 2 mM glutamine. Cells were cultured at 37°C in a 
humidified atmosphere of 5% (v/v) CO2 in media replaced every 48 h. 
2.2.1.6  Cell culture growth media for RAW 264.7 macrophages 
RAW 264.7 macrophages were maintained in RPMI 1640 supplemented with 10% 
(v/v) FCS, 100 U/ml (v/v) penicillin and streptomycin and 2 mM glutamine. Cells 
were cultured at 37°C in a humidified atmosphere of 5% (v/v) CO2 in media 
replaced every 48 h. 
2.2.1.7  Preparation of 3T3-L1 and 3T3-L1 CAR fibroblast 
differentiation medium 
Differentiation was initiated using DMEM containing 10% (v/v) FCS, 0.5 mM methyl 
isobutylxanthine (IBMX), 0.25 μM dexamethasone, 5 μM troglitazone, and porcine 
insulin (1 μg/ml), prepared as outlined below. 
A 2.5 mM solution of dexamethasone in ethanol was diluted 1:20 with 10% (v/v) 
FCS/DMEM medium immediately prior to use yielding a 500X stock solution. A 500X 
concentrated solution of IBMX was also prepared by dissolving 55 mg IBMX in 1 ml 
of 1M KOH. Insulin (1 mg/ml) was then prepared in 0.01 M HCl. 
3T3-L1 differentiation medium was prepared by diluting both the dexamethasone 
and IBMX solutions to a 1X concentration in 10% (v/v) FCS/DMEM and then adding 
insulin and troglitazone to final concentrations of 1 μg/ml and 5 μM, respectively. 
The medium was then filter-sterilised prior to use. 
2.2.1.8  3T3-L1 and 3T3-L1 CAR fibroblast differentiation protocol 
To differentiate the 3T3-L1 and 3T3-L1 CAR fibroblast cells into adipocytes, the 
cells were grown to confluency in 10% (v/v) NCS/DMEM. At 48 hr post-confluence, 
cell medium was aspirated and replaced with differentiation medium consisting 
of 10% (v/v) FCS/DMEM containing 0.25 μM dexamethasone, 0.5 mM IBMX, 5 μM 
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troglitazone and insulin (1 μg/ml). After a further three days this medium was 
aspirated and replaced with 10% (v/v) FCS/DMEM containing 5 μM troglitazone and 
insulin (1 μg/ml). The cells were incubated in this medium for three days before 
the medium was aspirated and replaced with 10% (v/v) FCS/DMEM, in which the 
cells were then maintained in. At 8-12 days post-induction of differentiation, cells 
were used for experimentation. 
2.2.1.9  Passaging of 3T3-L1 and 3T3-L1 CAR fibroblasts, MEFs, 
HEK 293 and HeLa cells 
When cells in T75 flasks were 70-80% confluent, DMEM growth medium was 
aspirated and the cells briefly washed in sterile PBS before 3 ml of sterile trypsin 
(0.05% (v/v) in diaminothanetetra-acetic acid, disodium salt (EDTA)) was added 
to each T75 flask. Flasks were then incubated at 37°C until the cells began to lift 
off. Trypsin was titurated over the surface of the flask until all of the cells were 
detached. An appropriate volume of DMEM growth medium was added to the 
trypsin and used to seed cell culture plastic ware as detailed in 2.2.1.1. 
2.2.1.10  Passaging of RAW 264.7 macrophages 
When cells in T150 flasks were 70-80% confluent, a cell lifter was gently passed 
over the surface of the flask to detach adherent cells into the medium. Cells were 
counted using a haemocytometer and an appropriate volume of RPMI 1640 growth 
medium added for seeding T150 flasks and 10 cm diameter dishes at a density of 
1 x 106 cells/dish. 
2.2.1.11  Resurrection of frozen cell stocks from liquid nitrogen 
Cell cryogenic vials were removed from liquid nitrogen and incubated in a water 
bath at 37°C until the cells were thawed. Vials were then transferred to a cell 
culture sterile flow hood where they were transferred to a T75 flask containing 10 
ml of the appropriate growth medium for the cell type as described in sections 
2.2.1.2 – 2.2.1.6 and maintained in an incubator at 37°C in an atmosphere of 5 or 
10% (v/v) CO2. The following day the medium was aspirated to remove dead cell 
debris and was replaced with fresh medium. 
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2.2.1.12  Preparation of 3T3-L1 and 3T3-L1 CAR fibroblasts, MEFs, 
HEK 293 and HeLa cells for freezing 
DMEM medium was aspirated from T75 flasks and 3 ml of trypsin (0.05% (v/v) in 
EDTA) was added to each flask. Flasks were then incubated at 37°C until the cells 
began to lift off. Trypsin was titurated over the surface of the flask until all of the 
cells were detached. 7 ml of the appropriate DMEM growth medium was added to 
each flask. The cell suspension was then transferred to a 15 ml universal tube. 
The trypsin/cell mix was centrifuged at 350 x g for 5 min and the trypsin 
supernatant aspirated. The cell pellet was then resuspended in 1 mL of freeze 
medium; FCS containing 10% (v/v) dimethyl sulphoxide (DMSO). The re-suspended 
pellet was then transferred into 1.8 ml polypropylene cryogenic tubes. The 
cryogenic tubes were then placed in a polycarbonate container and stored 
overnight at -80°C. The following morning the vials were transferred to liquid 
nitrogen and stored until required. 
2.2.1.13  Preparation of RAW 264.7 macrophages for freezing 
A cell lifter was gently passed over the surface of the flask to detach adherent 
cells into the medium. The cell suspension was then transferred to a 15 ml 
universal tube. The trypsin/cell mix was centrifuged at 350 x g for 5 min and the 
trypsin supernatant aspirated. The cell pellet was then re-suspended in 1 ml of 
freeze medium; FCS containing 10% (v/v) DMSO. The re-suspended pellet was then 
transferred into 1.8 ml polypropylene cryogenic tubes. The cryogenic tubes were 
then placed in a polycarbonate container and stored overnight at -80°C. The 
following morning the vials were transferred to liquid nitrogen and stored until 
required. 
2.2.2  Preparation of 3T3-L1 lysates 
3T3-L1 cells cultured in 6 well Falcon tissue culture dishes were preincubated for 
2 h in serum-free DMEM at 37°C before exchanging for 1 ml Krebs-Ringer 
phosphate (KRP) supplemented with 10 mM glucose per well. Test substances were 
then added to the wells for various durations at 37°C. The medium was removed 
and wells washed once with ice-cold PBS prior to addition of 0.1 ml lysis buffer to 
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each well on ice. The cell extract was scraped off using a cell lifter and transferred 
into pre-cooled 1.5 ml microcentrifuge tubes. The extracts were vortex-mixed and 
centrifuged (21,910 x g, 10 min, 4°C) on a bench top centrifuge. The supernatants 
were stored at -80°C. 
2.2.3  Preparation of MEF, HEK 293 and HeLa lysates 
MEFs, HEK 293 or HeLa cells cultured in 6 well Corning tissue culture dishes were 
preincubated for 2 h in serum-free DMEM at 37°C before adding test substances 
to the wells for various durations at 37°C. The medium was removed and wells 
washed once with ice-cold PBS prior to addition of 0.1 ml lysis buffer to each well 
on ice. The cell extract was scraped off using a cell lifter and transferred into pre-
cooled 1.5 ml microcentrifuge tubes. The extracts were vortex-mixed and 
centrifuged (21,910 x g, 5 min, 4°C) on a bench top centrifuge. The supernatants 
were stored at -80°C. 
2.2.4  Preparation of RAW 264.7 macrophage lysates 
RAW 264.7 macrophages cultured in 10 cm Corning tissue culture dishes were 
incubated in serum-free RPMI 1640 and test substances added to the dishes for 
various durations at 37°C. The medium was removed and wells washed once with 
ice-cold PBS prior to addition of 0.6 ml lysis buffer to each dish on ice. The cell 
extract was scraped off using a cell lifter and transferred into pre-cooled 1.5 ml 
microcentrifuge tubes. The extracts were vortex-mixed and centrifuged (21,910 x 
g, 5 min, 4°C) on a bench top centrifuge. The supernatants were stored at -80°C. 
2.2.5  Protein concentration determination 
Spectrophotometric analysis of cell lysates according to the Bradford method 
(Bradford 1976) was carried out at 595 nm in a spectrophotometer using disposable 
plastic cuvettes. Duplicates of 1 μg, 2 μg, 4 μg and 6 μg bovine serum albumin 
(BSA) were made up to 100 μl with H20 and utilised as reference standards. 
Lysates, analysed in duplicate, were diluted (1:10 – 3T3-L1 and HEK lysates; 1:5 – 
MEF, Hela and RAW 264.7 macrophage lysates) using distilled water. 5 μl of diluted 
lysate was then added to 95 μl of distilled water in a cuvette. To all samples and 
reference standards, 1 ml Bradford’s reagent was added and spectrophotometric 
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analysis performed in a WPA S2000 spectrophotometer within 10 min of reagent 
addition. The mean absorbance for each sample duplicate was calculated and the 
protein concentration determined by comparison to the calculated mean A595/μg 
BSA derived from the linear portion of the BSA reference standard curve. 
2.2.6  Immunoprecipitation 
2.2.6.1  Immunoprecipitation of AMPKα1/α2 or IKKβ from 3T3-L1 
adipocytes 
5 μl packed volume (per sample) of protein G-sepharose beads were washed 3 
times in screw cap microcentrifuge tubes using 1 ml of immunoprecipitation (IP) 
buffer (21,910 x g, 1 min at 4°C). AMPK1 (1 μg/sample) and AMPK2 (1 
μg/sample), or anti-IKK (1:50) were then added to the beads. 250 μl IP buffer 
was then added and mixed by rotation for 1 h at 4°C. The beads were pelleted 
(21,910 x g, 1 min at 4°C) and resuspended in IP buffer (25% v/v). In 1.5 ml 
microcentrifuge tubes, 3T3-L1 adipocyte lysate (200 μg) was added to 20 μl of the 
protein G-sepharose bead slurry pre-bound to either sheep anti-AMPK1/2 or 
rabbit anti-IKK antibody. The volume was made up to 250 μl with IP buffer and 
was mixed for 4 h at 4°C on a rotating mixer. The beads were then pelleted 
(21,910 x g, 1 min at 4°C) and the immunodeplete retained. The pellet was washed 
five times (21,910 x g, 1 min at 4°C) with 1 ml IP buffer. The pellets were stored 
at -20°C. 
2.2.6.2  Immunoprecipitation of JAK2 from 3T3-L1 adipocytes 
3T3-L1 adipocyte lysate (200 μg) was added to rabbit anti-JAK2 antibody (1:100), 
and made up to 250 μl with IP buffer and mixed by rotation overnight at 4°C in 
1.5 ml screw cap microcentrifuge tubes. The following morning, 5 μl packed 
volume (per sample) of protein A-sepharose beads were washed 3 times (21,910 x 
g, 1 min at 4°C) with 1 ml IP buffer. The beads were then resuspended in IP buffer 
(50% v/v). 20 μl of the protein A-sepharose bead slurry was added to the 
lysate/antibody mixture which was then mixed by rotation for 3 h at 4°C. The 
beads were then pelleted (21,910 x g, 1 min at 4°C) and the immunodeplete 
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retained. The pellet was washed five times (21,910 x g, 1 min at 4°C) with 1 ml 
IP buffer. The pellets were stored at -20°C.  
2.2.7  SDS-Polyacrylamide Gel Electophoresis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using 1.5 mm thick vertical slab gels containing between 8 and 12% 
acrylamide. Slab gels were prepared using Bio-Rad mini-Protean III gel units, with 
a stacking gel of approximately 2 cm deep. The stacking gel consisted of 5% (v/v) 
acrylamide/0.136% (v/v) bisacrylamide in 125 mM Tris-HCl, pH 6.8, 0.1% SDS, 
polymerised with 0.1% (w/v) ammonium peroxidisulphate (APS) and 0.05% (v/v) 
tetramethylethylenediamine (TEMED). Cell lysates were mixed 3:1 with 4 X SDS-
containing sample buffer and heated to 95°C in a heating block for 5 min prior to 
separation by SDS-PAGE on Tris buffered gels. Prestained broad range (6-175 kDa) 
protein markers were used as a standard. Gels were electrophoresed using the 
Bio-Rad Protean III system at a constant voltage of 80 V for stacking and 180 V 
through the separating gel. Gels were electrophoresed until the tracking dye had 
migrated to the bottom of the gel and good separation of the molecular weight 
markers had been obtained. 
2.2.8  Western Blotting of Proteins 
2.2.8.1  Electrophoretic transfer of proteins from gels onto 
nitrocellulose membranes 
Proteins were separated by SDS-PAGE as previously described (2.2.7). The gels 
were removed from the plates and placed on top of an equal-sized sheet of 
nitrocellulose (0.45 μm pore size), pre-wetted with transfer buffer and then 
placed between 2 layers of 3 mm filter paper also pre-wetted with transfer buffer. 
The ‘sandwich’ was then inserted between the plates of the gel holder cassette 
and transfer was performed using a Bio-Rad mini Protean III trans-blot 
electrophoretic transfer cell at a constant current of 40 mA overnight or at 60 V 
for 2.5 h. The nitrocellulose membranes were then removed from the transfer 
cassette and the efficiency of transfer determined by the presence and intensity 
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of pre-stained molecular weight standards. Membranes were also briefly stained 
with Ponceau to assess equal loading of protein. 
2.2.8.2  Blocking of membranes and probing with primary 
antibodies 
Non-specific sites on nitrocellulose membranes were blocked by incubation with 
shaking in phosphate-buffered saline (PBS)/5% (w/v) milk for 30 min at room 
temperature. After washing (3 x 5 min) the membrane in PBS, the primary 
antibody was applied to the blot and incubated, with shaking, overnight at 4°C in 
phosphate-buffered saline tween (PBST)/5% (w/v) milk or PBST/5% (w/v) BSA or 
PBST/50% (v/v) Odyssey® blocking buffer. 
2.2.8.3  Secondary antibodies and immunodetection of proteins 
using western blotting and the ECL detection system 
Following an overnight incubation in primary antibody, the membranes were 
washed (3 x 5 min) in PBST prior to incubation, with shaking, for 1 h at room 
temperature with the appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibody in PBST/5% (w/v) milk. The membranes were then washed (2 
x 5 min high salt (0.5 M NaCl) PBST, 2 x 5 min PBST, 1 x 5 min PBS). 
Equal volumes of ‘detection reagent 1’ and ‘detection reagent 2’ were mixed and 
the membranes, prepared as described in 2.2.7.2, were immersed in the mix with 
shaking for 60 seconds. The detection reagents were then removed, membranes 
wrapped in cling-film and exposed to Kodak film. The films were developed using 
the X-OMAT processor. 
2.2.8.4  Secondary antibodies and immunodetection of proteins 
using western blotting and the LI-COR detection system 
Following an overnight incubation in primary antibody, the membranes were 
washed (3 x 5 min) in PBST prior to incubation, with shaking, for 1 h at room 
temperature with the appropriate fluorescent IRDye®-conjugated secondary 
antibody in PBST/50% (v/v) Odyssey® blocking buffer. The membranes were then 
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washed (3 x 5 min) in PBST followed by (1 x 5 min) PBS. If required, membranes 
were initially washed (2 x 5 min) in high salt (0.5 M NaCl) PBST. 
2.2.8.5  Stripping of nitrocellulose membranes 
Nitrocellulose membranes were incubated in stripping buffer (2% (w/v) SDS, 63 
mM Tris-HCL (pH 6.8), 0.7% (v/v) -mercaptoethanol) at 50°C for 30 min with 
shaking. Membranes were then washed (3 x 5 min) in PBST followed by (1 x 5 min) 
PBS. 
2.2.8.6  Densitometric quantification of protein bands 
The antibody-detected bands on the developed film were scanned on a Mercury 
1200c scanner, using Adobe Photoshop software. The antibody-detected bands 
detected using the LI-COR Odyssey® Sa system were exported into Adobe 
Photoshop software. The intensity of the immune-detected protein bands was 
measured using ImageJ software. 
2.2.9  2-deoxy-D-glucose uptake assay 
Glucose uptake was measured by the uptake of 2-[3H]-deoxy-D-glucose according 
to the method of Gibbs (Gibbs, Lienhard, and Gould 1988). 3T3-L1 adipocytes were 
cultured on 12 well plates and incubated at 37°C in 1 ml/well of serum free DMEM 
for 2 h prior to use. Cells were subsequently incubated at 37°C in 475 μl/well of 
Krebs-Ringer phosphate (KRP) for 1 h and test substances added to the plates for 
various durations at 37°C. When longer incubations were required, test substances 
were added directly to serum-free DMEM with no prior serum starvation. Cells 
were then washed and incubated in KRP for 20 min prior to insulin stimulation. 
The cells were then stimulated with 10 nM insulin for 15 min. Glucose transport 
was initiated by the addition of 2-[3H]-deoxy-D-glucose (final concentration 50 
μmol/l and 1 μCi/ml) to each well. The reaction was terminated after 3 min by 
inverting the plates rapidly to remove the incubation buffer, and then by 
immersing them sequentially in 2 x 2 L and 1 L of ice-cold PBS. After air drying 
the plates for 1 h, 0.5 ml of 1% (v/v) Triton X-100/H20 was added to the cell 
monolayers for 24 h. A Beckman Multi-Purpose scintillation counter LS6500 was 
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used to measure 2-[3H]-deoxy-D-glucose uptake. 5 ml of scintillation fluid was 
used per sample. Non-specific association of radioactivity was determined in 
parallel incubations in the presence of 10 μmol/l cytochalasin B. 
2.2.10  RNA extraction and reverse transcription polymerase 
chain reaction (RT-PCR) 
2.2.10.1  Extraction of RNA from 3T3-L1 adipocytes 
3T3-L1 cells grown in 10 cm Falcon cell culture dishes were incubated in serum-
free DMEM at 37°C before test substances were added and incubated for various 
durations at 37°C. The media was removed and total RNA was isolated according 
to the RNeasy Mini Kit (Qiagen) centrifugation protocol, utilising 15 second 
centrifugation steps (13,226 x g) in a bench top centrifuge) for the lysate 
application and wash steps, discarding the flowthrough between each step. 
Briefly, cells were lysed by addition of 0.6 ml lysis (RLT) buffer to each dish and 
collected with a cell scraper. Lysates were homogenised by passing through a 
sterile 23-guage needle and syringe 10 times. Each lysate was mixed gently with 
an equal volume of 70% (v/v) ethanol and applied to separate RNeasy mini columns 
in 700 μl aliquots until the entire lysate had been passed over the column. Columns 
were washed with 350 μl of wash buffer 1 (RW1) twice and transferred to fresh 2 
ml collection tubes prior to addition of 2 x 500 μl wash buffer 2 (RPE). After 
discarding the flowthrough, columns were centrifuged at 13,226 x g for 2 min to 
dry the RNeasy silica gel membrane and to eliminate any chance of accidental 
carryover of buffer RPE. Columns were transferred to fresh, 1.5 ml collection 
tubes and RNA was eluted with 50 μl RNase-free water by centrifuging at 13,226 
x g for 1 minute. The RNA concentration was determined at A260 in a Nanodrop 
spectrophotometer (Thermo Scientific) prior to storage at -80°C. 
2.2.10.2  Reverse transcription 
For cDNA synthesis, total RNA extracted from 3T3-L1 adipocytes was reverse 
transcribed using the ImProm-II™ Reverse Transcription System (Promega) and a 
thermocycler. Per reaction, ~0.1–1 μg DNase-free RNA was added to 5x reaction 
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buffer, 6 mM MgCl2, 0.5 mM dNTPs, 20U recombinant RNasin ribonuclease 
inhibitor, 1 μl random primers and 1 μl ImProm-II™ reverse transcriptase. RNase-
free water was used to make up the reaction volume to 20 μl. For initial ‘no RT’ 
controls, the reverse transcriptase was replaced with 1 μl RNase-free water. 
Synthesis of cDNA was initiated by a primer extension step (5 min at 25°C), 
followed by a cDNA synthesis step (1 h at 42°C). The reverse transcriptase was 
inactivated during a reaction termination step (15 min at 70°C). Resulting cDNA 
was stored at -20°C. 
2.2.10.3  PCR and gel resolution of PCR products 
For amplification of gene transcripts, 2 μl of cDNA was mixed with a PCR 
mastermix (see below), and gene-specific primers to the transcript of interest 
were added. The PCR mastermix contained 1x Taq buffer, 0.25 mM dNTPs, 1.5 mM 
MgCl2, 0.5 μM primer mix, 1 µl Taq DNA polymerase, and RNase-free water to a 
total volume of 50 μl. PCR reactions were carried out in a thermocycler under the 
following conditions: 
. 
 94°C     3 min 
 94°C     30 s 
 55°C     30 s 
 72°C     90 s 
 72°C     10 min 
 4°C       Hold 
 
18S Forward Sequence: 5’-ACCGCGGTTCTATTTTGTTG 
18S Reverse Sequence: 5’-AGTCGGCATCGTTTATGGTC 
Mouse MCP-1 Forward Sequence: 5’-AGCCAACTCTCACTGAAGCC 
Mouse MCP-1 Reverse Sequence: 5’-CATTCAAAGGTGCTGAAGACC 
Analysis of PCR products was performed on 1% (w/v) agarose gels, resolved for 30 
minutes at 100 V, using a Mini-Sub Cell GT gel system (Bio-Rad). PCR products 
30 Cycles 
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were mixed 5:1 with 6x DNA loading buffer, and equal volumes (10 μl) of PCR 
products were applied to the agarose gels. The gels were then visualised by 
ethidium bromide staining. 
2.2.11  Plasmid DNA transformation and Purification 
2.2.11.1  Plasmid DNA transformation 
A JAK2 V617F plasmid (James et al. 2005) was a kind gift from Dr William Sands 
(University of Glasgow) and was maintained and propagated in TOP10 (Invitrogen) 
E. coli. Chemically-competent cells were defrosted on ice for 15 min. DNA was 
added (1-10 μl) and the cells incubated on ice for a further 15 min. The cells were 
then heat-shocked for 1 min at 42°C before recovering on ice for a further minute. 
SOC media (250 μl) was added and the tubes incubated at 37°C for at least 1 h 
with shaking. After incubation, the mixture was plated onto agar plates containing 
ampicillin. The plates were inverted and incubated overnight at 37°C. 
2.2.11.2  Small-scale DNA preparations from E.coli (Miniprep) 
A single colony from a fresh bacterial transformation was used to inoculate 5 ml 2 
YT media (1.6% (w/v) tryptone, 1% (w/v) yeast extract. 0.5% (w/v) NaCl) 
containing 0.1 mg/ml ampicillin, and the culture grown overnight with shaking at 
37°C. DNA purification was carried out using Promega Wizard® Plus SV Miniprep 
Kit. The DNA concentration was determined at A260 using a Nanodrop 
spectrophotometer (Thermo Scientific) prior to storage at -20°C. 
2.2.11.3  Transfection of HEK 293 or Hela cell lines with JAK2 
V617F plasmid 
HEK 293 or Hela cells were seeded in 6 well Corning tissue culture dishes and 
grown to 90-95% confluency before the medium was replaced with 500 µl/well of 
growth medium. For each well of cells to be transfected, 4 µg JAK2 V617F or 
empty pRK5 plasmid DNA was diluted in Opti-MEM® I Reduced Serum Media and 
complexed with Lipofectamine 2000 (Invitrogen) in a 1:1 (w/v) ratio. Following 
incubation, the DNA-Lipofectamine 2000 complex was added to appropriate wells 
Sarah Mancini, 2014   Chapter 2, 100 
and incubated at 37°C in a humidified atmosphere of 5% (v/v) CO2 for 48h prior to 
treatment. Non-specific transfection was determined in parallel incubations in the 
presence of 4 µl/well Lipofectamine 2000. 
2.2.12 Recombinant adenoviruses 
2.2.12.1  AMPK adenoviruses 
Adenoviruses encoding a dominant negative AMPK mutant (Ad.1-DN, full-length 
AMPKα1 containing a D157A mutation), and a constitutively active AMPK mutant 
(Ad.1312, residues 1-312 of AMPK1 containing a T172D mutation) have been 
described previously (Woods et al. 2000) and were a generous gift from Dr F. 
Foufelle, Centre Biomédical des Cordeliers, Paris. 
2.2.12.2  Adenovirus propagation 
HEK 293 cells in T75 flasks were cultured in DMEM growth media (see 2.2.1.3) and 
passaged at 70-80% confluency (see 2.2.1.8). Each T75 flask was split into 5 x T150 
flasks. Once 20 x T150 flasks were obtained, and grown to 70-80% confluency, 
recombinant adenoviruses were propagated in the HEK 293 cells. Detached cells 
were then pelleted in 50 ml falcon tubes (6 min at 604 x g). 100 mL of the 
supernatant was retained to infect more HEK 293 cells, and the pellets pooled and 
resuspended in 10 ml of sterile PBS. 
2.2.12.3  Adenovirus purification 
In order to lyse the HEK 293 cells containing the adenovirus particles, 10 mL of 
Arklone P (trichlorotrifluroethane) was added to the HEK 293 cell suspension 
(2.2.10.2) and mixed gently by inverting the tube for about 10 seconds. The 
mixture was then centrifuged at 340 x g for 15 min. The upper layer containing 
virus was separated from cell debris (interface) and the Arklone P layer (bottom 
layer). The upper layer was transferred to a clean 50 ml Falcon tube. 10 ml PBS 
was added to the left-over Arklone P layer, which was mixed and centrifuged as 
before, and the upper layer collected and added to the upper layer previously 
obtained. 
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2.5 ml sterile CsCl dissolved in Tris/EDTA (5 mM Tris-HCl, 1 mM EDTA pH 7.8) at a 
density of 1.33 g/ml was added to a sterile centrifuge tube. This was underlaid 
with 1.5 ml of sterile 1.45 g/ml CsCl. The virus layer was loaded on the CsCl 
gradient and centrifuged at 100,000 x g in a SW40 rotor using an Optima™ XL-80K 
ultracentrifuge at 8°C for 90 min. The tube was then punctured just below the 
virus band with a 21 guage needle, and withdrawn into a 2.5 ml syringe. The virus 
was transferred to a 10 micron Slide-A-Lyzer cassette and dialysed against cold 
Tris/EDTA buffer at 4°C overnight, and against fresh buffer containing 10% (v/v) 
glycerol for a further 2 h the following morning. The purified virus was removed 
and stored at -80°C. 
2.2.12.4  Adenovirus titration 
The Quick Titer™ Adenovirus Titer Immunoassay kit was used to titre the virus. 
Briefly, HEK cells were plated onto a 24 well plate. After 1 h 100 μl of 10-3, 10-4, 
10-5 and 10-6 diluted virus solutions were added to the wells. The cells were then 
incubated for 48 h at 37°C, 5% (v/v) CO2. To fix the cells the media was removed 
and replaced with 0.5 ml cold methanol and incubated for 20 min at 20°C. Cells 
were washed three times in PBS containing 1% (w/v) BSA. 250 μl of anti-Hexon 
antibody was added to each well and incubated for 1 h at room temperature. The 
cells were then washed 3 times in PBS prior to the addition of 250 μl of HRP-
conjugated secondary antibody to each well and incubated for 1 h at room 
temperature.  The cells were then washed five times in PBS. 250 μl of 
diaminobenzidine (DAB) was added to each well and incubated for 10 min at room 
temperature. DAB was then aspirated and the cells were washed twice with PBS. 
1 ml of PBS was added to each well. The positive stained cells were counted for a 
minimum of five separate fields per well using a light microscope and 10X 
objective. Calculation of adenovirus titre was determined (Infectious Units/ml). 
2.2.12.5  3T3-L1 adipocyte adenovirus infection 
6 days post-differentiation, 500 μl of serum-free DMEM was added to 3T3-L1 CAR 
cells cultured on 6 well plates. Adenovirus was added (Ad.Null and Ad.α1-DN: 600 
IFU/cell; Ad.GFP and Ad.α1312: 100 IFU/cell) to the dishes and incubated for 4 h 
at 37°C in a humidified atmosphere of 10% (v/v) CO2. 500 μl of DMEM / 20% FCS 
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was added to the cells for a further 48 h before experiments were conducted, cell 
lysates prepared (see section 2.2.2) and conditioned medium collected (see 
section 2.2.13). 
2.2.12.6  MEF adenovirus infection 
Adenovirus encoding human wild-type p53 (Riccioni et al. 1998) was a kind gift 
from Prof Andrew Baker. At 70-80% confluency, 500 μl/well of serum-free DMEM 
was added to MEFs cultured on 6 well plates. Adenovirus was added (Ad.Null and 
Ad.p53: 100 IFU/cell) to the dishes and incubated for 4 h at 37°C in a humidified 
atmosphere of 5% (v/v) CO2. DMEM / 20% FCS (500 μl/well) was added to the cells 
for a further 24 h before experiments were conducted. 
2.2.13  Stimulation of 3T3-L1 CAR cytokine/chemokine production 
3T3-L1 CAR adipocytes grown in 6-well Falcon plates infected with adenovirus (see 
section 2.2.12.5) were incubated in serum-free DMEM and stimulated with 10 
ng/ml IL-1 or IL-6 and sIL-6R (5 ng/ml and 25 ng/ml, respectively) for 6 h with 
or without 30 min preincubation with 300 μM A769662. After this incubation 
period, cells were washed three times in serum-free DMEM and incubated with 0.4 
ml/well SF-DMEM for 1 h at 37°C, 10% (v/v) CO2. After 1 h, the conditioned serum 
free DMEM was collected and stored at -20°C. 
2.2.14  Stimulation of RAW 264.7 macrophage 
cytokine/chemokine production 
RAW 264.7 macrophages grown in 10 cm diameter Corning dishes were incubated 
in serum-free RPMI 1640 medium and stimulated with 1 μg/ml lipopolysaccharide 
(LPS) for 6 h with or without 30 min preincubation with 100 μM A769662. After this 
incubation period, cells were washed three times in serum free RPMI 1640 and 
incubated with 0.4 ml/well serum-free RPMI 1640 for 1 h at 37°C, 5% (v/v) CO2. 
After 1 h, the conditioned serum-free RPMI 1640 was collected and stored at -
20°C. 
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2.2.15  Analysis of 3T3-L1 CAR / RAW 264.7 macrophage cytokine 
and chemokine production 
Conditioned medium from infected 3T3-L1 CAR adipocytes and RAW 264.7 
macrophages (see sections 2.2.13 and 2.2.14) was used for cytokine and 
chemokine analysis with a Multiplex Bead Immunoassay (mouse cytokine 20-Plex 
panel, Invitrogen), testing for the presence of murine basic-FGF, GM-CSF, IFN-, 
IL-1, IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IL-13, IL-17, IP-10, KC, 
MCP-1, MIG, MIP-1, TNF- and VEGF. This assay allows the simultaneous 
detection of several molecules bound specifically to beads coated with different 
antibodies. These beads have distinct spectral properties and are linked to 
fluorophores, which permit the Luminex® 100™ detection system to distinguish 
between different beads, and thus, different antibody-bound molecules, while 
simultaneously measuring the quantity of associated fluorophore. 
The assay was carried out following manufacturer’s instructions, but antibodies 
and enzyme substrates were used at half the recommended concentration. All 
steps were carried out at room temperature and in the dark. Briefly, 50 μl per 
sample of conditioned medium was added to 50 μl assay diluent and 50 μl 
incubation buffer, and incubated with primary antibody-coated beads for 2 h with 
shaking. After two washes with wash solution, biotinylated detector antibody was 
added for 1 h with agitation. Two further washes preceded incubation with 
streptavidin-RPE for 30 min. Prior to detection in a Bio-Plex system (Bio-Rad), the 
assay was washed three times with wash solution. Serial dilutions of cytokine and 
chemokine standards were included in duplicate as a reference, from which the 
cytokine and chemokine concentrations in each sample were then calculated. 
2.2.16 TCA precipitation 
3T3-L1 adipocytes grown in 10 cm diameter Falcon dishes were incubated in 
serum-free DMEM and stimulated with TNF- (10 ng/ml) or IL-6/sIL-6R (5 ng/ml; 
25 ng/ml) for 6 h with or without 30 min preincubation with 300 M A769662. The 
supernatant was centrifuged (1500 rpm, 15 min) to remove dead cells. 50 l 
sodium deoxycholate (0.15% w/v) was added per ml of supernatant and incubated 
for 5 min at room temperature before addition of 100 l trichloroacetic acid (TCA) 
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(72% w/v) per ml of supernatant. After 20 min on ice, the mixture was centrifuged 
(21,910 x g, 15 min at 4°C) before aspirating the supernatant. Pellets were 
resuspended in 1 ml chilled acetone and centrifuged (21,910 x g, 15 min at 4°C). 
Supernatant was removed and pellets air dried before resuspending in 60 l 1x 
SDS-PAGE sample buffer. Resuspended pellets were stored at -20°C. 
2.2.17  Oil Red O staining of 3T3-L1 adipocytes 
3T3-L1 adipocytes were grown on glass coverslips and differentiated as described 
in section 2.2.1, but in the absence of troglitazone. Duplicate coverslips were 
incubated with either A769662 or DMSO from the point of differentiation until cells 
were fixed and stained at various intervals. At appropriate time points, 
differentiation medium was aspirated and cells were incubated in 10% (v/v) 
formalin for 5 min, which was replaced with fresh formalin for 1h at room 
temperature in the dark. After 1 h, coverslips were washed once in 60% (v/v) 
isopropanol and left to dry completely. Oil red O working solution was prepared 
((60% (v/v) Oil red O stock (8.57 mM Oil red O (Sigma) in isopropanol) in dH2O) and 
placed in wells for 10 min, before coverslips were washed four times with dH20 
and left to dry. Dry coverslips were then dipped in Mayers Hematoxylin (193.64 
mM aluminium potassium alum, 16.54 mM hematoxylin, 2.02 mM sodium iodate, 
2% (v/v) glacial actetic acid) then dipped in 3% (v/v) ammonium hydroxide, pH 10 
in water, for 10 s. Coverslips were then mounted onto slides using Immumount 
adhesive and images captured using an Axiovision light microscope. 
2.2.18  Confocal microscopy and staining 
3T3-L1 adipocytes and 3T3-L1 CAR adipocytes were grown and differentiated on 
glass coverslips using the method described previously (see section 2.2.1.). 3T3-
L1 CAR adipocytes were infected with adenoviruses as described in section 
2.2.12.5 and utilised on Day 8 post-differentiation. 3T3-L1 adipocytes were 
utilised between day 8 to day 12 post-differentiation. Cells were stimulated with 
IL-1 (10 ng/ml for 15 min) with or without 30 min preincubation with A769662 
(300 μM). Cells were then washed twice with PBS and fixed in 3% (w/v) 
paraformaldehyde at room temperature for 20 min. Coverslips were then washed 
twice in PBS and twice in 20 mM glycine in PBS to quench paraformaldehyde. Cells 
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were permeabilised in permeabilisation media (2% (w/v) BSA, 0.1% (w/v) Saponin, 
20 mM glycine, PBS) for 20 min. Primary antibody was added in permeabilisation 
media for 45 min. Coverslips were then washed in permeabilisation media four 
times and the secondary antibody, also in permeabilisation media, was applied 
and the coverslips were incubated for 30 min in the dark. Cells were washed four 
times in permeabilisation media, and then washed once in PBS before being 
mounted on microscope slides using Immunomount adhesive. Slides were left 
overnight at 4°C before being visualised using a Ziess LSM exciter laser scanning 
microscope. 
2.2.18.1  Image acquisition and quantification of fluorescence 
intensity 
Immunolabelled samples were analysed using a Ziess LSM Exciter laser scanning 
microscope and LSM imaging software. Cells were visualised with a Plan-
Apochromat X63/1.4 Oil DIC objective and the relevant filter. Quantification of 
nuclear fluorescence was assessed using ImageJ to obtain values corresponding to 
density from multiple points within the nucleus and calculating the mean density 
of nuclear fluorescence for each individual cell. A minimum of 50 cells were 
analysed for each treatment in each experiment, and an average taken. 
2.2.19  Isolation of adipocytes from rat adipose 
Male WKY rats were housed under standard conditions with free access to food 
and water. At approximately 12 weeks of age, mice were sedated and sacrificed 
by cardiac puncture. Epididymal adipose tissue was harvested and primary 
adipocytes isolated by digestion with collagenase type I (Worthington). Adipocyte 
preparation was performed in collaboration with Dr Silvia Bijland, University of 
Glasgow. Cells (10% v/v cytocrit in 1% (w/v) BSA, 0.2 M adenosine, 10 mM glucose 
in KRH) were incubated in either IL-1 (10 ng/ml for 15 min), TNF- (10 ng/ml for 
15 min) or IL-6/sIL-6R (5 ng/ml; 25 ng/ml, respectively, for 1 h) with or without 
30 min preincubation with A769662 (300 μM). Lysates were made and separated 
by SDS-PAGE and immunoblotted for proteins of interest. 
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2.2.20  Murine adipose tissue analysis 
Female AMPK1-/- and wild-type sv129 mice were housed under standard 
conditions with free access to food and water. At approximately 4 months of age, 
mice were sacrificed by cervical dislocation. Organs were harvested (omental, 
subcutaneous and gonadal adipose). Lysates were made and separated by SDS-
PAGE and immunoblotted for proteins of interest. Sections were also taken for 
immunohistological analysis of adipocyte cell size. 
Omental and subcutaneous adipose tissue were fixed (10 % zinc formalin) for 24 
h, and transferred to ethanol before being embedded in paraffin and sliced to 
produce 5 μm sections using a microtome. Sections were heated at 60°C for 35 
min to soften before staining with haematoxylin and eosin. Briefly, sections were 
deparaffinised in Xylene then rehydrated through graded ethanol to water. 
Sections were then stained with Harris haematoxylin for 2 min followed by washing 
in water. Background staining was reduced by briefly submerging sections in 1% 
(v/v) HCl in 70% (v/v) ethanol followed by washing in Scotts tap water substitute 
for 30 s. Sections were counter stained in 1% (w/v) Eosin for 2 min before washing 
in water. Sections were then dehydrated through graded ethanol and then 
incubated in Xylene (3 min x 2). Tissue sections were mounted on coverslips using 
DPX mountant and images captured using an Axiovision light microscope. 
2.2.21  Statistical Analysis 
Results are expressed as mean ± SEM. Statistically significant differences were 
determined using a two-tail t-test, or one or two-way ANOVA where appropriate, 
with p < 0.05 as significant. 
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 Chapter 3 – The effect of AMPK on TNF- / 
IL-1-stimulated proinflammatory signalling 
3.1 Introduction 
3.1.1 TNF- and IL-1 signalling to NFB and MAP kinases 
TNF- and IL-1 are proinflammatory cytokines which are secreted primarily by 
macrophages and monocytes, and have been reported to be elevated in WAT in 
obese states (Gustafson 2010). These cytokines trigger proinflammatory effects 
via simultaneous activation of the canonical NFB and MAPK intracellular signalling 
cascades (see 1.2.2.1). Briefly, TNF- or IL-1 binding its cognate receptor 
stimulates an increase in IB kinase (IKK) activity, which in turn phosphorylates 
IB. Under basal conditions, IB is bound to the transcription factor NFB in the 
cytoplasm; however upon phosphorylation by IKK, NFB is released and 
translocates to the nucleus. The MAPK pathway is activated in parallel following 
cytokine stimulation, leading to the phosphorylation and activation of JNK, ERK 
and p38 MAPK. These pathways stimulate the transcription of genes involved in 
inflammation (e.g. IL-1, TNF-, IL-6 and MCP-1), survival (e.g. cFLIP) and 
adhesion (e.g. E-selectin, VCAM-1). 
3.1.2 Regulation of proinflammatory signalling by AMPK 
AMPK has been suggested to inhibit proinflammatory signalling in different cell 
types, including endothelial cells (Ewart, Kohlhaas, and Salt 2008) and 
macrophages (Sag et al. 2008); however the effect of AMPK activation on the MAPK 
and NFB signalling pathways in adipocytes was poorly characterised. Prior to the 
beginning of this study, AMPK activation had been reported to suppress cytokine-
stimulated NFB activation in multiple cell types, including cultured endothelial 
cells (Cacicedo et al. 2004), macrophages (Yang et al. 2010), neutrophils (Zhao et 
al. 2008), microglial cells, astrocytes (Giri et al. 2004) and hepatic stellate cells 
(Caligiuri et al. 2008). Only a very small number of studies had previously 
examined inhibition of MAPK by AMPK. Berberine was reported to inhibit LPS-
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stimulated phosphorylation of JNK, ERK1/2 and p38 MAPK in macrophages in an 
AMPK-dependent manner (Jeong et al. 2009), while elevated JNK phosphorylation 
was observed in aortic endothelial cells of AMPK2-/- mice and HUVECs with an 
siRNA-mediated ablation of AMPK1 or 2 (Dong et al. 2010). Furthermore, little 
was known about the mechanism by which AMPK might suppress proinflammatory 
cytokine signalling; however it was suggested that AMPK may inhibit the NFB 
signalling pathway at the level of IKK, as metformin has been reported to reduce 
TNF--stimulated IKK/ S180/181 phosphorylation in HUVECs in an AMPK-
dependent manner (Huang et al. 2009). 
3.1.3 Aims 
While AMPK has been reported to have anti-inflammatory effects in a few different 
cell types, its role in adipocytes has not yet been fully investigated. In the current 
study the ability of AMPK to modulate cytokine-stimulated MAPK and NFB 
signalling pathways in adipocytes was assessed. Furthermore, the effect of AMPK 
activation on the nuclear translocation of transcription factor NFB was 
determined. Finally, the molecular mechanism by which AMPK may elicit these 
anti-inflammatory effects was investigated. 
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3.2 Results 
3.2.1 AMPK activation in 3T3-L1 adipocytes 
To examine whether TNF- altered AMPK activity in 3T3-L1 adipocytes, cells were 
incubated with A769662 (a specific AMPK activator), Compound C (AMPK inhibitor) 
or TNF- and the extent of AMPK Thr172 phosphorylation was determined by 
western blotting analysis of 3T3-L1 adipocyte lysates. 
Incubation of 3T3-L1 adipocytes with A769662 (Fig. 3.1A) caused a significant (p < 
0.05) increase, compared to the basal level, in AMPK Thr172 phosphorylation. This 
was significantly inhibited following preincubation with Compound C (p < 0.001). 
Incubation of 3T3-L1 adipocytes with TNF- did not alter AMPK Thr172 
phosphorylation compared to the basal level when data were normalised to 
A769662 (Fig. 3.1A); however TNF- was found to cause a significant (p < 0.01) 
reduction in AMPK Thr172 phosphorylation compared to the basal level when data 
were normalised to vehicle (Fig. 3.1B). 
3.2.2 Effect of AMPK activation by A769662 on IL-1  and TNF- - 
stimulated MAPK activation in 3T3-L1 adipocytes 
To determine whether AMPK activation influenced MAPK stimulation by 
proinflammatory stimuli, MAPK activation parameters in response to IL-1 or TNF-
 in the presence or absence of A769662 were assessed in 3T3-L1 adipocytes. The 
extent of p38, ERK1/2 and JNK MAPK phosphorylation was assessed as a measure 
of activation by western blotting using phosphorylation site-specific antibodies. 
Incubation of 3T3-L1 adipocytes with IL-1 in the absence of A769662 (Fig. 3.2) 
caused a significant (p < 0.05) increase, compared to the basal level, in p38 MAPK 
T180/Y182 phosphorylation after 3 min, peaking at 5 and 10 min (p < 0.001). 
Statistically significant (p < 0.01) reductions in p38 MAPK phosphorylation were 
observed at 5 and 10 min in the presence of A769662 compared to IL-1 treatment 
alone. 
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Figure 3-1: Effect of A769662 and Compound C on AMPK phosphorylation 
3T3-L1 adipocytes were incubated with TNF- (10 ng/ml) for 15 min following 
preincubation for 30 min in the presence or absence of A769662 (300 M) and 60 
min in the presence or absence of Compound C (60 M) and lysates prepared. 
Lysates were resolved by SDS-PAGE and subjected to immunoblotting with the 
antibodies indicated. (A) & (B) Quantification of AMPK Thr172 phosphorylation 
was determined by comparison with total AMPK using densitometric analysis (A) 
Data shown represent the mean ± SEM % A769662-stimulated AMPK 
phosphorylation of six independent experiments. †p < 0.05 (one-way ANOVA), 
increase in AMPK Thr172 phosphorylation, relative to vehicle. ***p < 0.001 (one-
way ANOVA), reduction in AMPK1 Thr172 phosphorylation, relative to the 
absence of Compound C. (B) Data shown represent the mean ± SEM % vehicle AMPK 
phosphorylation of three independent experiments. **p < 0.01 (two-tail t-test), 
reduction in AMPK Thr172 phosphorylation, relative to vehicle. (C) 
Representative western blot. 
A B 
C 
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Incubation of 3T3-L1 adipocytes with TNF- in the absence of A769662 (Fig. 3.3) 
caused a significant (p < 0.01) increase, compared to the basal level, in p38 MAPK 
T180/Y182 phosphorylation after 5, 10 and 360 min. Preincubation with A769662 
caused significant reductions in p38 MAPK phosphorylation after 3 min (p < 0.05) 
and 360 min (p < 0.01), compared to TNF- treatment alone. A statistically 
significant (p < 0.05) reduction in basal p38 MAPK phosphorylation was observed 
following A769662 treatment. 
Incubation of 3T3-L1 adipocytes with IL-1 in the absence of A769662 (Fig. 3.4) 
caused a significant increase, compared to the basal level, in ERK1/2 T202/Y204 
phosphorylation after 10 and 15 min (p < 0.001 and p < 0.01, respectively). A 
statistically significant (p < 0.01) reduction in ERK1/2 phosphorylation was 
observed at 10 min in the presence of A769662 compared to IL-1 treatment alone. 
A statistically significant (p < 0.05) reduction in basal ERK1/2 T202/Y204 
phosphorylation was observed following A769662 treatment. Incubation of 3T3-L1 
adipocytes with TNF- in the absence of A769662 (Fig. 3.5) caused a significant (p 
< 0.05) increase, compared to the basal level, in ERK1/2 T202/Y204 
phosphorylation after 10 and 360 min. Preincubation with A769662 caused 
significant reductions in ERK1/2 T202/Y204 phosphorylation in ERK1 after 3, 10 (p 
< 0.05) and 360 (p < 0.01) min, and in ERK2 after 3 (p < 0.05), 10 (p < 0.01) and 
360 (p < 0.001) min compared to TNF- treatment alone. A statistically significant 
(p < 0.05) reduction in basal ERK1/2 T202/Y204 phosphorylation was observed 
following A769662 treatment. 
Incubation of 3T3-L1 adipocytes with IL-1 in the absence of A769662 (Fig. 3.6) 
caused a significant increase, compared to the basal level, in JNK T183/Y185 
phosphorylation (54 and 46 kDa isoforms) after 15 and 30 min (p < 0.001 and p < 
0.01, respectively) and JNK 54 kDa subunit phosphorylation after 10 min (p < 0.01). 
A statistically significant (p < 0.05) reduction in phosphorylation of both JNK 
subunits was observed at 15 min in the presence of A769662 compared to IL-1 
treatment alone. TNF- displayed a tendency to increase JNK T183/Y185 
phosphorylation (Fig. 3.7) in 3T3-L1 adipocytes, compared to the basal level, 
although this did not reach statistical significance. Similarly, A769662 displayed a 
tendency to reduce TNF--stimulated JNK T183/Y185 phosphorylation, although 
this did not reach statistical significance. 
Sarah Mancini, 2014   Chapter 3, 112 
 
 
   
 
 
 
Figure 3-2: Effect of A769662 on IL-1-stimulated p38 MAPK phosphorylation 
3T3-L1 adipocytes were incubated with IL-1 (10 ng/ml) for various durations 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated. (A) Quantification of p38 MAPK 
T180/Y182 phosphorylation was determined by comparison with total p38 MAPK 
using densitometric analysis. Data shown represent the mean ± SEM % maximum 
p38 phosphorylation of three independent experiments. †p < 0.05, †††p < 0.001 
(two-way ANOVA), increase in p38 MAPK T180/Y182 phosphorylation, relative to 
vehicle.  **p < 0.01 (two-way ANOVA), reduction in p38 MAPK T180/Y182 
phosphorylation, relative to the absence of A769662. (B) Representative western 
blot. 
A 
B 
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Figure 3-3: Effect of A769662 on TNF--stimulated p38 MAPK 
phosphorylation 
3T3-L1 adipocytes were incubated with TNF- (10 ng/ml) for various durations 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated.  (A) Quantification of p38 MAPK 
T180/Y182 phosphorylation was determined by comparison with total p38 MAPK 
using densitometric analysis. Data shown represent the mean ± SEM % maximum 
p38 phosphorylation of three independent experiments. ††p < 0.01 (two-way 
ANOVA), increase in p38 MAPK T180/Y182 phosphorylation, relative to vehicle. *p 
< 0.05, **p < 0.01 (two-way ANOVA), reduction in p38 MAPK T180/Y182 
phosphorylation, relative to the absence of A769662. (B) Representative western 
blot. 
A 
B 
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Figure 3-4: Effect of A769662 on IL-1-stimulated ERK1/2 phosphorylation 
3T3-L1 adipocytes were incubated with IL-1 (10 ng/ml) for various durations 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated. (A) & (B) ERK1 and ERK2, 
respectively. Quantification of ERK1/2 T202/Y204 phosphorylation was 
determined by comparison with total ERK1/2 using densitometric analysis. Data 
shown represent the mean ± SEM % maximum ERK1/2 phosphorylation of three 
independent experiments. ††p < 0.01, †††p < 0.001 (two-way ANOVA), increase in 
ERK1/2 T202/Y204 phosphorylation, relative to vehicle. *p < 0.05, **p < 0.01 (two-
way ANOVA), reduction in ERK1/2 T202/Y204 phosphorylation, relative to the 
absence of A769662. (C) Representative western blot. 
B A
C 
B 
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Figure 3-5: Effect of A769662 on TNF--stimulated ERK1/2 phosphorylation 
3T3-L1 adipocytes were incubated with TNF- (10 ng/ml) for various durations 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated. (A) & (B) ERK1 and ERK2, 
respectively. Quantification of ERK1/2 T202/Y204 phosphorylation was 
determined by comparison with total ERK1/2 using densitometric analysis. Data 
shown represent the mean ± SEM % maximum ERK1/2 phosphorylation of three 
independent experiments. (A) †p < 0.05, (two-way ANOVA), increase in ERK1/2 
T202/Y204 phosphorylation, relative to vehicle. *p < 0.05, **p < 0.01, ***p < 0.001 
(two-way ANOVA), reduction in ERK1/2 T202/Y204 phosphorylation, relative to 
the absence of A769662. (C) Representative western blot. 
A 
B 
C 
B 
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Figure 3-6: Effect of A769662 on IL-1-stimulated JNK phosphorylation 
3T3-L1 adipocytes were incubated with IL-1 (10 ng/ml) for various durations 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated. (A) & (B) p54 JNK and p46 JNK, 
respectively.  Quantification of JNK T183/Y185 phosphorylation was determined 
by comparison with total JNK using densitometric analysis. Data shown represent 
the mean ± SEM % maximum JNK phosphorylation of three independent 
experiments. ††p < 0.01, †††p < 0.001 (two-way ANOVA), increase in JNK T183/Y185 
phosphorylation, relative to vehicle. *p < 0.05 (two-way ANOVA), reduction in 
JNK T183/Y185 phosphorylation, relative to the absence of A769662. (C) 
Representative western blot. 
A 
B 
C 
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Figure 3-7: Effect of A769662 on TNF--stimulated JNK phosphorylation 
3T3-L1 adipocytes were incubated with TNF- (10 ng/ml) for various durations 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated. (A) & (B) p54 JNK and p46 JNK, 
respectively. Quantification of JNK T183/Y185 phosphorylation was determined 
by comparison with total JNK using densitometric analysis. Data shown represent 
the mean ± SEM % maximum JNK phosphorylation of three independent 
experiments. (C) Representative western blot. 
A 
C 
B 
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3.2.3 Investigating whether inhibition of MAPK signalling by 
A769662 is dependent on AMPK activation 
3.2.3.1 Effect of Compound C on A769662–mediated inhibition of 
MAPK signalling 
The pharmacological AMPK inhibitor, Compound C, was utilised to determine 
whether the A769662-mediated inhibition of TNF--stimulated p38 MAPK 
phosphorylation was dependent upon AMPK activation. Incubation of 3T3-L1 
adipocytes with TNF- caused a 67.6  23.6 % or 39.3 15.2 % stimulation of p38 
MAPK T180/Y182 phosphorylation (Fig. 3.8), compared to the basal level in the 
absence or presence of Compound C, respectively. Preincubation with A769662 
caused a 51.3  17.7 % reduction in p38 MAPK phosphorylation relative to TNF- 
treatment alone, while this was reduced to 39.3  28.5 % in the presence of 
Compound C (Fig. 3.8). 
3.2.3.2 Effect of a DN or CA AMPK mutant on A769662–mediated 
inhibition of MAPK signalling 
Adenovirus-mediated gene transfer was used to overexpress a dominant negative 
AMPK mutant (Ad.1DN) or a constitutively active AMPK mutant (Ad.1CA) in 3T3-
L1 CAR adipocytes in order to investigate the effect of down- or up-regulation of 
AMPK on A769662-mediated inhibition of MAPK signalling. 
Incubation with A769662 caused a 29.2  47.4 % increase in ACC S79 
phosphorylation in Ad.Null infected cells and a 2  22.9 % reduction in Ad.1DN 
infected cells, relative to the basal level (Fig. 3.9A). Ad.1CA infected cells 
exhibited an 68.4  6.8 % increase in basal ACC Ser79 phosphorylation compared 
with the basal level in cells infected with Ad.GFP, however this was not 
statistically significant (Fig. 3.9C). As neither the A769662 nor Ad.1CA were able 
to significantly stimulate AMPK activity, it was not possible to assess the effect of 
adenovirus mediated up- or down-regulation of AMPK on IL-1-stimulated MAPK 
phosphorylation. 
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Figure 3-8: Effect of Compound C on A769662-mediated p38 MAPK inhibition 
3T3-L1 adipocytes were incubated with TNF- (10 ng/ml) for 15 min following 
preincubation for 30 min in the presence or absence of A769662 (300 M) and 60 
min in the presence or absence of Compound C (60 M) and lysates prepared. 
Lysates were resolved by SDS-PAGE and subjected to immunoblotting with the 
antibodies indicated.  (A) Quantification of p38 MAPK T180/Y182 phosphorylation 
was determined by comparison with p38 MAPK using densitometric analysis. Data 
shown represent the mean ± SEM % TNF--stimulated p38 phosphorylation of 
three independent experiments. (B) Representative western blot. 
A 
B 
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Figure 3-9: Effect of overexpression of a dominant negative or constitutively 
active AMPK mutant on ACC phosphorylation in 3T3-L1 CAR adipocytes 
(continued overleaf) 
A 
B 
C 
Sarah Mancini, 2014   Chapter 3, 121 
   
 
Figure 3-9: Effect of overexpression of a dominant negative or constitutively 
active AMPK mutant on ACC phosphorylation in 3T3-L1 CAR adipocytes 
(A) 3T3-L1 CAR adipocytes were infected with (600 ifu/cell) for 48 h with Ad.1DN 
or Ad.null prior to stimulation for 10 min with IL-1 (10 ng/ml) following 
preincubation for 30 min in the presence or absence of A769662 (300 M) and cell 
lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated.  Quantification of ACC Ser79 
phosphorylation was determined by comparison with ACC using densitometric 
analysis. Data shown represent the mean ± SEM % vehicle ACC phosphorylation of 
three independent experiments. (B) Representative western blot. (C) 3T3-L1 CAR 
adipocytes were infected with (100 ifu/cell) for 48 h with Ad.1CA or Ad.GFP 
prior to stimulation for 10 min with IL-1 (10 ng/ml) and cell lysates prepared. 
Quantification of ACC Ser79 phosphorylation was determined by comparison with 
ACC using densitometric analysis. Data shown represent the mean ± SEM % vehicle 
GFP ACC phosphorylation of three independent experiments. (D) Representative 
western blot. 
D 
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3.2.4 Endogenous MAPK phosphorylation in adipose tissue 
To examine the role of AMPK in the basal inflammatory status of adipose tissue, 
gonadal and subcutaneous adipose tissue was collected from female AMPK1-/- 
and litter-matched wild-type sv129 mice. The extent of JNK and p38 MAPK 
phosphorylation in lysates was assessed as a measure of activation by western 
blotting using phosphorylation site-specific antibodies. ERK1/2 phosphorylation 
was undetectable in either gonadal or subcutaneous tissues (data not shown). Lane 
2 of AMPK1-/- was omitted for analysis purposes as AMPK1 was detectable in the 
lysate. 
Phosphorylation of JNK p54 was significantly (p < 0.01) increased in AMPK1-/- 
gonadal adipose tissue compared to wild-type (Fig. 3.10A). Similarly, Fig. 3.11A 
shows JNK p54 phosphorylation was significantly (p < 0.05) increased in AMPK1-
/- subcutaneous adipose tissue compared to wild-type. Phosphorylation of JNK p46 
was undetectable in either wild-type or AMPK1-/- tissues. 
Phosphorylation of p38 MAPK was increased 1.22 fold in AMPK1-/- gonadal adipose 
tissue compared to wild-type (Fig. 3.10B), however this did not reach significance. 
Similarly, it can be seen from Fig. 3.11B that p38 phosphorylation was increased 
1.43 fold in AMPK1-/- subcutaneous adipose tissue compared to wild-type, but 
failed to reach significance.  
3.2.5 Effect of AMPK activation by A769662 on IL-1 /TNF- -
stimulated MAPK activation in rat epididymal adipocytes 
Data thus far have demonstrated that A769662 inhibits proinflammatory signalling 
in 3T3-L1 adipocytes. It was of interest, therefore, to investigate if this could be 
recapitulated in primary cells. Adipocytes isolated from rat epididymal adipose 
were incubated with IL-1 in the presence or absence of A769662. The extent of 
ACC, JNK, ERK1/2 and p38 MAPK phosphorylation in lysates was assessed as a 
measure of activation by western blotting using phosphorylation site-specific 
antibodies. JNK phosphorylation was undetectable (data not shown). 
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Figure 3-10: Basal JNK and p38 MAPK phosphorylation in gonadal adipose 
tissue from AMPK1+/+ and AMPK1-/- mice 
Gonadal adipose tissue obtained from AMPK1-/- and wild-type mice was resolved 
by SDS-PAGE and subjected to immunoblotting with the antibodies indicated. 
Data shown represent the mean ± SEM arbitrary units of 5 wild-type and 3 
AMPK1-/- samples. (A) Quantification of JNK T183/Y185 phosphorylation was 
determined by comparison with JNK using densitometric analysis. **p < 0.01 (two-
tail t-test) increase in JNK T183/Y185 phosphorylation, relative to wild-type. (B) 
Quantification of p38 MAPK T180/Y182 phosphorylation was determined by 
comparison with p38 MAPK using densitometric analysis. (C) Representative 
western blot. 
A B 
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Figure 3-11: Basal JNK and p38 MAPK phosphorylation in subcutaneous 
adipose tissue from AMPK1+/+ and AMPK1-/- mice 
Subcutaneous adipose tissue obtained from AMPK1-/- and wild-type was resolved 
by SDS-PAGE and subjected to immunoblotting with the antibodies indicated. 
Data shown represent the mean ± SEM arbitrary units of 5 wild-type and 3 
AMPK1-/- samples. (A) Quantification of JNK T183/Y185 phosphorylation was 
determined by comparison with JNK using densitometric analysis. *p < 0.05 (two-
tail t-test) increase in JNK T183/Y185 phosphorylation, relative to wild-type. (B) 
Quantification of p38 MAPK T180/Y182 phosphorylation was determined by 
comparison with p38 MAPK using densitometric analysis. (C) Representative 
western blot. 
A B 
C 
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Incubation with A769662 caused a 30.4  17.5 % increase in ACC Ser79 
phosphorylation compared to the basal level (Fig. 3.12); however this was not 
statistically significant (p = 0.1). IL-1 treatment induced a 190.2  17.3 % increase 
in ERK1 T202/Y204 phosphorylation, relative to the basal level. Preincubation with 
A769662 caused a 19.6  3.6 % inhibition of ERK1 phosphorylation, compared to 
IL-1 treatment alone (Fig. 3.13A). ERK2 phosphorylation was increased by 137.6 
 2.1 % in response to IL-1, relative to the basal level. Pretreatment with A769662 
caused a 30.6  6.5 % inhibition of ERK2 phosphorylation, compared to IL-1 
treatment alone (Fig. 3.13B). 
IL-1 treatment induced a 97.1  15.1 % increase in p38 MAPK phosphorylation 
relative to the basal level, however this did not reach statistical significance. 
Preincubation with A769662 caused a 23  21.8 % inhibition of p38 MAPK 
phosphorylation, compared to IL-1 treatment alone (Fig. 3.13C). 
3.2.6 Effect of AMPK on IL-1/TNF-  – stimulated NFB nuclear 
translocation 
3.2.6.1 Temporal parameters of NFB nuclear localisation in 3T3-
L1 adipocytes 
3T3-L1 adipocytes were incubated with IL-1 or TNF- for various durations to 
ascertain the optimum incubation time for subsequent experiments examining 
cytokine-induced nuclear translocation of NFB. Fig. 3.14 demonstrated that NFB 
nuclear translocation peaks at 15 min incubation with IL-1 or TNF-, with a 10.6 
or 2.5 fold increase, respectively. 
3.2.6.2 Effect of A769662 on IL-1β/TNF-  – stimulated NFκB 
nuclear translocation in 3T3-L1 adipocytes 
Translocation of NFB to the nucleus induces transcription of a variety of 
proinflammatory genes; therefore it was of interest to determine whether 
activation of AMPK by A769662 attenuated nuclear localisation of this 
transcription factor. 
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Figure 3-12: Effect of A769662 on AMPK activation in primary rat adipocytes 
Adipocytes isolated from rat epididymal adipose tissue were incubated for 30 min 
with A769662 (300 M) and lysates prepared. Lysates were resolved by SDS-PAGE 
and subjected to immunoblotting with the antibodies indicated. (A) 
Quantification of ACC Ser79 phosphorylation was determined by comparison with 
total ACC using densitometric analysis. Data shown represent the mean ± SEM % 
vehicle ACC phosphorylation of nine independent experiments. (B) 
Representative blot. 
A 
B 
Sarah Mancini, 2014   Chapter 3, 127 
 
 
     
Figure 3-13: Effect of A769662 on IL-1-stimulated ERK1/2 and p38 MAPK 
phosphorylation in rat adipocytes 
Adipocytes isolated from rat epididymal adipose tissue were incubated with IL-
1 (10 ng/ml) for 10 min following preincubation for 30 min in the presence or 
absence of A769662 (300 M) and lysates prepared. Lysates were resolved by SDS-
PAGE and subjected to immunoblotting with the antibodies indicated. (A & B) 
Quantification of ERK1 and ERK2 T202/Y204 phosphorylation respectively was 
determined by comparison with total ERK1/2 using densitometric analysis. Data 
shown represent the mean ± SEM % IL-1-stimulated ERK1/2 phosphorylation of 
two independent experiments. (C) Quantification of p38 MAPK T180/Y182 
phosphorylation was determined by comparison with total p38 MAPK using 
densitometric analysis. Data shown represent the mean ± SEM % IL-1-stimulated 
p38 phosphorylation of three independent experiments. (D) Representative 
western blot. 
A B 
C D 
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Figure 3-14: Temporal parameters of IL-1 and TNF- - stimulated NFB 
nuclear translocation in 3T3-L1 adipocytes 
3T3-L1 adipocytes were incubated with IL-1 (10 ng/ml) or TNF- (10 ng/ml) for 
various durations and stained for NFB. Quantification of nuclear NFB was 
determined by densitometric analysis of nuclear fluorescence. Data shown 
represent the % maximum IL-1 or TNF- stimulated nuclear fluoresence, 
respectively, of a single experiment where a minimum of 50 cells were analysed 
for each treatment. 
A 
B 
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Incubation of 3T3-L1 adipocytes with IL-1 caused a significant (p < 0.001) 
increase, compared to the basal level, in translocation of NFB to the nucleus 
(Fig. 3.15). A significant (p < 0.001) 68.4  8.4 % inhibition of IL-1-stimulated 
NFB nuclear translocation was observed following preincubation with A769662 
(Fig. 3.15).Similarly, incubation of 3T3-L1 adipocytes with TNF- caused a 
significant (p < 0.001) increase, compared to the basal level, in NFB nuclear 
translocation (Fig. 3.16). Preincubation with A769662 caused a more modest, but 
still statistically significant (p < 0.05) 33.3  8.9 % inhibition of NFB nuclear 
translocation compared to TNF- treatment alone (Fig. 3.16). 
3.2.6.3 Effect of a DN or CA AMPK mutant on A769662 – mediated 
inhibition of NFB nuclear translocation 
Adenovirus-mediated gene transfer was used to overexpress a dominant negative 
AMPK mutant (Ad.1DN) or a constitutively active AMPK mutant (Ad.1CA) in 3T3-
L1 CAR adipocytes in order to investigate the effect of down- or up-regulation of 
AMPK on A769662 mediated inhibition of NFB nuclear translocation. 
IL-1 caused a 3.1 fold increase in nuclear translocation of NFB in Ad.Null 
infected cells and a 2.5 fold increase in Ad.1DN infected cells, relative to the 
basal level (Fig. 3.17). This was inhibited 3 fold in Ad.Null infected cells following 
preincubation with A769662 (Fig. 3.17). In contrast, preincubation with A769662 
in Ad.1DN infected cells caused a 1.3 fold increase in NFB nuclear translocation 
relative to IL-1 treatment alone (Fig. 3.17).  
Efficiency of Ad.1DN viral infection was estimated to be approximately 60-70 %, 
as demonstrated by staining for the myc tag. Incubation with IL-1 caused a 2.5 
and 1.22 fold stimulation of NFB nuclear translocation in Ad.GFP and Ad.1CA 
infected cells, respectively, relative to the basal level (Fig. 3.18). This 
corresponded to a 2 fold reduction in IL-1-stimulated NFB nuclear translocation 
in Ad.1CA compared to Ad.GFP infected cells (Fig. 3.18). Efficiancy of Ad.1CA 
viral infection was detected by the presence of GFP and estimated to be 
approximately 50 %. 
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Figure 3-15: Effect of A769662 on IL-1 - stimulated NFB nuclear 
translocation in 3T3-L1 adipocytes 
3T3-L1 adipocytes were incubated with IL-1 (10 ng/ml) for 15 min following 
preincubation for 30 min in the presence or absence of A769662 (300 M) and 
stained for NFB. (A) Quantification of nuclear NFB was determined by 
densitometric analysis of nuclear fluorescence. Data shown represent the mean 
± SEM % maximum nuclear fluorescence of three independent experiments with > 
50 cells analysed for each treatment in each experiment.  †††p < 0.001 (one-way 
ANOVA), increase in nuclear NFB, relative to vehicle. ***p < 0.001 (one-way 
ANOVA), reduction in nuclear NFB, relative to the absence of A769662. (B) 
Representative confocal images. 
B 
A 
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Figure 3-16: Effect of A769662 on TNF- - stimulated NFB nuclear 
translocation in 3T3-L1 adipocytes 
3T3-L1 adipocytes were incubated with TNF- (10 ng/ml) for 15 min following 
preincubation for 30 min in the presence or absence of A769662 (300 M) and 
fluorescently stained for NFB. (A) Quantification of nuclear NFB was 
determined by densitometric analysis of nuclear fluorescence. Data shown 
represent the mean ± SEM % maximum nuclear fluorescence of three independent 
experiments with > 50 cells analysed for each treatment in each experiment. †††p 
< 0.001 (one-way ANOVA), increase in nuclear NFB, relative to vehicle. *p < 0.05 
(one-way ANOVA), reduction in nuclear NFB, relative to the absence of A769662. 
(B) Representative confocal images. 
A 
B 
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Figure 3-17: Effect of overexpression of a dominant negative AMPK mutant 
on IL-1-stimulated NFB nuclear translocation in 3T3-L1 CAR adipocytes 
3T3-L1 CAR adipocytes were infected with (600 ifu/cell) Ad.1DN or Ad.null for 
48 h prior to stimulation for 15 min with IL-1 (10 ng/ml) following preincubation 
for 30 min in the presence or absence of A769662 (300 M) and fluorescently 
stained for NFB (green) and c-myc (blue). (A) Quantification of nuclear NFB was 
determined by densitometric analysis of nuclear fluorescence. Data shown 
represent the mean ± SEM % maximum nuclear fluorescence of two independent 
experiments with > 50 cells analysed for each treatment in each experiment. (B) 
Representative confocal images (NFB green, c-myc blue). 
A 
B 
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Figure 3-18: Effect of overexpression of a constitutively active AMPK mutant 
on IL-1-stimulated NFB nuclear translocation in 3T3-L1 CAR adipocytes 
3T3-L1 CAR adipocytes were infected with (100 ifu/cell) Ad.1CA or Ad.GFP for 
48 h prior to stimulation for 15 min with IL-1 (10 ng/ml) following preincubation 
for 30 min in the presence or absence of A769662 (300 M) and fluorescently 
stained for NFB (blue). (A) Quantification of nuclear NFB was determined by 
densitometric analysis of nuclear fluorescence. Data shown represent the mean 
± SEM % maximum nuclear fluorescence of two independent experiments with > 
50 cells analysed for each treatment in each experiment. (B) Representative 
confocal images (GFP green, NFB blue). 
A 
B 
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3.2.7 Effect of AMPK activation by A769662 on TNF- and IL-1 - 
stimulated NFB pathway activation in 3T3-L1 adipocytes 
In light of the AMPK-mediated inhibition of cytokine-stimulated NFB nuclear 
translocation, NFB pathway activation parameters in response to IL-1 or TNF- 
in the presence or absence of A769662 were assessed in 3T3-L1 adipocytes. The 
extent of IB and NFB phosphorylation was assessed as a measure of activation 
by western blotting using phosphorylation site-specific antibodies. 
Incubation of 3T3-L1 adipocytes with IL-1 in the absence of A769662 caused a 
significant increase, compared to the basal level, in IB Ser32 phosphorylation 
after 3, 5, 10, 15, 30 and 60 min (Figure 3.19A). Statistically significant reductions 
in IB phosphorylation were observed at 3 (p < 0.05), 5 and 10 (p < 0.001) min in 
the presence of A769662 compared to IL-1 treatment alone (Fig. 3.19A). 
Furthermore, total IB protein levels were significantly diminished following 10 
(p < 0.05), 15 and 30 (p < 0.01) min IL-1 treatment (Fig. 3.19B). A769662-
mediated AMPK activation demonstrated a tendency to increase IB protein 
levels; however this did not reach significance (Fig. 3.19B). Incubation of 3T3-L1 
adipocytes with TNF- in the absence of A769662 caused a significant increase, 
compared to the basal level, in IB Ser32 phosphorylation after 3, 5 and 10 min 
(p < 0.001) and 15 min (p < 0.05) (Fig. 3.20A). Preincubation with A769662 caused 
significant reductions in IB Ser32 phosphorylation after 3 and 5 min (p < 0.001) 
and 10 min (p < 0.01), compared to TNF- treatment alone (Fig. 3.20A). Incubation 
of 3T3-L1 adipocytes with IL-1 in the absence of A769662 caused a significant 
increase, compared to the basal level, in NFB Ser536 phosphorylation after 3 (p 
< 0.01), 5 (p < 0.001), 10 (p < 0.01) and 15 (p < 0.05) min (Fig. 3.19C). 
Preincubation with A769662 caused a tendency to inhibit NFB phosphorylation 
compared to IL-1 treatment alone; however this did not reach statistical 
significance (Fig. 3.19C). Incubation of 3T3-L1 adipocytes with TNF- in the 
absence of A769662 caused a significant increase, compared to the basal level, in 
NFB Ser536 phosphorylation after 3 min (p < 0.01), 5 and 10 min (p < 0.001), and 
15 min (p < 0.01) (Fig. 3.20B). Preincubation with A769662 caused significant 
reductions after 3 and 5 min (p < 0.05) in NFB phosphorylation, compared to TNF-
 treatment alone (Fig. 3.20B).
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Figure 3-19: Effect of A769662 on IL-1 - stimulated IB and NFB 
phosphorylation (continued overleaf) 
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Figure 3-19: Effect of A769662 on IL-1 - stimulated IB and NFB 
phosphorylation 
3T3-L1 adipocytes were incubated with IL-1 (10 ng/ml) for various durations 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated. Data shown represent the mean ± 
SEM % maximum of three independent experiments. (A) Quantification of IB 
Ser32 phosphorylation was determined by comparison with total IB using 
densitometric analysis. ††p < 0.01, †††p < 0.001 (two-way ANOVA), increase in IB 
Ser32 phosphorylation, relative to vehicle. *p < 0.05, ***p < 0.001 (two-way 
ANOVA), reduction in IB Ser32 phosphorylation, relative to the absence of 
A769662. (B) Quantification of total IB was determined by comparison with 
GAPDH using densitometric analysis. †p < 0.05, ††p < 0.01 (two-way ANOVA), 
reduction in IB expression, relative to vehicle. (C) Quantification of NFB 
Ser536 phosphorylation was determined by comparison with total NFB using 
densitometric analysis. †p < 0.05, ††p < 0.01, †††p < 0.001 (two-way ANOVA), 
increase in NFB Ser536 phosphorylation, relative to vehicle. (D) Representative 
western blot. 
D 
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Figure 3-20: Effect of A769662 on TNF- - stimulated IB and NFB 
phosphorylation (legend overleaf) 
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Figure 3-20: Effect of A769662 on TNF- - stimulated IB and NFB 
phosphorylation 
3T3-L1 adipocytes were incubated with IL-1 (10 ng/ml) for various durations 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated. Data shown represent the mean ± 
SEM % maximum of three independent experiments (A) Quantification of IB 
Ser32 phosphorylation was determined by comparison with total IB using 
densitometric analysis. †p < 0.05, †††p < 0.001 (two-way ANOVA), increase in IB 
Ser32 phosphorylation, relative to vehicle. **p < 0.01, ***p < 0.001 (two-way 
ANOVA), reduction in IB Ser32 phosphorylation, relative to the absence of 
A769662. (B) Quantification of NFB Ser536 phosphorylation was determined by 
comparison with total NFB using densitometric analysis. ††p < 0.01, †††p < 0.001 
(two-way ANOVA), increase in NFB Ser536 phosphorylation, relative to vehicle. 
*p < 0.05 (two-way ANOVA), reduction in NFB Ser536 phosphorylation, relative 
to the absence of A769662 (C) Representative western blot. 
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3.2.8 Investigating the mechanism of AMPK-mediated inhibition 
of IL-1 /TNF- signalling 
3.2.8.1 Effect of L-NAME on AMPK-mediated inhibition of IL-
1/TNF- signalling 
AMPK has been reported to stimulate the phosphorylation and activation of eNOS 
(Morrow et al. 2003), therefore it was of interest to determine whether the effects 
of AMPK on the MAPK signalling pathway are sensitive to eNOS inhibition by L-
NAME, with the inactive isomer D-NAME utilised as a control. 
IL-1 stimulated a significant (p < 0.001) increase in p38 T180/Y182 
phosphorylation (Fig. 3.21A) in the presence of either L-NAME or D-NAME 
compared to the basal level. Preincubation with A769662 caused a significant (p 
< 0.01) 24  1.5 % and 24.1  3 % inhibition of p38 MAPK phosphorylation in D-
NAME and L-NAME – treated cells, respectively, compared to IL-1 treatment alone 
(Fig. 3.21A). Incubation with TNF- was also found to cause a significant (p < 
0.001) increase in p38 MAPK phosphorylation in the presence of either L-NAME or 
D-NAME compared to the basal level (Fig. 3.21B). Preincubation with A769662 
caused a significant (p < 0.05) 30.2  4.6 % inhibition of p38 MAPK phosphorylation 
in L-NAME – treated cells compared to TNF- stimulation alone; however no such 
inhibition was observed with A769662 preincubation in cells incubated with D-
NAME, compared to TNF- treatment alone (Fig. 3.21B). 
IL-1 stimulated a significant (p < 0.001) increase in ERK1/2 T202/Y204 
phosphorylation (Fig. 3.21C/D) in the presence of either L-NAME or D-NAME, 
compared to the basal level. Preincubation with A769662 caused a significant (p 
< 0.001) 54  13.7 % and 47.6  3.4 % inhibition of ERK1 phosphorylation (Fig. 
3.21C) and 58.1  7.6 % and 49.7  9.2 % inhibition of ERK2 phosphorylation in D-
NAME and L-NAME – treated cells respectively, compared to treatment with IL-1 
alone (Fig. 3.21D). Incubation with TNF- was also found to cause a significant (p 
< 0.01) increase in ERK1/2 T202/Y204 phosphorylation in the presence of either 
D-NAME or L-NAME, respectively, compared to the basal level (Fig. 3.21E/F). 
Preincubation with A769662 caused a 45.2  17.5 % and 13.6  14.4 % reduction in 
Sarah Mancini, 2014   Chapter 3, 140 
ERK1 phosphorylation and 24.1  17.8 % and 29.3  9.9 % reduction in ERK2 
phosphorylation in D-NAME and L-NAME – treated cells, respectively, compared to 
TNF- treatment alone; however this was not statistically significant (Fig. 
3.21E/F). 
3.2.8.2 Investigating effect of AMPK on IKK activation 
Data thus far demonstrate AMPK inhibits the NFB signalling pathway as far 
upstream as IB (as demonstrated by inhibition of IB phosphorylation, Fig. 3.19 
and 3.20). It was of interest, therefore, to investigate the effect of AMPK on 
upstream IKK activation. 
 
Incubation of 3T3-L1 adipocytes with IL-1 in the absence of A769662 caused a 
significant (p < 0.001) increase, compared to the basal level, in IKK/ Ser176/177 
phosphorylation after 3 and 15 min. A modest, but significant (p < 0.05) increase 
was still observed after 30 min IL-1 treatment (Fig. 3.22). Statistically significant 
reductions in IKK/ phosphorylation were observed at 3 min (p < 0.01) and 15 
min (p < 0.01) in the presence of A769662 compared to IL-1 treatment alone (Fig. 
3.22). IKK/ expression/phosphorylation was undetectable in TNF--treated 
lysates (data not shown). In order to determine whether a potential interaction 
may occur between AMPK and IKK, AMPK or IKK was immunoprecipitated from 
3T3-L1 adipocyte lysates that had been incubated with IL-1 in the presence or 
absence of A769662 in order to determine whether AMPK activation induced a 
detectable interaction with cytokine-stimulated IKK. As shown in Fig. 3.23, IKK 
was successfully immunoprecipitated from lysates, with no observable levels 
found in the immunodeplete. AMPK was detected in the IKK immunoprecipitate 
only when cells were incubated with A769662 compared to the basal level, 
however AMPK was not found to be present in the immunodeplete of lysates under 
any condition. In this preliminary experiment there was found to be only a modest 
immunoprecipitation of AMPK from the aforementioned lysates, while there was 
none present in the immunodeplete (Fig. 3.23). IKK was undetectable in the 
AMPK immunoprecipitate; however it was absent in the immunodeplete. 
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Figure 3-21: Effect of eNOS inhibition by L-NAME on AMPK-mediated 
inhibition of IL-1 or TNF--stimulated ERK1/2 and p38 MAPK 
phosphorylation (continued overleaf) 
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Figure 3-21: Effect of eNOS inhibition by L-NAME on AMPK-mediated 
inhibition of IL-1-stimulated ERK1/2 and p38 MAPK phosphorylation 
3T3-L1 cells were incubated with IL-1 (10 ng/ml) or TNF- (10 ng/ml) for 15 min 
following preincubation for 30 min in the presence or absence of A769662 (300 
M) and 2 h in the presence or absence of L-NAME (1 mM) and lysates prepared. 
Lysates were resolved by SDS-PAGE and subjected to immunoblotting with the 
antibodies indicated. Quantification of p38 MAPK T180/Y182 and ERK1/2 
T202/Y204 phosphorylation was determined by comparison with p38 MAPK and 
ERK1/2, respectively, using densitometric analysis. (A & B) Data shown represent 
the mean ± SEM % IL-1 or TNF- stimulated of three independent experiments. 
†††p < 0.001 (one-way ANOVA), increase in p38 MAPK T180/Y182 phosphorylation, 
relative to respective vehicle. **p < 0.01, *p < 0.05 (one-way ANOVA), reduction 
in p38 MAPK T180/Y182 phosphorylation, relative to respective absence of 
A769662. (C & D) ERK1 and ERK2, respectively. Data shown represent the mean ± 
SEM % IL-1 stimulated of three independent experiments. †††p < 0.001 (one-way 
ANOVA), increase in ERK1/2 T202/Y204 phosphorylation, relative to respective 
vehicle. ***p < 0.001 (one-way ANOVA), reduction in ERK1/2 T202/Y204 
phosphorylation, relative to respective absence of A769662. (E & F) ERK1 and 
ERK2, respectively. Data shown represent the mean ± SEM % TNF- stimulated of 
two independent experiments. (G) Representative blot. 
G 
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Figure 3-22: Effect of A769662 on IL-1 - stimulated IKK/ phosphorylation 
3T3-L1 cells were incubated with IL-1 (10 ng/ml) for various durations following 
preincubation for 30 min in the presence or absence of A769662 (300 M) and 
lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated. (A) Quantification of IKK/ 
Ser176/177 phosphorylation was determined by comparison with total IKK using 
densitometric analysis. Data shown represent the mean ± SEM % maximum IKK/ 
phosphorylation of three independent experiments. †p < 0.05, †††p < 0.001 (two-
way ANOVA), increase in IKK/ S176/177 phosphorylation, relative to vehicle. 
**p < 0.01, ***p < 0.001 (two-way ANOVA), reduction in IKK/ S176/177 
phosphorylation, relative to absence of A769662. (B) Representative western 
blot. 
A 
B 
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Figure 3-23: Effect of IL-1 and A769662 on IKK and AMPK interaction 
Total AMPK1 and 2 and IKK were immunoprecipitated with a mixture of 
AMPK1 and 2 and IKK antibodies, respectively, from 3T3-L1 lysates (80-200 
g) obtained from cells incubated with IL-1 (10 ng/ml) for 15 min following 30 
min preincubation with A769662 (300 M). Immunoprecipitates were resolved on 
7% SDS-PAGE, transferred to nitrocellulose and probed with anti-IKK and anti-
AMPK antibodies. Western blot from a single experiment. ID, immunodeplete; 
IP, immunoprecipitate. 
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3.3 Discussion 
The key findings of this chapter are that AMPK activation in adipocytes inhibited 
both IL-1 and TNF- - stimulated phosphorylation of MAPK and NFB signalling 
pathway intermediates. Furthermore, NFB nuclear translocation was attenuated 
in an AMPK-dependent manner as demonstrated by the utilisation of AMPK 
adenoviruses. The mechanism by which AMPK elicits these anti-inflammatory 
effects in adipocytes is unlikely to be mediated by eNOS, but does occur upstream 
of or directly at the level of IKK and MAP kinases p38, ERK and JNK. 
Initial studies were undertaken to investigate activation of AMPK in adipocytes. 
This study found that A769662 significantly (p < 0.05) stimulated AMPK Thr172 
phosphorylation in 3T3-L1 adipocytes (Fig. 3.1A), which supports previous studies 
reporting stimulation of AMPK activity in 3T3-L1 adipocytes by A769662 (Zhou, 
Wang, et al. 2009). Furthermore, Fig. 3.1A shows A769662-mediated AMPK Thr172 
phosphorylation is significantly (p < 0.001) ablated in the presence of the AMPK 
inhibitor Compound C, which acts by competing for ATP. It is important to note, 
however, that Compound C is not specific for AMPK, therefore data generated 
using Compound C should be interpreted with care. Bain and co-workers found 
that it also inhibits several other protein kinases in vitro including ERK 8, MAPK-
interacting-kinase 1 (MNK1), phosphorylase kinase (PHK), dual specificity tyrosine 
phosphorylation and regulated kinase (DYRK) isoforms, homeodomain-interacting 
protein kinase 2 (HIPK2), sarcoma kinase (Src), and lymphocyte cell-specific 
protein-tyrosine kinase (Lck) (Bain et al. 2007). 
In order to investigate whether the ability of A769662 to stimulate AMPK activation 
could be recapitulated in primary cells, adipocytes were isolated from rat 
epididymal adipose tissue. AMPK activity was assessed as a measure of 
phosphorylation of the AMPK target protein acetyl CoA carboxylase (ACC), at 
Ser79. There are a number of lines of evidence demonstrating that AICAR 
stimulates an increase in AMPK activation in rat primary adipocytes (Daval et al. 
2005, Gaidhu et al. 2010, Sullivan et al. 1994), however the effect of A769662 has, 
to our knowledge, not been examined. The current study found that A769662 
appeared to induce a small increase in ACC Ser79 phosphorylation in rat 
adipocytes; however this did not reach significance (Fig. 3.12). It is possible that 
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a high degree of basal AMPK activation or variability between animals could 
account for the modest effect of A769662 in this study; alternatively, A769662 
may not be particularly effective in primary adipocytes. 
A small number of studies have suggested that AMPK activation can be modulated 
by proinflammatory cytokines including TNF- in certain cells. The reports are 
conflicting, with TNF- shown to activate AMPK in endothelial and kidney cell lines 
(Tang et al. 2010), while it has been demonstrated to be inhibitory in myotubes 
and muscle (Steinberg et al. 2006). To our knowledge, the effect of TNF- on 
AMPK activation in adipocytes has not previously been assessed. This study found 
that in 3T3-L1 adipocytes TNF- had no effect on AMPK Thr172 phosphorylation 
when data were normalised to A769662 (Fig. 3.1A); interestingly, however, TNF-
 significantly (p < 0.01) reduced AMPK Thr172 phosphorylation compared to the 
basal level when data were normalised to vehicle (Fig. 3.1B). An inhibition of AMPK 
Thr172 phosphorylation by TNF- could be the result of an increase in protein 
phosphatase 2C (PP2C) which dephosphorylates AMPK Thr172. Indeed, Steinberg 
and co-workers reported the TNF--mediated suppression of AMPK activity via 
transcriptional upregulation of PP2C in cultured skeletal muscle cells (Steinberg 
et al. 2006). 
AMPK and MAPK 
Proinflammatory cytokines TNF- and IL-1 have been found to be upregulated in 
obese adipose tissue (Guilherme et al. 2008, Schenk, Saberi, and Olefsky 2008). 
In this study the temporal activation of components of the TNF-/IL-1 - 
stimulated MAPK and NFB pathways and their subsequent inhibition by AMPK was 
assessed in 3T3-L1 adipocytes. 
Figures 3.2 – 3.7 demonstrated that both IL-1 and TNF- were found to acutely 
stimulate MAPK signalling in 3T3-L1 adipocytes, with phosphorylation of ERK1/2 
and p38 MAPK signalling intermediates peaking within 15 min of cytokine 
stimulation (Fig. 3.2 – 3.5). Furthermore, p38 and ERK1/2 MAPK appeared to 
undergo biphasic activation in response to TNF-, with the disappearance of 
phosphorylation following 10-15 min cytokine stimulation which increased again 
after 6 h (Fig. 3.3 and 3.5). This is not unexpected; ERK1/2 and p38 MAPK have 
been reported to undergo biphasic activation in response to adenosine (Haq, 
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Clerk, and Sugden 1998) and oxidative stress (Jayakumar et al. 2006). In addition, 
IL-1 significantly (p < 0.01) stimulated phosphorylation of JNK (Fig. 3.6), while 
this did not reach significance in response to TNF- due to a high degree of 
variability (Fig. 3.7). IL-1 appeared to be a more potent activator of the MAPK 
pathways than TNF-, which correlates with recent data suggesting that IL-1 may 
be more relevant than TNF- in terms of adipose tissue inflammation (Wieser, 
Moschen, and Tilg 2013). Activation of AMPK with A769662 significantly reduced 
IL-1-stimulated p38 MAPK, ERK1/2 and JNK phosphorylation (Fig. 3.2, 3.4 and 
3.6). Similarly, A769662 significantly inhibited TNF- - stimulated p38 and ERK1/2 
MAPK phosphorylation (Fig. 3.3 and 3.5), with a tendency to inhibit JNK activation 
(Fig. 3.7). These data support the few studies to date investigating the effect of 
AMPK on cytokine-stimulated MAPK phosphorylation and activation. Elevated JNK 
phosphorylation has been reported in macrophages of AMPK1-/- mice (Galic et al. 
2011), and endothelial cells of mice deficient in AMPK2 (Dong et al. 2010). 
Similarly, LPS-stimulated JNK, ERK1/2 and p38 MAPK phosphorylation was found 
to be reduced by berberine in an AMPK-dependent manner in macrophages (Jeong 
et al. 2009). To our knowledge, inhibition of cytokine-stimulated MAPK activation 
by AMPK in adipocytes had not been explored prior to this study. 
Interestingly, while the finding that AMPK inhibited p38 MAPK phosphorylation in 
this study fits with the anti-inflammatory paradigm, it contradicts some published 
studies which suggest that AMPK may in fact activate p38 MAPK phosphorylation 
(Li et al. 2005, Xi, Han, and Zhang 2001). In contrast, Jacquet and co-workers 
found that while AMPK and p38 activation were temporally related in myocardial 
ischemia, p38 MAPK activation was independent of AMPK (Jacquet et al. 2007). 
Thus, it is possible that cell-type specific mechanisms may exist. 
The effect of A769662 on IL-1-stimulated ERK1/2 and p38 MAPK was also assessed 
in primary adipocytes isolated from rat epididymal adipose tissue. It can be seen 
in Fig. 3.13B/C that there appeared to be a tendency for A769662 to suppress IL-
1-stimulated ERK1/2 phosphorylation in isolated rat adipocytes. While A769662-
mediated AMPK activation did not significantly reduce IL-1-stimulated p38 MAPK 
phosphorylation (Fig. 3.13A), there did appear to be a subtle reduction. This 
marginal effect of A769662 on inhibition of MAPK phosphorylation is likely to relate 
to the very modest stimulation of AMPK activation in isolated adipocytes (Fig. 
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3.12). This study was carried out in a small number of independent experiments 
due to availability; therefore it is possible that more convincing data could be 
generated with a greater number of animals. 
It was of importance to ascertain whether the inhibition of proinflammatory 
signalling could be directly attributed to AMPK, therefore the pharmacological 
AMPK inhibitor Compound C and adenoviruses to up- or downregulate AMPK were 
utilised. While Compound C showed a slight tendency to suppress A769662-
mediated inhibition of p38 phosphorylation in 3T3-L1 adipocytes (Fig. 3.8), a 
significant degree of variability was observed across experimental replicates. 
Furthermore, Compound C was not found to significantly suppress A769662-
mediated AMPK activation within these experimental replicates (data not shown); 
thus it is not feasible to draw any conclusions from these data. Adenoviruses 
overexpressing a dominant negative (Ad.1DN) or constitutively active (Ad.1CA) 
AMPK were also used to investigate whether the effect of A769662 on 
proinflammatory signalling in 3T3-L1 adipocytes is mediated by AMPK activation 
(Fig. 3.9). Differentiated adipocytes are relatively genetically intractable due to 
the abundance of lipid droplets and lack of CAR receptors required for adenoviral 
entry into the cell. To address this, 3T3-L1 adipocytes overexpressing the CAR 
receptor were utilised (Ross et al. 2003). Fig. 3.9A shows that A769662 failed to 
stimulate ACC Ser79 phosphorylation in cells infected with Ad.1DN or Ad.Null 
control infected cells, indicating that A769662 failed to produce the expected 
effect. Similarly, there was no significant increase in ACC Ser79 phosphorylation 
in cells infected with Ad.1CA virus compared to the Ad.GFP control (Fig. 3.9C). 
These data demonstrate that viral transfection in these experiments was likely to 
have been insufficient to manipulate AMPK activity as assessed in whole cell 
lysates, as implied by the lack of ACC Ser79 phosphorylation in Ad.1CA infected 
cells.  AMPK adenoviruses and Compound C have been successfully utilised in other 
cell lines to demonstrate AMPK-dependent inhibition of proinflammatory 
signalling. A study by Jeong and co-workers reported that inhibition or 
downregulation of AMPK with Compound C or Ad.1DN infection, respectively, 
ablated berberine-mediated inhibition of proinflammatory gene expression in 
macrophages (Jeong et al. 2009). Taken together, this study was unable to show 
in whole cell lysates that the inhibition of cytokine-stimulated MAPK 
phosphorylation by A769662 was dependent upon AMPK activation, as not only did 
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A769662 fail to activate AMPK in control Ad.Null-infected cells, but AMPK 
activation in Ad.1CA infected cells could not be convincingly demonstrated. No 
conclusions regarding the extent of MAPK phosphorylation could therefore be 
drawn from these experiments. 
Nitric oxide has been reported to attenuate proinflammatory signalling via the S-
nitrosylation of p65 and subsequent inhibition of NFB DNA binding (Kelleher et 
al. 2007). AMPK has been reported to phosphorylate and activate endothelial nitric 
oxide synthase (eNOS) (Morrow et al. 2003), thereby providing a possible 
mechanism by which AMPK could inhibit proinflammatory signalling pathway 
activation. Expression of eNOS in 3T3-L1 adipocytes has been reported (Tanaka et 
al. 2003) and its activity can be inhibited using L-NAME. As Fig. 3.21A and 3.21C/D 
demonstrated, statistically significant inhibition of IL-1-stimulate p38 MAPK (p < 
0.01) or ERK1/2 (p < 0.001) phosphorylation by A769662 was not affected by 
inhibition of eNOS with L-NAME. TNF- treatment induced a clear increase in 
ERK1/2 phosphorylation, which was modestly reduced following A769662 
preincubation in both L-NAME and D-NAME-treated cells (Fig.3.21E/F). Curiously, 
while TNF- significantly stimulated p38 MAPK phosphorylation, A769662-
mediated AMPK activation appeared to significantly reduce TNF--stimulated p38 
MAPK phosphorylation in L-NAME, but not D-NAME control treated cells (Fig. 
3.21B). This is likely to be a result of very faint bands compared to those observed 
with IL-1 treatment, and proved difficult to analyse. Overall, these data indicate 
that AMPK-mediated inhibition of MAPK signalling is likely to be independent of 
NO production. It should be noted that positive controls were lacking in these 
experiments; nitrotyrosine, which is an indicator of NO production, was 
undetectable in lysates (data not shown). These data support the findings of Bess 
and co-workers, who reported that AMPK activation was sufficient to inhibit TNF-
-stimulated phosphorylation of IB and NFB p65 in COS-7 cells which do not 
express endogenous eNOS (Bess et al. 2011). 
AMPK and NFB 
The current study investigated the effect of AMPK on the cytokine-stimulated 
translocation of proinflammatory transcription factor NFB to the nucleus. An 
initial time course revealed that both TNF- and IL-1-induced nuclear 
translocation of NFB in 3T3-L1 adipocytes occurred following 15 min cytokine 
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treatment (Fig. 3.14), with IL-1 being the more potent activator. A769662 
significantly reduced IL-1 (p < 0.001) and TNF- (p < 0.05) – stimulated NFB 
nuclear localisation (Fig. 3.15 and 3.16, respectively). In order to establish AMPK 
dependency, IL-1-stimulated NFB nuclear translocation was examined using DN 
or CA AMPK adenoviruses. The Ad.1DN and Ad.1CA viruses were myc and GFP–
tagged, respectively; thereby providing a means to identify successfully infected 
cells for analysis and the efficiency of the viral infection (approximately 60-70% 
and 50%, respectively). It is clear from Fig. 3.17 that A769662 effectively reduced 
IL-1-stimulated NFB nuclear translocation in cells infected with Ad.Null, but 
crucially, had no effect in Ad.1DN infected cells. IL-1 did not appear to 
stimulate NFB nuclear translocation in Ad.1DN infected cells to the same extent 
as in Ad.Null infected cells. Likewise, Fig. 3.18 demonstrated a clear reduction in 
NFB nuclear translocation in Ad.1CA infected cells compared to the Ad.GFP 
infected control. Despite these data being generated from only two independent 
experiments, it is clear that, taken together with the results generated with 
A769662, AMPK activation inhibited cytokine-stimulated NFB nuclear 
translocation in 3T3-L1 adipocytes. These data support previous findings that 
there was an increase in NFB present in the nuclear fraction of endothelial cells 
deficient in AMPK2 (Wang, Zhang, et al. 2010). 
It was important to elucidate the effect of AMPK activation on signalling 
intermediates upstream of NFB. IL-1 and TNF- were shown to rapidly stimulate 
the IKK/IB/NFB signalling pathway in 3T3-L1 adipocytes, with phosphorylation 
of IB peaking within 15 min of cytokine stimulation with a concomitant 
reduction in total protein levels. A769662-mediated AMPK activation caused a 
significant reduction in IB phosphorylation (Fig. 3.19A and 3.20A) and reduced 
total protein degradation (Fig. 3.19B), in line with NFB nuclear localisation 
findings (Fig. 3.15 - 3.18). Furthermore, AMPK activation significantly ablated the 
rapidly induced IL-1-stimulated IKK/ phosphorylation (Fig. 3.22); however 
TNF--stimulated IKK/ phosphorylation was undetectable (data not shown). It 
is unlikely that TNF- was unable to induce IKK/ phosphorylation, as activation 
of downstream components IB and NFB were observed. Thus, it is more likely 
that it simply was not detected by the antibody. Activation of AMPK significantly 
reduced TNF--stimulated NFB phosphorylation (Fig. 3.20B), and while there 
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appeared to be a tendency for A769662 to inhibit IL-1-stimulated NFB 
phosphorylation, this did not reach statistical significance (p < 0.05) (Fig. 3.19C). 
Recent studies have suggested a number of different mechanisms for the inhibition 
of NFB signalling by AMPK. Firstly, it has been reported in COS-7 cells that 
hyperphosphorylation of IKK by constitutively active AMPK resulted in the 
inhibition of IB phosphorylation, NFB p65 activation and subsequent NFB-
mediated gene transcription (Bess et al. 2011). In contrast, this study 
demonstrated AMPK acutely and significantly reduced IKK phosphorylation in 3T3-
L1 adipocytes (Fig. 3.22). This observation supports recent studies reporting the 
AMPK-mediated inhibition of IKK phosphorylation in different cell types. 
Metformin or AICAR were reported to attenuate TNF--stimulated IKK/ 
Ser180/181 phosphorylation in HUVECs in an AMPK-dependent manner (Huang et 
al. 2009), while A769662 was reported to reduce IKK/ phosphorylation in 
myocytes from obese individuals with type 2 diabetes (Green et al. 2011). The 
current study also found that there may be a potential interaction between AMPK 
and IKK in 3T3-L1 adipocytes (Fig. 3.23), as a preliminary experiment suggested 
AMPK may co-immunoprecipitate with IKK following A769662 stimulation. The 
reverse (IKK co-immunoprecipitating with AMPK) was not observed; however 
there was no detectable IKK in the immunodeplete, which could potentially be a 
result of it being co-immunoprecipitated with AMPK but not being detected on the 
western blot. These data suggest it is possible IKK and AMPK could interact, which 
may indicate a potential mechanism; however this data has yet to be replicated 
care should be taken in interpreting the results. While AMPK has been reported to 
modulate IKK phosphorylation, it has not, to our knowledge, been found to 
physically interact with it. 
Alternatively, it has been suggested that AMPK may inhibit DNA binding directly. 
Zhang and co-workers reported that in endothelial cells AMPK phosphorylates the 
transcriptional coactivator p300, blocking acetylation of p65 which is required for 
full transcriptional activation of NFB; however, this report did not investigate 
the effect of AMPK activation upstream of NFB (Zhang et al. 2011). Similarly, it 
has been reported that AMPK may inhibit NFB-mediated gene transcription via 
activation of the deacetylase SIRT1 which was demonstrated to deacetylate 
Lys310 of p65, stimulating Ser9-mediated methylation of Lys314/315 (Yang, 
Tajkhorshid, and Chen 2010). This leads to the polyubiquitination and subsequent 
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proteasomal degradation of p65, thus ablating transcription of NFB target genes. 
The rapid inhibition of IKK/IB/NFB phosphorylation and NFB nuclear 
translocation by AMPK observed in the current study suggests the existence of a 
more acute mechanism of inhibition occurring upstream of, or at the level of, IKK 
in adipocytes.  Finally, AICAR-mediated AMPK activation had no effect on LPS-
stimulated IB phosphorylation or degradation in either macrophages (Kuo et al. 
2008) or mesangial cells (Peairs et al. 2009), which suggests that the mechanism 
by which AMPK inhibits cytokine-stimulated NFB signalling may be cell-type 
specific. 
Finally, to explore the importance of AMPK on the basal inflammatory status of 
adipose tissue, subcutaneous and gonadal depots were obtained from AMPK1-/- 
and genetically matched wild-type mice. Basal phosphorylation of JNK was found 
to be significantly increased in both adipose depots from AMPK1-/- mice 
compared to wild-type (Fig. 3.10A and 3.11A). This correlates with a study by 
Galic and co-workers, which reported elevated JNK phosphorylation in AMPK1-/- 
mouse macrophages in response to palmitate exposure (Galic et al. 2011). There 
was no significant difference in p38 MAPK phosphorylation between the 
phenotypes (Fig. 3.10B and 3.11B), although there did appear to be a tendency 
toward increased p38 MAPK phosphorylation in AMPK1-/- adipose compared to 
wild-type (Fig. 3.10B and 3.11B). These are convincing data indicating an anti-
inflammatory role of AMPK in adipose tissue, particularly as gonadal is a form of 
visceral adipose, which is central to the production of proinflammatory mediators 
in obesity (Gauthier et al. 2011). While the anti-inflammatory role of AMPK in 
adipose tissue has not previously been well characterised, these data correlate 
with a report suggesting that berberine reduced cytokine expression in adipose 
tissue of obese db/db mice; however the AMPK dependence of this was not 
confirmed (Jeong et al. 2009). Likewise, AICAR has been reported to inhibit TNF-
 secretion in human subcutaneous adipose tissue cultured ex vivo (Lihn et al. 
2004).  
Overall, this current work demonstrates for the first time in adipocytes that AMPK 
suppresses cytokine-stimulated MAPK and NFB signalling pathways and 
subsequent nuclear translocation of NFB via a mechanism likely to be upstream 
of IKK and MAPKs and independent of NO production. 
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 Chapter 4 - The effect of AMPK on IL-6-
stimulated proinflammatory signalling 
4.1 Introduction 
4.1.1 IL-6 signalling via the JAK/STAT pathway 
In most cell types, IL-6 initially forms a complex with a soluble receptor (sIL-6R) 
before binding to the signal-transducing gp130 receptor subunits, stimulating 
activation of JAK, which phosphorylates tyrosine residues on the cytoplasmic tails 
of gp130. These phospho-tyrosine residues function as docking sites for SH2-
containing proteins including STAT proteins and SHP-2, which are subsequently 
phosphorylated by JAK (Heinrich et al. 1998). Phosphorylated STAT proteins 
dimerise and translocate to the nucleus where they regulate the transcription of 
target genes, including CRP (Zhang et al. 1996) and MCP-1 (Fasshauer, Klein, et 
al. 2004), which are involved in the inflammatory response. SHP-2 activation 
stimulates the ERK MAPK cascade (Fukada et al. 1996). 
4.1.2 IL-6 inflammatory signalling in disease and regulation by 
AMPK 
IL-6 is produced by multiple cell types including macrophages and adipocytes; 
indeed, increased concentrations are found to be secreted by WAT in obesity 
(Sopasakis et al. 2004, Gustafson 2010). Interestingly, it has been reported that  
IL-6 secretion is greater in visceral, rather than subcutaneous adipocytes (Fried, 
Bunkin, and Greenberg 1998). Furthermore, plasma concentrations of IL-6 are 
positively correlated with body mass and insulin resistance (Lee et al. 2009). It is 
well established that elevated levels of IL-6 are associated with the development 
of some chronic inflammatory and autoimmune diseases, such as diabetes 
(Pradhan et al. 2001), atherosclerosis (Amar et al. 2006) and rheumatoid arthritis 
(Nishimoto 2006); indeed, IL-6 is often considered a marker or predictor for these 
diseases. Prior to the beginning of this study, very little was known about the 
effect of AMPK on IL-6-stimulated proinflammatory signalling. AMPK activation 
was reported to suppress leptin-mediated STAT3 phosphorylation and SOCS-3 
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induction in hepatic stellate cells (Handy et al. 2010); however, to our knowledge, 
the current study was the first to investigate the effect of AMPK on IL-6 signalling 
in adipocytes. 
4.1.3 Aims 
While AMPK has been found to inhibit MAPK/NFB proinflammatory pathways 
triggered by cytokines such as TNF- and IL-1 in different cell types, its ability 
to regulate IL-6-stimulated JAK/STAT proinflammatory signalling in adipocytes 
remains to be investigated. 
In the current study the ability of AMPK to modulate the IL-6-stimulated JAK/STAT 
signalling pathway in adipocytes was assessed. Furthermore, the molecular 
mechanism by which AMPK may elicit these anti-inflammatory effects was 
investigated. 
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4.2 Results 
4.2.1 Effect of IL-6 on AMPK activation in 3T3-L1 adipocytes 
To examine whether IL-6 altered AMPK activity in 3T3-L1 adipocytes, cells were 
incubated with A769662, Compound C or IL-6/sIL-6R and the extent of AMPK 
Thr172 and ACC Ser79 phosphorylation was determined by western blotting 
analysis of 3T3-L1 and rat epididymal adipocyte lysates, respectively. 
Incubation of 3T3-L1 adipocytes with A769662 (Fig. 4.1A) caused a 37  7 % 
increase in AMPK Thr172 phosphorylation, compared to the basal level. This was 
significantly reduced following preincubation with Compound C (p < 0.001). 
Incubation of 3T3-L1 adipocytes with IL-6/sIL-6R did not alter AMPK Thr172 
phosphorylation compared to the basal level when data were normalised to 
A769662-stimulated (Fig. 4.1A) or vehicle (Fig. 4.1B). Similarly, incubation with 
IL-6/sIL-6R did not alter ACC Ser79 phosphorylation in adipocytes isolated from 
rat epididymal adipose tissue (Fig. 4.1D/E). 
4.2.2 Effect of AMPK activation by A769662 on IL-6-stimulated 
STAT3 and ERK1/2 in 3T3-L1 adipocytes 
To determine whether AMPK activation influenced stimulation of downstream 
components of the IL-6 signalling pathway, STAT3 and ERK1/2 activation 
parameters in response to IL-6/sIL-6R in the presence or absence of A769662 
were assessed in 3T3-L1 adipocytes. The extent of STAT3 and ERK1/2 
phosphorylation was assessed as a measure of activation by western blotting using 
phosphorylation site-specific antibodies. Incubation of 3T3-L1 adipocytes with IL-
6/sIL-6R (Fig. 4.2) caused a significant increase, compared to the basal level, in 
STAT3 Y705 phosphorylation at 15, 30 and 60 min (p < 0.001) and 360 min (p < 
0.05). A769662 caused a statistically significant reduction in IL-6-stimulated STAT3 
phosphorylation at 15, 30, 60 and 360 min (p < 0.001) and 180 min (p < 0.05). In 
contrast, incubation with IL-6/sIL-6R did not stimulate ERK1/2 phosphorylation 
in 3T3-L1 adipocytes (Fig. 4.3); similarly preincubation with A769662 was found 
to have no effect on ERK1/2 phosphorylation. 
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Figure 4-1: Effect of IL-6/sIL-6R on AMPK phosphorylation 
(A – C) 3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) 
for 60 min following preincubation for 30 min in the presence or absence of 
A769662 (300 M) and 60 min in the presence or absence of Compound C (60 M); 
(D – E) adipocytes isolated from rat epididymal adipose were incubated for 60 
min with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) and lysates prepared. Lysates were 
resolved by SDS-PAGE and subjected to immunoblotting with the antibodies 
indicated. (A & B) Quantification of AMPK Thr172 phosphorylation relative to 
total AMPK1 and (D) Quantification of ACC S79 phosphorylation relative to 
GAPDH was determined by densitometric analysis. (A) Data shown represent the 
mean ± SEM % A769662-stimulated AMPK phosphorylation of three independent 
experiments. **p < 0.01, ***p < 0.001 (one-way ANOVA), reduction in AMPK1 
Thr172 phosphorylation, relative to the absence of Compound C. (B) Data shown 
represent the mean ± SEM % vehicle AMPK phosphorylation of three independent 
experiments. (C) Representative western blot. (D) Data shown represent the 
mean ± SEM % vehicle of three independent experiments. (E) Representative blot; 
samples resolved on the same SDS-PAGE gel. 
A 
C 
D E 
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Figure 4-2: Effect of A769662 on IL-6-stimulated STAT3 phosphorylation 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 
various durations following preincubation for 30 min in the presence or absence 
of A769662 (300 M) and lysates prepared. Lysates were resolved by SDS-PAGE 
and subjected to immunoblotting with the antibodies indicated. (A) 
Quantification of STAT3 Y705 phosphorylation relative to total STAT3 was 
determined by densitometric analysis. Data shown represent the mean ± SEM % 
maximum STAT3 phosphorylation of six independent experiments. †p < 0.05, †††p 
< 0.001 (two-way ANOVA), increase in STAT3 Y705 phosphorylation, relative to 
vehicle.  *p < 0.05, ***p < 0.001 (two-way ANOVA), reduction in STAT3 Y705 
phosphorylation, relative to the absence of A769662. (B) Representative western 
blot. 
B 
A 
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Figure 4-3: Effect of A769662 on IL-6-stimulated ERK1/2 phosphorylation 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 
various durations following preincubation for 30 min in the presence or absence 
of A769662 (300 M) and lysates prepared. Lysates were resolved by SDS-PAGE 
and subjected to immunoblotting with the antibodies indicated. (A) & (B) ERK1 
and ERK2, respectively. Quantification of ERK1/2 T202/Y204 phosphorylation 
relative to total ERK1/2 was determined by densitometric analysis. Data shown 
represent the mean ± SEM % maximum ERK1/2 phosphorylation of three 
independent experiments. (C) Representative western blot. 
A 
B 
C 
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4.2.3 Investigating whether inhibition of IL-6 signalling is 
dependent upon AMPK activation 
The pharmacological AMPK inhibitor, Compound C, was utilised to determine 
whether the A769662-mediated inhibition of IL-6-stimulated STAT3 
phosphorylation was dependent upon AMPK activation. Incubation of 3T3-L1 
adipocytes with IL-6/sIL-6R caused a 59.4  18.4 % or 52.6  20.1 stimulation of 
STAT3 Y705 phosphorylation, compared to the basal level in the absence or 
presence of Compound C, respectively. Preincubation with A769662 caused a 
subtle 36  20.2 % reduction in STAT3 phosphorylation relative to IL-6/sIL-6R 
treatment alone, while this was reduced to 28.5  29.2 % in the presence of 
Compound C (Fig. 4.4).  
3T3-L1 adipocytes are relatively genetically intractable; however siRNA-mediated 
AMPK1 knockdown in HUVECs caused a reduction in the ability of AICAR to 
suppress IL-6-stimulated STAT3 phosphorylation (Fig. 4.5). Moreover, three 
compounds which activate AMPK via diverse mechanisms all suppressed IL-6/sIL-
6R-stimulated STAT3 phosphoryaltion in HUVECs (Fig. 4.6). The data shown in 
Figures 4.5 and 4.6 were generated and analysed by Dr Claire Rutherford, 
University of Glasgow. 
4.2.4 Endogenous STAT3 phosphorylation in adipose tissue 
To examine the role of AMPK in the basal inflammatory status of adipose tissue, 
gonadal and subcutaneous adipose tissue was collected from female AMPK1-/- 
and litter-matched wild-type sv129 mice. The extent of STAT3 phosphorylation in 
lysates was assessed as a measure of activation by western blotting using 
phosphorylation site-specific antibodies. Lane 2 of AMPK1-/- was omitted for 
analysis purposes as AMPK was detectable in the lysates suggesting it may have 
been heterozygous or wild type with respect to AMPK1. 
Phosphorylation of STAT3 was increased 2 fold in AMPK1-/- gonadal adipose tissue 
compared to wild-type (p < 0.05) (Fig. 4.7). STAT3 phosphorylation was increased 
1.28 fold in AMPK1-/- subcutaneous adipose tissue compared to wild-type (Fig. 
4.8), however this did not reach significance (p = 0.17).  
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Figure 4-4: Effect of Compound C on A769662-mediated STAT3 inhibition 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 60 
min following preincubation for 30 min in the presence or absence of A769662 
(300 M) and 60 min in the presence or absence of Compound C (60 M) and 
lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated.  (A) Quantification of STAT3 Y705 
phosphorylation relative to total STAT3 was determined by densitometric 
analysis. Data shown represent the mean % ± SEM IL-6-stimulated STAT3 
phosphorylation of three independent experiments. (B) Representative western 
blot. 
A 
B 
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Figure 4-5: Effect of AMPK1 knockdown on AICAR-mediated STAT3 inhibition 
in HUVECs 
HUVECs transfected with AMPK1 or scrambled control siRNA were incubated 
with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 30 min following preincubation for 5 h 
in the presence or absence of AICAR (1 mM) and lysates prepared. Lysates were 
resolved by SDS-PAGE and subjected to immunoblotting with the antibodies 
indicated.  (A) Quantification of STAT3 Y705 phosphorylation relative to total 
STAT3 was determined by densitometric analysis. Data shown represent the mean 
% ± SEM maximum of two independent experiments. (B) Representative western 
blot. (Data generated and analysed by Dr Claire Rutherford, University of 
Glasgow) 
A 
B 
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Figure 4-6: Effect of AMPK activators on STAT3 inhibition in HUVECs 
HUVECs were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 30 min 
following preincubation in the presence or absence of Rosiglitazone (Rosi) (10 M; 
24 h), AICAR (1 mM; 2 h) or A769662 (100 M; 40 min) and lysates prepared. 
Lysates were resolved by SDS-PAGE and subjected to immunoblotting with the 
antibodies indicated.  (A) Quantification of STAT3 Y705 phosphorylation relative 
to total STAT3 was determined by densitometric analysis. Data shown represent 
the mean % ± SEM maximum of three independent experiments. (B) 
Representative western blots. (Data generated and analysed by Dr Claire 
Rutherford, University of Glasgow) 
A 
B 
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Figure 4-7: Basal STAT3 phosphorylation in gonadal adipose tissue from 
AMPK1+/+ and AMPK1-/- mice 
Gonadal adipose tissue obtained from AMPK1-/- and wild-type mice was resolved 
by SDS-PAGE and subjected to immunoblotting with the antibodies indicated. 
Data shown represent the mean ± SEM arbitrary densitometry units of 5 wild-type 
and 3 AMPK1-/- samples. (A) Quantification of STAT3 Y705 phosphorylation 
relative to total STAT3 was determined by densitometric analysis. *p < 0.05 
increase in STAT3 phosphorylation, relative to wild-type. (B) Representative 
western blot. 
A 
B 
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Figure 4-8: Basal STAT3 phosphorylation in subcutaneous adipose tissue from 
AMPK1+/+ and AMPK1-/- mice 
Subcutaneous adipose tissue obtained from AMPK1-/- and wild-type was resolved 
by SDS-PAGE and subjected to immunoblotting with the antibodies indicated. 
Data shown represent the mean ± SEM arbitrary densitometry units of 5 wild-type 
and 3 AMPK1-/- samples. (A) Quantification of STAT3 Y705 phosphorylation 
relative to total STAT3 was determined by densitometric analysis. (B) 
Representative western blot. 
A 
B 
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4.2.5 Investigating the mechanism: TSC2/mTOR/TC-PTP 
4.2.5.1 Effect of mTOR inhibition on IL-6 signalling 
AMPK has been reported to inhibit the mammalian target of rapamycin (mTOR) via 
activation of tuberous sclerosis protein 1/2 (TSC1/2) (Inoki, Zhu, and Guan 2003, 
Shaw et al. 2004). Furthermore, it has been suggested that mTOR mediates 
phosphorylation of STAT3 S727 (Yokogami et al. 2000); serine phosphorylation of 
STAT3 at this site has been proposed to promote full transcriptional activation of 
STAT3 (Wen, Zhong, and Darnell 1995). Thus, it was of interest to investigate the 
role of mTOR in the regulation of IL-6-stimulated STAT3 phosphorylation. PP242 
was chosen as a pharmacological inhibitor of mTOR, and it specifically inhibits 
both mTORC1 and mTORC2, as it binds directly to the ATP binding site of either 
(Feldman et al. 2009). Incubation of 3T3-L1 adipocytes with IL-6/sIL-6R caused 
a significant (p < 0.001) stimulation of STAT3 Y705 phosphorylation, compared to 
the basal level. A769662 modestly decreased IL-6-stimulated STAT3 
phosphorylation although this did not reach significance (Fig. 4.9A). Preincubation 
with PP242 caused a significant (p < 0.05) reduction in STAT3 Y705 
phosphorylation, relative to IL-6/sIL-6R treatment alone, to which A769662 had 
no additional effect (Fig. 4.9A). Phosphorylation of STAT3 S727 was unaffected by 
IL-6/sIL-6R, A769662 or PP242 in 3T3-L1 adipocytes (Fig. 4.9B). Phosphorylation 
of a well-characterised downstream target of mTOR, p70 S6 kinase (p70 S6K), was 
found to be significantly (p < 0.05) reduced following treatment with PP242 
compared to the absence of PP242. In contrast, incubation with A769662 caused 
a trend toward increased p70 S6K S371 phosphorylation compared to the absence 
of A769662; however, this did not reach significance (Fig. 4.9C). To determine 
whether the effects of A769662 and PP242 were specific to adipocytes, these 
experiments were repeated in MEFs. Incubation of MEFs with IL-6/sIL-6R caused 
a significant (p < 0.001) stimulation of STAT3 Y705 phosphorylation, compared to 
the basal level. Preincubation with A769662 caused a significant (p < 0.001) 
inhibition of STAT3 Y705 phosphorylation, relative to the absence of A769662 (Fig. 
4.10A). Preincubation with PP242 induced a subtle 18.6  4.9 % reduction in STAT3 
Y705 phosphorylation compared to IL-6/sIL-6R treatment alone; however this did 
not reach significance when analysed using one-way ANOVA. 
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Figure 4-9: Effect of mTOR inhibition on IL-6 signalling in 3T3-L1 adipocytes 
(continued overleaf) 
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Figure 4-9: Effect of mTOR inhibition on IL-6 signalling in 3T3-L1 adipocytes 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 60 
min following preincubation for 30 min in the presence or absence of A769662 
(300 M) and 3 h in the presence or absence of PP242 (2 M) and lysates prepared. 
Lysates were resolved by SDS-PAGE and subjected to immunoblotting with the 
antibodies indicated.  (A) Quantification of STAT3 Y705 phosphorylation relative 
to total STAT3 was determined by densitometric analysis. Data shown represent 
the mean ± SEM % IL-6-stimulated STAT3 Y705 phosphorylation of three 
independent experiments.  †††p < 0.001 (one-way ANOVA), increase in STAT3 Y705 
phosphorylation, relative to vehicle. *p < 0.05, (one-way ANOVA) reduction in 
STAT3 Y705 phosphorylation, relative to the absence of A769662. (B) 
Quantification of STAT3 S727 phosphorylation relative to total STAT3 was 
determined by densitometric analysis. Data shown represent the mean ± SEM % 
IL-6-stimulated STAT3 S727 phosphorylation of three independent experiments. 
(C) Quantification of p70 S6K S371 phosphorylation relative to total p70 S6K was 
determined by densitometric analysis. Data shown represent the mean ± SEM % 
vehicle p70 S6K phosphorylation of three independent experiments.  *p < 0.05 
(one-way ANOVA), increase in p70 S6K S371 phosphorylation, relative to vehicle. 
(D) Representative western blot. 
 
D 
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A two-tail t-test yielded a p value of 0.02, indicating there may be a tendency 
toward a PP242-mediated inhibition of STAT3 phosphorylation in MEFs. The 
inhibition of STAT3 phosphorylation observed following preincubation with 
A769662 remained unaffected in the presence of PP242 (Fig. 4.10A). 
Phosphorylation of STAT3 S727 was unaffected by IL-6/sIL-6R, A769662 or PP242 
in MEFs (Fig. 4.10B). Phosphorylation of p70 S6K S371 was significantly (p < 0.01) 
reduced following preincubation with PP242 compared to the absence of PP242 
(Fig. 4.10C). 
4.2.5.2 Effect of TSC2 knockout on A769662-mediated inhibition 
of STAT3 phosphorylation 
To determine whether the reduction in STAT3 phosphorylation by A769662 was 
mediated to any degree via inhibition of mTOR, TSC2-/-p53-/- MEFs and wild type 
control TSC2+/+p53-/- MEFs were incubated with IL-6/sIL-6R in the presence or 
absence of A769662 and the extent of STAT3 Y705 phosphorylation was 
determined by western blotting analysis of lysates. Incubation with A769662 
caused a significant increase, compared to the basal level, in ACC Ser79 
phosphorylation in both TSC2+/+p53-/- and TSC2-/-p53-/- MEFs (Fig. 4.11A). IL-6/sIL-
6R treatment caused a clear increase, compared to the basal level, in STAT3 
phosphorylation in both TSC2+/+p53-/- and TSC2-/-p53-/- MEFs; however this did not 
reach statistical significance with one-way ANOVA analysis. Using an alternative 
method of statistical analysis STAT3 Y705 phosphorylation was found to be 
significantly increased, compared to the basal level, in both TSC2+/+p53-/- (p < 
0.001) and TSC2-/-p53-/- (p < 0.05) MEFs (two-tail t-test). Preincubation with 
A769662 had no effect on IL-6/sIL-6R-stimulated STAT3 Y705 phosphorylation in 
either TSC2+/+p53-/- or TSC2-/-p53-/- MEFs compared to the absence of A769662 (Fig. 
4.9B). TSC2-/-p53-/- MEFs displayed a tendency towards increased IL-6/sIL-6R-
stimulated STAT3 Y705 phosphorylation compared to TSC2+/+p53-/- MEFs; however 
this did not reach significance (Fig. 4.11B). 
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Figure 4-10: Effect of mTOR inhibition on IL-6 signalling in mouse embryonic 
fibroblasts (continued overleaf) 
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Figure 4-10: Effect of mTOR inhibition on IL-6 signalling in mouse embryonic 
fibroblasts 
MEFs were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 60 min following 
preincubation for 30 min in the presence or absence of A769662 (300 M) and 3 h 
in the presence or absence of PP242 (2 M) and lysates prepared. Lysates were 
resolved by SDS-PAGE and subjected to immunoblotting with the antibodies 
indicated.  (A) Quantification of STAT3 Y705 phosphorylation relative to total 
STAT3 was determined by densitometric analysis. Data shown represent the mean 
± SEM % IL-6-stimulated STAT3 Y705 phosphorylation of three independent 
experiments.  †††p < 0.001 (one-way ANOVA), increase in STAT3 Y705 
phosphorylation, relative to vehicle. ***p < 0.001, (one-way ANOVA) reduction in 
STAT3 Y705 phosphorylation, relative to the absence of A769662. (B) 
Quantification of STAT3 S727 phosphorylation relative to total STAT3 was 
determined by densitometric analysis. Data shown represent the mean ± SEM % 
IL-6-stimulated STAT3 S727 phosphorylation of three independent experiments.  
(C) Quantification of p70 S6K S371 phosphorylation relative to total p70 S6K was 
determined by densitometric analysis. Data shown represent the mean ± SEM % 
vehicle p70 S6K phosphorylation of three independent experiments.  **p < 0.01 
(one-way ANOVA), increase in p70 S6K S371 phosphorylation, relative to vehicle. 
(D) Representative western blot. 
D 
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Figure 4-11: Effect of TSC2 knockout on AMPK-mediated inhibition of STAT3 
phosphorylation (legend overleaf) 
A 
B 
C 
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Figure 4-11: Effect of TSC2 knockout on AMPK-mediated inhibition of STAT3 
phosphorylation 
TSC2+/+p53-/- or TSC2-/-p53-/- MEFs were incubated with IL-6/sIL-6R (5 ng/ml; 25 
ng/ml) for 60 min following preincubation for 30 min in the presence or absence 
of A769662 (300 M) and lysates prepared. Lysates were resolved by SDS-PAGE 
and subjected to immunoblotting with the antibodies indicated.  (A) 
Quantification of ACC S79 phosphorylation relative to ACC was determined by 
densitometric analysis. Data shown represent the mean ± SEM % A769662-
stimulated ACC phosphorylation of three independent experiments.  †††p < 0.001, 
p < 0.05, p < 0.01 (one-way ANOVA), increase in ACC S79 phosphorylation, 
relative to TSC2+/+p53-/- or TSC2-/-p53-/- vehicle, respectively. (B) Quantification 
of STAT3 Y705 phosphorylation relative to STAT3 was determined by 
densitometric analysis. Data shown represent the mean ± SEM % TSC2+/+p53-/- IL-
6 stimulated STAT3 phosphorylation of three independent experiments. (C) 
Representative western blot. 
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4.2.5.3 Potential role of p53 in AMPK-mediated reduction in 
STAT3 phosphorylation 
As IL-6/sIL-6R-stimulated STAT3 phosphorylation was not inhibited by A769662 
in TSC2+/+p53-/- MEFs, it was important to determine whether p53 was necessary 
for AMPK-mediated regulation of STAT3 phosphorylation. Adenovirus-mediated 
gene transfer was used to express wild-type p53 in TSC2+/+p53-/- mouse embryonic 
fibroblasts in order to investigate the effect of p53 in AMPK-mediated inhibition 
of IL-6/sIL-6R-stimulated STAT3 Y705 phosphorylation. 
Incubation with A769662 caused a significant increase in ACC Ser79 
phosphorylation in both Ad.Null and Ad.p53 infected TSC2+/+p53-/- MEFs (p < 0.05 
and p < 0.001, respectively) (Fig. 4.12A). IL-6/sIL-6R caused a significant (p < 
0.001) increase in STAT3 Y705 phosphorylation in both Ad.Null and Ad.p53 infected 
TSC2+/+p53-/- MEFs; however preincubation with A769662 failed to reduce STAT3 
Y705 phosphorylation in either Ad.Null or Ad.p53 infected TSC2+/+p53-/- MEFs (Fig. 
4.12B). 
4.2.6 Effect of phosphatases on AMPK-mediated regulation of IL-
6 signalling 
In order to determine whether inhibition of IL-6-stimulated STAT3 phosphorylation 
by AMPK was mediated by the increased action of a phosphatase, genetic and 
pharmacological approaches were utilised to ablate the action of two key 
phosphatases known to be upstream of STAT3 in the JAK/STAT pathway. 
4.2.6.1 T-cell protein tyrosine phosphatase (TC-PTP) 
STAT3 and JAK1 have been reported to be substrates of TC-PTP (Fukushima et al. 
2010), while AMPK activation has been reported to alter cellular localisation of 
TC-PTP (Lam et al. 2001). This study therefore sought to determine whether 
inhibition or ablation of T cell protein tyrosine phosphatase (TC-PTP) altered AMPK 
or mTOR-mediated inhibition of STAT3 phosphorylation. 
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Figure 4-12: Effect of p53 on AMPK-mediated inhibition of STAT3 
phosphorylation (legend overleaf) 
A 
B 
C 
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Figure 4-12: Effect of p53 on AMPK-mediated inhibition of STAT3 
phosphorylation 
TSC2+/+p53-/- MEFs were infected with 100 ifu/cell for 48 h with Ad.p53 or Ad.Null 
prior to stimulation with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 60 min following 
preincubation for 30 min in the presence or absence of A769662 (300 M) and 
lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated.  (A) Quantification of ACC S79 
phosphorylation relative to total ACC was determined by densitometric analysis. 
Data shown represent the mean  SEM % A769662-stimulated ACC phosphorylation 
of three independent experiments.  †p < 0.05, p < 0.001, (one-way ANOVA), 
increase in ACC S79 phosphorylation, relative to Ad.Null or Ad.p53 vehicle, 
respectively. (B) Quantification of STAT3 Y705 phosphorylation relative to total 
STAT3 was determined by densitometric analysis. Data shown represent the mean 
 SEM % IL-6 stimulated STAT3 phosphorylation of three independent 
experiments. †††p < 0.001, p < 0.001 (one-way ANOVA), increase in STAT3 Y705 
phosphorylation, relative to Ad.Null or Ad.p53 vehicle, respectively. (C) 
Representative western blot. 
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AMPK 
Incubation of 3T3-L1 adipocytes with IL-6/sIL-6R caused a significant (p < 0.001) 
increase, compared to the basal level, in STAT3 Y705 phosphorylation. This was 
significantly inhibited following preincubation with A769662 (p < 0.01) (Fig. 4.13). 
Preincubation with a pharmacological TC-PTP inhibitor (Zhang et al. 2009) had no 
effect on either IL-6/sIL-6R-stimulated STAT3 phosphorylation or the A769662-
mediated reduction in IL-6/sIL-6R-stimulated STAT3 phosphorylation (Fig. 4.13). 
IL-6/sIL-6R induced a significant (p < 0.001) increase, compared to the basal 
level, in STAT3 Y705 phosphorylation in both TC-PTP+/+ (wild-type) and TC-PTP-/- 
MEFs (Fig. 4.14). Preincubation with A769662 caused a significant (p < 0.001) 
reduction in STAT3 Y705 phosphorylation in both wild-type and TC-PTP-/- MEFs, 
relative to IL-6/sIL-6R treatment alone (Fig. 4.14). 
mTOR 
IL-6/sIL-6R induced a significant (p < 0.05) increase, compared to the basal level, 
in STAT3 Y705 phosphorylation in wild-type, but not TC-PTP-/- MEFs (Fig. 4.15A). 
In wild-type MEFs, preincubation with PP242 caused a 36.9  9.2 % reduction in 
phosphorylation of STAT3 Y705, compared to IL-6/sIL-6R treatment alone; 
however PP242 had no effect on IL-6/sIL-6R-stimulated STAT3 Y705 
phosphorylation in TC-PTP-/- MEFs (Fig. 4.15A). STAT3 protein expression was 
significantly (p < 0.001) increased in TC-PTP-/- MEFs compared to wild-type TC-
PTP+/+ MEFs (Fig. 4.15B). 
4.2.6.2 SH2-containing tyrosine phosphatase (SHP-2) 
SHP-2 has been reported to negatively regulate IL-6-stimulated STAT3 
phosphorylation (Ohtani et al. 2000). Thus, in order to determine whether 
inhibition of SHP-2 in 3T3-L1 adipocytes could ablate the AMPK-mediated 
inhibition of IL-6-stimulated STAT3 phosphorylation, 3T3-L1 adipocytes were 
incubated with a SHP-2 pharmacological inhibitor NSC 87877 (Chen et al. 2006), 
IL-6/sIL-6R or A769662 and the extent of STAT3 Y705 phosphorylation was 
assessed as a measure of activation by western blotting using phosphorylation site-
specific antibodies. IL-6/sIL-6R induced a significant (p < 0.001) increase, 
compared to the basal level, in STAT3 Y705 phosphorylation in both the presence 
and absence of NSC 87877 (Fig. 4.16). 
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Figure 4-13: Effect of TC-PTP on AMPK-mediated inhibition of STAT3 
phosphorylation in 3T3-L1 adipocytes 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 60 
min following preincubation for 30 min in the presence or absence of A769662 
(300 M) and 2 h in the presence or absence of TC-PTP inhibitor (Lysates were 
resolved by SDS-PAGE and subjected to immunoblotting with the antibodies 
indicated.  (A) Quantification of STAT3 Y705 phosphorylation relative to total 
STAT3 was determined by densitometric analysis. Data shown represent the mean 
± SEM % IL-6-stimulated STAT3 phosphorylation of three independent 
experiments.  †††p < 0.001 (one-way ANOVA), increase in STAT3 Y705 
phosphorylation, relative to vehicle. **p < 0.01, ***p < 0.001, (one-way ANOVA) 
reduction in STAT3 Y705 phosphorylation, relative to the absence of A769662. (B) 
Representative western blot. 
B 
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Figure 4-14: Effect of TC-PTP on AMPK-mediated inhibition of STAT3 
phosphorylation in mouse embryonic fibroblasts 
TC-PTP+/+ (wild-type) and TC-PTP-/- MEFs were incubated with IL-6/sIL-6R (5 
ng/ml; 25 ng/ml) for 60 min following preincubation for 30 min in the presence 
or absence of A769662 (300 M) and lysates prepared. Lysates were resolved by 
SDS-PAGE and subjected to immunoblotting with the antibodies indicated.  (A) 
Quantification of STAT3 Y705 phosphorylation relative to total STAT3 was 
determined by densitometric analysis. Data shown represent the mean ± SEM % 
IL-6-stimulated STAT3 phosphorylation of six independent experiments.  †††p < 
0.001 (one-way ANOVA), increase in STAT3 Y705 phosphorylation, relative to 
vehicle. ***p < 0.001, (one-way ANOVA) reduction in STAT3 Y705 phosphorylation, 
relative to the absence of A769662. (B) Representative western blot with samples 
resolved at the same time on separate gels. 
A 
B 
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Figure 4-15: Effect of TC-PTP on mTOR-mediated inhibition of STAT3 
phosphorylation (legend overleaf)
A 
B 
C 
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Figure 4-15: Effect of TC-PTP on mTOR-mediated inhibition of STAT3 
phosphorylation 
TC-PTP+/+ (wild-type) and TC-PTP-/- MEFs were incubated with IL-6/sIL-6R (5 
ng/ml; 25 ng/ml) for 60 min following preincubation for 3 h in the presence or 
absence of PP242 (2 M) and lysates prepared. Lysates were resolved by SDS-PAGE 
and subjected to immunoblotting with the antibodies indicated.  (A) 
Quantification of STAT3 Y705 phosphorylation relative to total STAT3 was 
determined by densitometric analysis. Data shown represent the mean ± SEM % 
IL-6-stimulated STAT3 phosphorylation of three independent experiments.  †p < 
0.05 (one-way ANOVA), increase in STAT3 Y705 phosphorylation, relative to 
vehicle. (B) Quantification of STAT3 expression was determined relative to 
GAPDH by densitometric analysis. Data shown represent the mean ± SEM % wild-
type STAT3 expression of three independent experiments. ***p < 0.001 (two-tail 
t-test), increase in STAT3 expression, relative to wild-type. (C) Representative 
western blot.
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Preincubation with A769662 caused a significant reduction in STAT3 Y705 
phosphorylation, in both the presence and absence of NSC 87877 (p < 0.01 and p 
< 0.05, respectively), compared to IL-6/sIL-6R treatment alone (Fig. 4.16). 
4.2.6.3 Sodium orthovanadate 
In order to determine whether AMPK inhibited IL-6-stimulated STAT3 
phosphorylation via a dephosphorylation mechanism in 3T3-L1 adipocytes, cells 
were incubated with the tyrosine phosphatase inhibitor sodium orthovanadate, 
A769662 or IL-6/sIL-6R and the extent of STAT3 Y705 phosphorylation 
determined by western blotting analysis. 
Incubation of 3T3-L1 adipocytes with IL-6/sIL-6R caused a significant (p < 0.05) 
increase, compared to the basal level, in STAT3 Y705 phosphorylation (Fig. 4.17). 
IL-6/sIL-6R-stimulated STAT3 Y705 phosphorylation was further increased in the 
presence of sodium orthovanadate (p < 0.001), compared to IL-6/sIL-6R 
treatment alone. Preincubation with A769662 caused a 49.3  9.9 % reduction in 
STAT3 Y705 phosphorylation, relative to IL-6/sIL-6R treatment alone. This did 
not reach significance upon analysis using one-way ANOVA; however a two-tail t-
test generated a p value of 0.008. A769662 treatment significantly (p < 0.001) 
reduced IL-6/sIL-6R-stimulated STAT3 Y705 phosphorylation in the presence of 
sodium orthovanadate, compared to the absence of A769662 (Fig. 4.17). The 
presence of total phosphorylated tyrosine in these experiments was examined in 
order to confirm the effectiveness of sodium orthovanadate as a tyrosine 
phosphatase inhibitor. The representative blot (Fig. 4.17C) demonstrated an 
increase in phosphorylated tyrosine following sodium orthovanadate treatment, 
relative to the absence of the compound. 
4.2.7 Role of JAK2 in AMPK-mediated inhibition of STAT3 
phosphorylation 
To determine whether AMPK activation influenced JAK stimulation by IL-6, JAK 
activation parameters in response to IL-6/sIL-6R in the presence or absence of 
A769662 were assessed in 3T3-L1 adipocytes.  
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Figure 4-16: Effect of SHP-2 on AMPK-mediated inhibition of STAT3 
phosphorylation 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 60 
min following preincubation for 30 min in the presence or absence of A769662 
(300 M) and 1 h in the presence or absence of the SHP-2 inhibitor NSC 87877 (50 
M) and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated.  (A) Quantification of STAT3 Y705 
phosphorylation relative to total STAT3 was determined by densitometric 
analysis. Data shown represent the mean ± SEM % IL-6-stimulated STAT3 
phosphorylation of three independent experiments.  †††p < 0.001 (one-way 
ANOVA), increase in STAT3 Y705 phosphorylation, relative to vehicle. *p < 0.05, 
**p < 0.01, (one-way ANOVA) reduction in STAT3 Y705 phosphorylation, relative 
to the absence of A769662. (B) Representative western blot. 
B 
A 
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Figure 4-17: Effect of sodium orthovanadate on AMPK-mediated inhibition of 
STAT3 phosphorylation (legend overleaf) 
 
A 
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Figure 4-17: Effect of sodium orthovanadate on AMPK-mediated inhibition of 
STAT3 phosphorylation 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 60 
min following preincubation for 30 min in the presence or absence of A769662 
(300 M) and 30 min in the presence or absence of sodium orthovanadate (2 mM) 
and lysates prepared. Lysates were resolved by SDS-PAGE and subjected to 
immunoblotting with the antibodies indicated.  (A) Quantification of STAT3 Y705 
phosphorylation relative to total STAT3 was determined by densitometric 
analysis. Data shown represent the mean % IL-6-stimulated STAT3 
phosphorylation of three independent experiments. †p < 0.05, †††p < 0.001 (one-
way ANOVA), increase in STAT3 Y705 phosphorylation, relative to vehicle. p < 
0.001 (one-way ANOVA) reduction in STAT3 Y705 phosphorylation, relative to the 
absence of A769662. ***p < 0.001, (one-way ANOVA) increase in STAT3 Y705 
phosphorylation, relative to the absence of sodium orthovanadate. (B & C) 
Representative western blots. 
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The extent of JAK1 and JAK2 phosphorylation was assessed as a measure of 
activation by western blotting using phosphorylation site-specific antibodies. 
Incubation of 3T3-L1 adipocyte lysates with IL-6/sIL-6R in the absence of 
A769662 induced an increase in an immunoreactive band of approximately 70-75 
kDa at 15 and 30 min when probed with an antibody raised against JAK2 
Y1007/1008 (Fig. 4.18A). Preincubation with A769662 reduced the intensity of 
these bands. In contrast, incubation with an antibody raised against total JAK2 
produced bands of the predicted molecular mass (125 kDa) (Fig. 4.18E). Incubation 
with IL-6/sIL-6R did not alter JAK1 Y1022/1023 phosphorylation in 3T3-L1 
adipocytes (Fig. 4.18C). Furthermore, there was no difference in total protein 
levels of JAK1 (Fig. 4.18B) or JAK2 (4.18D). 
As the anti-JAK2 Y1007/1008 antibody detected bands of the incorrect size, it was 
of interest to immunoprecipitate JAK2 from the whole cell lysate to avoid any 
potential cross-reactivity with another protein. JAK2 was immunoprecipitated 
from 3T3-L1 adipocyte lysates in which cells had been incubated in the presence 
or absence of IL-6/sIL-6R for 15 min. JAK2 was detected at approximately 125 
kDa in the lysate and the immunoprecipitate; however there appeared to be less 
immunoprecipitated in the presence of IL-6/sIL-6R, relative to unstimulated 
cells. JAK2 was also detected in the immunodeplete, indicating incomplete 
immunoprecipitation (Fig. 4.19). JAK2 Y1007/1008 was undetectable in the whole 
cell lysate; however a band which could correspond to JAK2 Y1007/1008 was 
detected in the JAK2 immunoprecipitate; however this appeared reduced in the 
presence of IL-6/sIL-6R, compared to vehicle. Interestingly, the band 
corresponding to 70-75 kDa was also present in the whole cell lysate, 
immunodeplete and JAK2 immunoprecipitate when probed with anti-JAK2 
Y1007/1008, and was increased in the presence of IL-6/sIL-6R relative to the 
basal level (Fig. 4.19).
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Figure 4-18: Effect of A769662 on IL-6-stimulated JAK phosphorylation 
(continued overleaf) 
A 
B 
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Figure 4-18: Effect of A769662 on IL-6-stimulated JAK phosphorylation 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 
various durations following preincubation for 30 min in the presence or absence 
of A769662 (300 M) and lysates prepared. Lysates were resolved by SDS-PAGE 
and subjected to immunoblotting with the antibodies indicated. The unknown 
band refers to the band detected at 70-75 kDa with anti-JAK2 Y1007/1008. (A) 
Quantification of unknown band phosphorylation relative to GAPDH was 
determined by densitometric analysis. Data shown represent the mean ± SEM % 
maximum unknown band phosphorylation of three independent experiments. †p < 
0.05, †††p < 0.001 (two-way ANOVA), increase in unknown band phosphorylation, 
relative to vehicle. ***p < 0.001 (two-way ANOVA), reduction in unknown band 
phosphorylation, relative to the absence of A769662. (B) Quantification of JAK2 
expression relative to GAPDH was determined by densitometric analysis. Data 
shown represent the mean ± SEM % maximum JAK2 of three independent 
experiments. (C) Quantification of JAK1 Y1022/1023 phosphorylation relative to 
total JAK1 was determined by densitometric analysis. Data shown represent the 
mean ± SEM % maximum JAK1 phosphorylation of three independent experiments. 
(D) Quantification of JAK1 expression relative to GAPDH was determined by 
densitometric analysis. Data shown represent the mean % maximum JAK1 of three 
independent experiments. (E) Representative western blot. 
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Figure 4-19: Effect of IL-6 on JAK2 phosphorylation 
JAK2 was immunoprecipitated from 3T3-L1 lysates (200 g) obtained from cells 
incubated in the presence or absence of IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 15 
min. Immunoprecipitates (IP) and immunodepleted lysates (ID) were resolved on 
10 % SDS-PAGE, transferred to nitrocellulose and probed with anti-JAK2 and anti-
JAK2 Y1007/1008 antibodies. Western blot from a single experiment. 
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4.2.8 Effect of JAK2 V617F mutant on AMPK-mediated inhibition 
of JAK/STAT phosphorylation 
4.2.8.1 HEK-293 cells 
The data presented in Figures 4.18 and 4.19 suggest that JAK2 phosphorylation 
may be altered by A769662 stimulation. In order to determine whether AMPK may 
reduce STAT3 phosphorylation via direct inhibition of JAK2, a mutant JAK2 (V617F) 
which is essentially constitutively active, or the empty plasmid control pRK5, was 
transfected into HEK-293 cells. Cells were incubated in the presence or absence 
of A769662 and the extent of ACC S79, JAK2 Y1007/1008, STAT3 Y705 and STAT5 
Y694 phosphorylation were determined by western blotting analysis of HEK-293 
lysates. 
Incubation of HEK-293 cells with A769662 caused a significant (p < 0.001) increase, 
compared to the basal level, in ACC S79 phosphorylation in both JAK2 V617F and 
pRK5 transfected cells (Fig. 4.20A). Transfection of HEK-293 cells with the JAK2 
V617F mutant caused a significant (p < 0.001) increase in phosphorylation of JAK2 
Y1007/1008, STAT3 Y705 and STAT5 Y694, compared to control cells transfected 
with pRK5 (Fig. 4.20B, 4.20C and 4.20D, respectively). Preincubation with A769662 
had no effect on the extent of JAK2 Y1007/1008, STAT3 Y705 or STAT5 Y694 
phosphorylation in HEK-293 cells transfected with the JAK2 V617F mutant, relative 
to the absence of A769662 (Fig. 4.20B, 4.20C and 4.20D, respectively). Incubation 
with IL-6/sIL-6R did not stimulate phosphorylation of JAK2 Y1007/1008, STAT3 
Y705 or STAT5 Y694 in HEK-293 cells (Fig. 4.20E). 
4.2.8.2 HeLa cells 
In this study, HEK-293 cells did not respond to IL-6/sIL-6R. It was therefore of 
interest to determine whether AMPK could inhibit IL-6-stimulated STAT3 
phosphorylation in the presence of the JAK2 V617F mutant. In this preliminary 
experiment the JAK2 V617F mutant or pRK5 empty plasmid were transfected into 
HeLa cells, which were then incubated with IL-6/sIL-6R in the presence or 
absence of A769662 and the extent of ACC S79 and STAT3 Y705 phosphorylation 
was determined by western blotting analysis of HeLa lysates. 
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Incubation of HeLa cells with A769662 caused an increase, compared to the basal 
level, in ACC S79 phosphorylation in untransfected, JAK2 V617F, pRK5 and mock 
transfected cells (Fig. 4.21A). Transfection of HeLa cells with the JAK2 V617F 
mutant caused an increase in STAT3 Y705 phosphorylation, compared to control 
cells transfected with pRK5 (Fig. 4.21B). Incubation with IL-6/sIL-6R clearly 
increased STAT3 Y705 phosphorylation, relative to the absence of IL-6/sIL-6R in 
both JAK2 V617F and pRK5 control transfected HeLa cells. Preincubation with 
A769662 had no effect on STAT3 Y705 phosphorylation in HeLa cells transfected 
with the JAK2 V617F mutant, compared to the absence of A769662 (Fig. 4.21B). 
In untransfected, mock and pRK5 transfected cells, preincubation with A769662 
inhibited IL-6/sIL-6R-stimulated STAT3 Y705 phosphorylation relative to the 
absence of A769662 (Fig. 4.21B).
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Figure 4-20: Effect of JAK2 mutant on AMPK-mediated inhibition of JAK/STAT 
signalling in HEK-293 cells (continued overleaf) 
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Figure 4-20: Effect of JAK2 mutant on AMPK-mediated inhibition of JAK/STAT 
signalling in HEK-293 cells 
HEK-293 cells were transfected with mutant JAK2 V617F or pRK5 for 48 h prior to 
stimulation for 30 min with A769662 (300 M) and cell lysates prepared. Lysates 
were resolved by SDS-PAGE and subjected to immunoblotting with the antibodies 
indicated. (A) Quantification of ACC S79 phosphorylation relative to total ACC 
was determined by densitometric analysis. Data shown represent the mean ± SEM 
% A769662 stimulated phosphorylation of five independent experiments. †††p < 
0.001 (one-way ANOVA), increase in ACC S79 phosphorylation, relative to vehicle. 
(B – D) Data shown represent the mean ± SEM % vehicle stimulated 
phosphorylation of five independent experiments. (B) Quantification of JAK2 
Y1007/1008 phosphorylation relative to total JAK2 was determined by 
densitometric analysis. ***p < 0.001 (one-way ANOVA), increase in JAK2 
Y1007/1008 phosphorylation, relative to pRK5-transfected. (C) Quantification of 
STAT3 Y705 phosphorylation relative to total STAT3 was determined by 
densitometric analysis. ***p < 0.001 (one-way ANOVA), increase in STAT3 Y705 
phosphorylation, relative to pRK5-transfected. (D) Quantification of STAT5 Y694 
phosphorylation relative to total STAT5 was determined by densitometric 
analysis. ***p < 0.001 (one-way ANOVA), increase in STAT5 Y694 phosphorylation, 
relative to pRK5-transfected. (E) Representative western blot. 
E 
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Figure 4-21: Effect of JAK2 mutant on AMPK-mediated inhibition of JAK/STAT 
signalling in HeLa cells (legend overleaf) 
B 
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Figure 4-21: Effect of JAK2 mutant on AMPK-mediated inhibition of JAK/STAT 
signalling in HeLa cells 
HeLa cells were transfected with mutant JAK2 V617F or pRK5 for 48 h prior to 
stimulation for 60 min with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) following 
preincubation for 30 min with A769662 (300 M) and cell lysates prepared. 
Lysates were resolved by SDS-PAGE and subjected to immunoblotting with the 
antibodies indicated. (A) Quantification of ACC S79 phosphorylation relative to 
total ACC was determined by densitometric analysis. Data shown represent the % 
A769662 stimulated phosphorylation of a single experiment. (B) Quantification of 
STAT3 Y705 phosphorylation relative to total STAT3 was determined by 
densitometric analysis. Data shown represent the % vehicle stimulated 
phosphorylation of a single experiment. (C) Western blot from a single 
experiment. 
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4.3 Discussion 
The key findings of this chapter are that AMPK activation in adipocytes inhibited 
IL-6-stimulated phosphorylation of STAT3, by a mechanism likely to be via 
inhibition of JAK phosphorylation, and not via the action of a phosphatase. 
Furthermore, inhibition of mTOR also inhibited IL-6-stimulated STAT3 
phosphorylation, and this may be mediated, at least in part, via TC-PTP, and is 
likely to occur independently of AMPK activation.  
Initial studies were undertaken to initially assess whether IL-6 could induce AMPK 
activation in 3T3-L1 adipocytes. IL-6 has been reported to have a varied influence 
on AMPK activity in different cell types, with multiple lines of evidence suggesting 
IL-6 stimulates AMPK in muscle (Kelly et al. 2004, Carey et al. 2006); conversely, 
IL-6-deficient mice have been reported to have reduced AMPK activity in muscle 
and adipose tissue (Kelly et al. 2004). Furthermore, Wan and co-workers recently 
reported increased IL-6-stimulated phosphorylation of AMPK and ACC in cultured 
epididymal adipose tissue (Wan et al. 2012), while in contrast, there was reported 
to be no difference in AMPK activity in SCAT of both wild-type and IL-6-deficient 
mice (Brandt et al. 2012).  IL-6 has been reported to inhibit AMPK activity in 
endothelial cells (Yuen et al. 2009), while it has recently been found that IL-6 has 
no effect on AMPK activity in HepG2 cells (Nerstedt et al. 2010, Nerstedt et al. 
2013) or rat primary hepatocytes (Kim et al. 2012). In this study, Figure 4.1 
demonstrated that IL-6 had no effect on AMPK Thr172 phosphorylation in 3T3-L1 
adipocytes, either relative to A769662-stimulated (Fig. 4.1A) or vehicle (Fig. 
4.1B). Furthermore, ACC Ser79 phosphorylation remained unaltered following IL-
6 treatment in adipocytes isolated from rat epididymal adipose tissue (Fig. 4.1D). 
Taken together, these data strongly suggest AMPK activity is not influenced 
acutely by IL-6 in adipocytes. IL-6 may, however, influence AMPK activity in other 
tissues, particularly muscle during exercise by an as yet uncharacterised 
mechanism.  
In addition to proinflammatory cytokines such as TNF- and IL-1, IL-6 has also 
been found to be upregulated in obese adipose tissue. In this study the temporal 
activation of downstream components of the IL-6 signalling pathway and their 
subsequent inhibition by AMPK was examined. Figure 4.2 demonstrated that the 
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IL-6/sIL-6R complex stimulated the JAK-STAT pathway in 3T3-L1 adipocytes, with 
increased phosphorylation of STAT3 Y705 over the duration of the experiment, 
peaking at 30 to 60 min of cytokine stimulation. In contrast, treatment with the 
IL-6/sIL-6R complex did not stimulate ERK1/2 T202/204 phosphorylation (Fig. 
4.3). This is consistent with previous reports in 3T3-L1 adipocytes and isolated 
human adipocytes (Andersson et al. 2007, Rotter, Nagaev, and Smith 2003). 
A769662 significantly reduced IL-6-stimulated STAT3 phosphorylation (Fig. 4.2). 
Prior to this study, very little was known about the regulation of IL-6-stimulated 
inflammatory signalling by AMPK. Shortly after this study began, Nerstedt and co-
workers reported that AICAR-mediated AMPK activation inhibited IL-6-stimulated 
inflammatory signalling in the human hepatocarcinoma cell line HepG2 via 
inhibition of STAT3 phosphorylation (Nerstedt et al. 2010). Moreover, it has 
recently been reported that both AICAR and metformin suppressed IL-6-stimulated 
STAT3 phosphorylation in both HepG2 and mouse liver cells (Nerstedt et al. 2013), 
thus data generated in the current study supports these published findings. In 
contrast, a recent study found that metformin, but not AICAR, reduced STAT3 
phosphorylation in a STAT3-positive lung cancer cell line (Lin et al. 2013), thereby 
suggesting an AMPK-independent mechanism of metformin. Interestingly, 
adiponectin has been reported to suppress STAT3 S727 phosphorylation in an 
AMPK-dependent manner; however STAT3 Y705 was not examined (Wu et al. 
2012). The role of serine phosphorylation of STAT3 is controversial: it has been 
reported to promote full transcriptional activation of STAT3 (Wen, Zhong, and 
Darnell 1995), while others propose that serine phosphorylation may negatively 
regulate STAT3 Y705 phosphorylation, dimerisation, nuclear translocation and 
subsequent transcriptional activity (Chung et al. 1997, Wakahara et al. 2012). In 
the current study STAT3 S727 phosphorylation was not altered by IL-6 or A769662 
treatment in 3T3-L1 adipocytes or mouse embryonic fibroblasts (Fig. 4.9B and Fig. 
4.10B, respectively); these data support similar findings recently reported by 
Nerstedt and co-workers, in which STAT3 S727 phosphorylation was not affected 
by acute IL-6, AICAR or metformin treatment in HepG2 cells (Nerstedt et al. 2013). 
In contrast, sustained (24 h) IL-6 treatment has been reported to induce STAT3 
S727 phosphorylation in 3T3-L1 adipocytes, with a simultaneous increase in Y705 
phosphorylation (Serrano-Marco et al. 2011). Taken together, the mechanism and 
consequences of serine phosphorylation of STAT3 are still poorly understood; 
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however these data suggest that IL-6 does not acutely stimulate STAT3 S727 
phosphorylation in 3T3-L1 adipocytes.  
In order to determine whether the ability of A769662 to suppress IL-6-stimulated 
STAT3 phosphorylation was dependent upon AMPK activation, the pharmacological 
inhibitor Compound C was utilised. Figure 4.4 suggested that the tendency toward 
A769662-mediated inhibition of STAT3 phosphorylation may be abolished in the 
presence of Compound C; however there was a high degree of variability 
associated with these particular experiments. This is likely due to the reduced 
number of replicates, as it was necessary to only select data where inhibition of 
AMPK activation by Compound C was also observed (Fig. 4.1A). As discussed in 
Chapter 3, results generated using Compound C should be interpreted with care 
as it has been found to inhibit other protein kinases. 3T3-L1 adipocytes are 
relatively intractable to transient transfection or infection with adenoviruses, as 
discussed in Chapter 3. siRNA-mediated knockdown of AMPK1 in HUVECs 
ameliorated suppression of STAT3 phosphorylation by AICAR, relative to cells 
transfected with the scrambled control (Fig. 4.5). Furthermore, IL-6-stimulated 
STAT3 phosphorylation was reduced following activation of AMPK by rosiglitazone, 
AICAR and A769662. This further supports the AMPK dependence of inhibition of 
STAT3 phosphorylation as these compounds all activate AMPK via different 
mechanisms.  
Adipose tissue obtained from AMPK1-/- and genetically matched wild-type mice 
provided further evidence for the anti-inflammatory role of AMPK in adipose 
tissue. Basal phosphorylation of STAT3 was found to be significantly increased in 
gonadal adipose tissue from AMPK1-/- mice compared to wild-type (Fig. 4.7), 
while there appeared to be a subtle increase in STAT3 phosphorylation in 
subcutaneous adipose tissue from AMPK1-/- mice compared to wild-type (Fig. 
4.8). These data support the finding that adipose tissue from AMPK1-/- mice 
exhibited increased basal JNK phosphorylation compared to wild-type (Fig. 3.10 
and 3.11). To our knowledge, this is the first time such an observation has been 
made in adipose tissue. Taken together, these data demonstrate for the first time 
that basal JNK and STAT3 signalling are increased in adipose tissue the absence of 
AMPK1. This could suggest a role for AMPK in the suppression of basal cytokine 
synthesis or signalling; however it is important to note that adipose-specific 
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AMPK1-/- mice do not currently exist, therefore these observations could be the 
result of secondary indirect effects from other tissues in which AMPK1 is ablated. 
Another member of the STAT family, STAT4, has recently been proposed to play a 
key role in the development of inflammation and insulin resistance in adipocytes. 
Dobrian and co-workers found that while STAT4-deficient mice developed obesity 
similar to their wild-type controls when challenged with a high-fat diet, they 
exhibited greater insulin sensitivity. Furthermore, they displayed improved 
adipocyte inflammation and insulin signalling (Dobrian et al. 2013). STAT4 is 
primarily activated by IL-12, and while the source and temporal production of IL-
12 in WAT remains unclear (Knudsen and Lee 2013), this work further implicates 
the JAK/STAT pathway in the development of inflammation and insulin resistance 
in adipocytes. 
mTOR is a serine/threonine kinase found as two structurally and functionally 
different complexes, mTORC1 and mTORC2, and regulates cell growth and 
proliferation, controlling energy-consuming processes such as mRNA translation 
and ribosomal biogenesis. The presence of amino acids are required for mTOR 
activation, while under low cellular energy conditions AMPK has been found to 
reduce mTOR activity, as measured by phosphorylation of downstream target p70 
S6 kinase (Kimura et al. 2003). AMPK has been proposed to do so indirectly via 
phosphorylation of TSC2, a negative regulator of mTOR (Inoki, Zhu, and Guan 
2003), or directly via raptor, a component of mTORC1 (Gwinn et al. 2008).  
Studies utilising TSC2-deficient cells or siRNA-mediated knockdown of TSC2 have 
reported an increase in STAT3 Y705 and S727 phosphorylation; conversely, 
inhibition of mTOR with rapamycin ameliorated STAT3 phosphorylation with a 
subsequent reduction in transcriptional activity (Weichhart et al. 2008, Onda et 
al. 2002, Goncharova et al. 2009, Chen et al. 2012). It was of interest, therefore, 
to investigate the role of mTOR in the regulation of IL-6-stimulated STAT3 
phosphorylation in adipocytes using the pharmacological mTORC1/2 inhibitor 
PP242. In the current study phosphorylation of STAT3 S727 was not found to be 
altered by PP242 treatment in either 3T3-L1 adipocytes or MEFs (Fig. 4.9B and Fig. 
4.10B, respectively). mTORC1 has previously been reported to stimulate 
phosphorylation of STAT3 at S727 in CNTF-stimulated  neuroblastoma cells 
(Yokogami et al. 2000), though as described above, the mechanism and the effects 
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of STAT3 serine phosphorylation are largely poorly understood. PP242-mediated 
mTOR inhibition significantly reduced IL-6-stimulated STAT3 Y705 phosphorylation 
in 3T3-L1 adipocytes (Fig. 4.9A) and A769662 had no further effect on PP242-
mediated suppression of STAT3 phosphorylation (Fig. 4.9A). The same experiments 
performed in MEFs demonstrated a significant reduction in IL-6-stimulated STAT3 
phosphorylation in response to A769662 (Fig. 4.10A); while inhibition of mTOR 
with PP242 induced a tendency toward a reduction in STAT3 phosphorylation (p < 
0.02, two-tail t-test), and had no further effect on A769662-mediated inhibition 
(Fig. 4.10A). It can be seen in Fig 4.9C and 4.10C that PP242 successfully inhibited 
mTOR activity in both 3T3-L1 adipocytes and MEFs, respectively, as measured by 
p70 S6 kinase phosphorylation. A769662-mediated AMPK activation was not found 
to reduce phosphorylation of p70 S6 kinase in either cell type. This was 
unexpected as AMPK has been reported to suppress mTOR activation (Kimura et 
al. 2003); however basal levels of phosphorylated p70 S6 kinase were low due to 
the lack of serum in the experimental media.  
To our knowledge, this is the first time mTOR inhibition has been linked to a 
reduction in STAT3 phosphorylation in adipocytes, and supports previous reports 
that inhibition of mTOR with rapamycin suppressed STAT3 phosphorylation in 
other cell types (Weichhart et al. 2008, Onda et al. 2002, Goncharova et al. 2009, 
Chen et al. 2012). It is not possible from these data to ascertain whether the 
reduction in IL-6-stimulated STAT3 phosphorylation previously observed with 
AMPK activation in 3T3-L1 adipocytes is mediated by mTOR inhibition, or whether 
AMPK activation and mTOR inhibition act independently to suppress STAT3 
phosphorylation, as unusually, A769662 was not found to significantly reduce 
STAT3 phosphorylation in these experiments (Fig. 4.9A). 
In order to further explore the mTOR pathway as a potential mechanism for 
inhibition of IL-6-stimulated STAT3 phosphorylation, TSC2-deficient MEFs were 
utilised together with genetically-matched wild-type cells. In order for the TSC2-
/- MEFs to be viable and grow without undergoing premature senescence, they (in 
addition to the wild-type control cells) were generated as p53-/- (Zhang et al. 
2003). If the inhibition of STAT3 Y705 phosphorylation by AMPK occurred at least 
in part via the TSC/mTOR pathway, a reduction in the degree of inhibition of 
STAT3 phosphorylation by AMPK when TSC2 is no longer present would be 
expected. 
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IL-6  stimulated STAT3 Y705 phosphorylation in both TSC2+/+p53-/- and TSC2-/-p53-
/- MEFs, with further increased STAT3 phosphorylation in TSC2-/-p53-/- MEFs 
compared with TSC2+/+p53-/- (Fig. 4.11B). These data support numerous reports 
that STAT3 is hyper-activated in the absence of TSC2 (Weichhart et al. 2008, Onda 
et al. 2002, Goncharova et al. 2009, Chen et al. 2012), which is consistent with 
the constitutive activation of mTOR in the TSC2 null MEFs.  A769662 was found to 
successfully activate AMPK in both TSC2+/+p53-/- and TSC2-/-p53-/- MEFs, as 
measured by ACC S79 phosphorylation (Fig. 4.11A); however IL-6-stimulated STAT3 
phosphorylation was completely unaffected by AMPK activation, not only in TSC2-
/-p53-/- cells but also in TSC2+/+p53-/- cells (Fig. 4.11B). This was unexpected, as it 
has previously been demonstrated in this study that A769662-mediated AMPK 
activation abolished IL-6-stimulated STAT3 phosphorylation in MEFs (Fig. 4.10). 
These findings implied a potential requirement for the presence of p53 in the 
AMPK-mediated inhibition of STAT3 phosphorylation. The relationship between 
AMPK and p53 in cancer is well established (Hardie 2004, Lee et al. 2012); however 
to our knowledge there have been no reports to suggest an interaction between 
AMPK and p53 is necessary for inhibition of inflammatory signalling. To investigate 
this further, an adenovirus overexpressing human wild-type p53 was utilised in 
order to determine whether p53 expression is necessary for the AMPK-mediated 
inhibition of STAT3 phosphorylation. Mouse and human p53 share a strong 
sequence homology, reported to be approximately 81 % (Zakut-Houri et al. 1985). 
IL-6 significantly stimulated STAT3 Y705 phosphorylation in both Ad.Null and 
Ad.p53 infected MEFs; however, this was not diminished in MEFs infected with 
either Ad.Null or Ad.p53 following AMPK activation (Fig. 4.12B). It has been 
reported that p53 may induce transcription of AMPK1 in human, but not in mouse 
(Feng et al. 2007); therefore is unlikely to underlie any potential effect of p53 in 
MEFs. The same study reported that TSC2 is also regulated by p53 in both human 
and mouse (Feng et al. 2007), so while it is possible that TSC2 may not be 
functioning properly in TSC2+/+p53-/- MEFs, this is unlikely as Figure 4.9B 
demonstrated a tendency toward hyperphosphorylation of STAT3 in TSC2-/-p53-/- 
relative to the wild-type TSC2+/+p53-/- MEFs, indicating TSC2 is functional in the 
TSC2+/+p53-/- MEFs. Moreover, if TSC2 was functionally impaired in the TSC2+/+p53-
/- MEFs, this would imply that TSC2 was essential for the A769662-mediated 
inhibition of STAT3 phosphorylation as A769662 had no effect on IL-6-stimulated 
STAT3 phosphorylation in TSC2+/+p53-/- MEFs (Fig. 4.11B); however there is no 
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evidence to suggest this. AMPK was functional in TSC2+/+p53-/- MEFs infected with 
either ad.null or ad.p53 adenoviruses, as measured by phosphorylation of ACC 
Ser79 (Fig. 4.12A); however, ACC was phosphorylated to a greater extent in 
TSC2+/+p53-/- MEFs infected with ad.p53 adenovirus, relative to ad.null infected 
cells (Fig. 4.12A). This could suggest that AMPK activation was retarded in the 
absence of p53; however adenoviral-mediated p53 expression did not restore the 
ability of A769662 to inhibit IL-6-stimulated STAT3 phosphorylation. It is not 
possible to elucidate from these experiments whether the level of p53 expressed 
in the TSC2+/+p53-/- MEFs infected with Ad.p53 was in line with endogenous p53, 
or that it was functional, as we were unable to examine MEFs from the original 
mice they were derived from. Therefore these data suggest that p53 may regulate 
the transcription of a gene involved in the AMPK-mediated inhibition of the 
JAK/STAT pathway, and that simply expressing p53 using adenovirus in TSC2+/+p53-
/- MEFs may not be sufficient to restore its function, possibly due to expression 
levels or species difference.   
Taken together, these data suggest that both AMPK activation and mTOR inhibition 
suppress IL-6-stimulated STAT3 phosphorylation, and this is likely to occur via 
mutually exclusive mechanisms. 
Protein phosphorylation and dephosphorylation are key processes which control 
the JAK/STAT pathway, mainly occurring at tyrosine residues and carried out by 
protein tyrosine kinases and protein tyrosine phosphatases (PTP), respectively 
(Shuai and Liu 2003, Tonks and Neel 2001). While the expression of some PTPs, 
including SHP-1 and CD45 are restricted to hematopoietic cells (Hermiston, 
Zikherman, and Zhu 2009), others such as TC-PTP, PTP1B and SHP-2 are more 
ubiquitously expressed (Xu and Qu 2008). In the current study it was of interest to 
investigate whether inhibition of IL-6-stimulated STAT3 phosphorylation by AMPK 
was mediated by the action of a phosphatase.  
TC-PTP has been demonstrated to negatively regulate the JAK/STAT pathway via 
dephosphorylation of target substrates. JAK1 and JAK3 were reported to be 
directly dephosphorylated by TC-PTP (Simoncic et al. 2002), while Yamamoto and 
co-workers employed a similar substrate-trapping technique to identify STAT3 as 
a substrate for TC-PTP (Yamamoto et al. 2002). In line with JAK as a substrate for 
TC-PTP, TC-PTP was reported to suppress IL-2-stimulated STAT5 phosphorylation, 
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while conversely, TC-PTP-deficient lymphocytes exhibited increased STAT5 
phosphorylation upon IL-2 treatment, compared to wild-type control cells 
(Simoncic et al. 2002). Two isoforms of TC-PTP exist: an endoplasmic reticulum-
targeted 48 kDa form (TC48) and a nuclear 45 kDa form (TC45); overexpression of 
TC45 in 293T cells was reported to ameliorate IL-6-stimulated STAT3 
phosphorylation (Yamamoto et al. 2002). Conversely, isolated hepatocytes 
deficient in TC-PTP displayed elevated STAT3 phosphorylation in response to IL-6 
treatment compared to wild-type control cells (Fukushima et al. 2010). 
Furthermore, TC-PTP has recently been reported to be expressed in WAT (Loh et 
al. 2011). Interestingly, TC-PTP has recently been identified as a substrate of 
mTOR in a screen defining the mTOR-regulated phosphoproteasome (Hsu et al. 
2011). In the current study pharmacological and genetic approaches were utilised 
to investigate whether TC-PTP mediated the inhibition of STAT3 phosphorylation 
by AMPK activation or mTOR inhibition observed in Figures 4.9 and 4.10. 
Figure 4.13 demonstrated that inhibition of TC-PTP in 3T3-L1 adipocytes using a 
pharmacological inhibitor did not ameliorate the ability of AMPK to reduce IL-6-
stimulated STAT3 phosphorylation. The inhibitor has been reported to confer 
specificity to TC-PTP as it was designed to recognise residues surrounding the 
active site, rather than the active site itself (Zhang et al. 2009); however these 
data should be interpreted with care as a positive control for these experiments 
did not exist. Similar observations were made in MEFs; IL-6-stimulated STAT3 
phosphorylation was significantly ablated following AMPK activation in both wild-
type and TC-PTP-/- MEFs (Fig. 4.14). As TC-PTP was identified as a substrate of 
mTOR (Hsu et al. 2011), it was of interest to ascertain whether the moderate 
reduction in STAT3 Y705 phosphorylation observed following mTOR inhibition 
could be attributed to TC-PTP. Inhibition of mTOR by PP242 suppressed IL-6-
stimulated STAT3 phosphorylation in wild-type MEFs; however this was abolished 
in TC-PTP-/- MEFs (Fig. 4.15). Furthermore, protein expression of STAT3 was 
significantly increased in TC-PTP-/- MEFs compared to wild-type control cells (Fig. 
4.15B); this is not unexpected, as these cells are deficient in a negative regulator 
of STAT3 signalling. Taken together, these data suggest that AMPK activation and 
mTOR inhibition both suppress IL-6-stimulated STAT3 Y705 phosphorylation via 
independent mechanisms. It is likely that the moderate reduction in STAT3 
phosphorylation following mTOR inhibition may be mediated by TC-PTP, as 
Sarah Mancini, 2014   Chapter 4, 203 
suppression of mTOR activity may relieve the inhibitory phosphorylation of TC-
PTP, thereby facilitating the subsequent dephosphorylation of STAT3. 
SH2-containing protein tyrosine phosphatase (SHP-2) is another ubiquitously 
expressed PTP which has been implicated in multiple signalling pathways 
downstream of a variety of growth factors and cytokines, including IL-6 (Neel and 
Tonks 1997). It has been reported to be involved in the Ras/Raf/MAPK, PI3 kinase, 
NFB and JAK/STAT pathways, where it can either enhance or diminish signal 
transduction; thus is thought to have dual functions in growth factor and cytokine 
transduction (Kim and Baumann 1999). IL-6 signalling leads to the induction of 
both the SHP-2/ERK MAPK and JAK/STAT pathways with SHP-2 being proposed to 
play a role in the negative regulation of the JAK/STAT pathway via 
dephosphorylation of JAK and STAT proteins (You, Yu, and Feng 1999, Chen et al. 
2003). SHP-2-/- fibroblasts have been reported to exhibit elevated IFN--stimulated 
JAK1 phosphorylation (You, Yu, and Feng 1999), while SHP-2 has been found to 
dephosphorylate STAT5 in the cytoplasm; conversely, this is inhibited in SHP-2-/- 
cells (Chen et al. 2003). 
The compound curcumin has been reported to suppress LPS- and IFN--stimulated 
phosphorylation of JAK1, JAK2, STAT1 and STAT3 via activation of SHP-2 in brain 
microglial cells (Kim et al. 2003). Interestingly, curcumin was later identified to 
elicit many of its anti-inflammatory effects via activation of AMPK in a variety of 
cells (Kim et al. 2009, Yu et al. 2008, Xiao et al. 2013). In contrast, it has recently 
been reported that both AICAR and metformin reduced IL-6-stimulated SHP-2 
phosphorylation in HepG2 cells (Nerstedt et al. 2013). In the current study, 
pharmacological inhibition of SHP-2 in 3T3-L1 adipocytes did not attenuate the 
AMPK-mediated inhibition of IL-6-stimulated STAT3 phosphorylation (Fig. 4.16). 
The role of SHP-2 in signal transduction is complex, as it plays a role as both a 
positive and a negative regulator of different pathways depending on the stimuli, 
and compared to tyrosine kinases, much less is known regarding the actions of 
particular PTPs on specific pathways in response to different stimuli. Previous 
reports suggesting that SHP-2 dephosphorylated components of the JAK/STAT 
pathway involved stimulation with IFN- or IL-3 rather than IL-6 (You, Yu, and Feng 
1999, Chen et al. 2003). It is possible IL-6 may not stimulate the SHP/ERK arm in 
3T3-L1 adipocytes; a suggestion supported by Figure 4.3, which demonstrated a 
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lack of ERK1/2 activation by IL-6. These data lack direct evidence, however, that 
SHP-2 was activated by IL-6 in these cells. It is also possible that AMPK simply may 
not have any effect on the action of SHP-2 in 3T3-L1 adipocytes. As with previous 
data (Fig. 4.13), there was no positive control for this experiment demonstrating 
the inhibition of SHP-2 by NSC 87877, therefore data should be interpreted with 
care. 
Taken together, it appeared that the mechanism by which AMPK inhibited IL-6-
stimulated STAT3 phosphorylation may not have been via the action of a 
phosphatase. In order to further confirm this, 3T3-L1 adipocytes were incubated 
with the tyrosine phosphatase inhibitor sodium orthovanadate. If AMPK-mediated 
inhibition of STAT3 phosphorylation was indeed mediated via the action of a 
tyrosine phosphatase, then this would be expected to be abolished upon 
incubation with a phosphatase inhibitor. Figure 4.17 demonstrated that inhibition 
of PTPs with sodium orthovanadate did not ablate the AMPK-mediated suppression 
of IL-6-stimulated STAT3 phosphorylation. STAT3 phosphorylation was significantly 
increased following incubation with IL-6 in combination with sodium 
orthovanadate; this was not unexpected, as tyrosine phosphorylation was being 
maintained. Furthermore, probing the cell lysates with anti-phosphotyrosine 
confirmed that sodium orthovanadate effectively blocked tyrosine 
dephosphorylation (Fig. 4.17C). Taken together, these data have demonstrated 
that AMPK inhibited IL-6-stimulated STAT3 phosphorylation via a mechanism 
independent of protein tyrosine phosphatases. 
Next, this study sought to determine whether the mechanism underlying the 
inhibition of STAT3 phosphorylation by AMPK involved regulation of the upstream 
JAKs. During the course of this study, to our knowledge there was no evidence in 
the literature regarding the effect of AMPK on JAK regulation; indeed evidence 
concerning the regulation of proinflammatory IL-6 signalling by AMPK was sparse, 
and virtually non-existent in adipocytes. Proteasomal degradation of JAK has been 
suggested to negatively regulate the JAK/STAT pathway (Yu and Burakoff 1997); 
however no difference in total protein level of JAK1 or JAK2 was observed 
following AMPK activation with A769662 in this study (Fig. 4.18B and 4.18D). These 
data support a recent study in which JAK1 and JAK2 protein levels were unaffected 
by AICAR or metformin in HepG2 cells (Nerstedt et al. 2013). Relatively few studies 
exist focussing on the expression, activation and function of JAKs in adipocytes; 
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however there is evidence suggesting JAK1 and JAK2 are expressed at similar 
levels in 3T3-L1 adipocytes (Stewart et al. 1999), and have been found to be 
expressed in adipose tissue in vivo (Hellgren et al. 2001). Furthermore, JAK3 and 
Tyk2 have also been reported to be expressed in adipose tissue (Hellgren et al. 
2001, Derecka et al. 2012); however adipose tissue is comprised of several cell 
types as discussed previously (1.1.1), therefore these proteins are not necessarily 
expressed in adipocytes in vivo. In the current study, JAK1 phosphorylation 
remained unaltered following incubation with IL-6 or A769662 (Fig. 4.18C). 
Curiously, immunoblotting of 3T3-L1 lysates with anti-JAK2 Y1007/1008 revealed 
a band of around 70-75 kDa in size (4.18E), while JAK2 has a predicted mass of 
125 kDa. This unknown band appeared to resolve at a mass similar to STAT3 and 
followed a similar pattern as observed in Figure 4.2. To further investigate this, 
JAK2 was immunoprecipitated from lysates where 3T3-L1 adipocytes had been 
incubated with or without IL-6/sIL-6R for 15 min. Immunoblotting revealed bands 
corresponding to 125 kDa, indicating JAK2 had been successfully 
immunoprecipitated; however there appeared to be a slight decrease in JAK2 in 
the presence of IL-6 compared to vehicle. This was consistent with a subtle 
increase in JAK2 detected in the corresponding immunodepleted lysate. 
Phosphorylated JAK2 was detected in the immunoprecipitate at a mass which 
coincided with that observed with total JAK2. The level appeared diminished in 
the presence of IL-6 relative to vehicle, which was the converse of what would be 
expected; however this was consistent with the appearance of reduced total JAK2 
immunoprecipitated from this sample. Interestingly, the unknown band previously 
observed with IL-6 treatment in the lysate was also present in the 
immunoprecipitate when immunoblotted with anti-JAK2 Y1007/1008. Taken 
together, these data indicate the presence of a protein closely associated with 
phospho-JAK2, which was of a molecular mass comparable to STAT3 and 
responded to IL-6 and A769662 in a similar manner to STAT3. Curiously, JAK2 
Y1007/1008 was observed at the predicted molecular mass of 125 kDa in HEK-293 
and HeLa cell lysates (Fig. 4.20 and 4.21), suggesting JAK2 Y1007/1008 may be 
recognised in cell lines derived from human and not mouse. 
To further address the role of JAK2 in the AMPK-mediated inhibition of STAT3 
phosphorylation, a mutant JAK2 was utilised, whereby the valine at position 617 
had been mutated to a phenylalanine, rendering it essentially constitutively 
Sarah Mancini, 2014   Chapter 4, 206 
active. JAKs are composed of seven JH (JAK homology) domains: the JH3-7 
segment of the protein contains a FERM and SH2 domain, and is essential for 
receptor binding. At the C-terminus, JH1 is a catalytically active tyrosine kinase 
(Feng et al. 1997), while the adjacent JH2 pseudokinase domain suppresses the 
basal kinase activity of the JH1 domain (Saharinen, Takaluoma, and Silvennoinen 
2000, Saharinen and Silvennoinen 2002). Upon ligand binding, JAK2 undergoes a 
conformational change, which through a currently unknown mechanism prevents 
the inhibitory JH2 domian from interacting with JH1, and orientates the JAK2 
proteins such that the activation loop can be phosphorylated by the adjacent 
JAK2. Once this transphosphorylation is complete, the activated JAKs then 
phosphorylate tyrosine residues on the cytoplasmic tails of the receptor, creating 
docking sites for SH2 domain-containing proteins such as STATs (Darnell, Kerr, and 
Stark 1994). It is thought that the JAK2 V617F mutation disrupts inhibition of JH1 
by JH2, as the activation loop of JH1 becomes extended and is 
transphosphorylated by an adjacent JAK2 V617F kinase without any requirement 
for ligand binding (Lu et al. 2005). For this to occur, the JAK2 V617F proteins must 
be physically close to each other, therefore this mutant is not strictly 
constitutively active as the proteins still require the presence of the receptor (Lu 
et al. 2005). 
If AMPK-mediated inhibition of STAT3 phosphorylation was dependent upon 
inhibition of JAK2 activation, then this would be expected to be abolished when 
JAK2 could no longer be inactivated. A769662 significantly stimulated AMPK 
activation in HEK-293 cells transfected with the active mutant JAK2 V617F or the 
empty plasmid control as measured by ACC Ser79 phosphorylation (Fig. 4.20A). 
Figure 4.20B demonstrated significant upregulation of JAK2 Y1007/1008 
phosphorylation upon transfection with the active mutant, which was not reduced 
with AMPK activation. Moreover, AMPK activation failed to reduce the JAK2 V617F-
induced phosphorylation of STAT3 and STAT5 (Fig. 4.20C and 4.20D). 
Unexpectedly, incubation with IL-6/sIL-6R did not stimulate STAT3 
phosphorylation in HEK-293 cells (Fig. 4.20E); therefore while these data clearly 
indicated that suppression of JAK was required for the AMPK-mediated inhibition 
of STAT3 phosphorylation, it could not be demonstrated that this was the 
mechanism by which AMPK inhibited IL-6-stimulated STAT3 phosphorylation. 
Transfection of HeLa cells, which did respond to IL-6/sIL-6R, with the active 
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JAK2 mutant generated data which supported the observations made in HEK-293 
cells. AMPK activation reduced IL-6-stimulated STAT3 phosphorylation in empty 
plasmid, mock and untransfected HeLa cells, but had no effect on basal or IL-6-
stimulated STAT3 phosphorylation in JAK2 V617F mutant-transfected HeLa cells 
(Fig. 4.21). Interestingly, incubation with IL-6/sIL-6R in JAK2 V617F mutant-
transfected cells further increased STAT3 phosphorylation, relative to the basal 
level (Fig. 4.21), thus indicating incomplete transfection efficiency. Taken 
together, these data suggest that AMPK does not inhibit STAT3 phosphorylation 
directly, and is likely to be dependent upon inhibition of JAK activity. 
Furthermore, these data support a very recent study by Nerstedt and co-workers, 
which reported an AICAR-mediated inhibition of JAK1 and JAK2 phosphorylation in 
HepG2 cells (Nerstedt et al. 2013). Conversely, IL-6-stimulated JAK1 
phosphorylation was enhanced following siRNA-mediated knockdown of AMPK, 
further supporting the inhibitory role of AMPK in this pathway (Nerstedt et al. 
2013). Finally, Kim and co-workers recently suggested that the mechanism by 
which long-term AMPK activation may suppress IL-6 signalling in the liver is via 
induction of the orphan nuclear receptor small heterodimer partner (SHP). They 
reported that the metformin-mediated induction of SHP caused a direct 
interaction between SHP and the DNA-binding domain of STAT3, thus blocking 
recruitment of STAT3 to target gene promoters, such as Socs3, thereby 
attenuating IL-6 signalling (Kim et al. 2012). It is possible that acute and sustained 
AMPK activation could differentially modulate the JAK/STAT pathway. 
Overall, this current study has demonstrated for the first time in adipocytes that 
activation of AMPK suppresses IL-6-stimulated STAT3 phosphorylation, potentially 
via inhibition of JAK activity. Furthermore, this study has demonstrated for the 
first time that inhibition of mTOR also reduced IL-6-stimulated STAT3 
phosphorylation via a mutually exclusive mechanism, possibly involving the 
phosphatase TC-PTP. 
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 Chapter 5 - Functional effects of AMPK on 
inflammatory signalling 
5.1 Introduction 
5.1.1 Proinflammatory adipocytokines and obesity 
Obesity is associated with the chronic, low-level inflammation of WAT. Briefly, 
adipocytes become hypertrophic and dysfunctional which can lead to the secretion 
of proinflammatory cytokines and chemokines, such as TNF-, IL-1, IL-6 and MCP-
1. The induction of proinflammatory signalling pathways in addition to increased 
necrosis of adipocytes in obese WAT can result in the recruitment of macrophages. 
Upon migration into adipose tissue, macrophages undergo a shift in polarisation 
from an anti-inflammatory ‘alternatively activated’ M2 state, to a ‘classically 
activated’ proinflammatory M1 state; M1 macrophages are key producers of 
proinflammatory mediators in adipose tissue (Olefsky and Glass 2010). The variety 
of proinflammatory cytokines and chemokines secreted by both macrophages and 
adipocytes in obese WAT give rise to a complex proinflammatory profile, with the 
interplay between adipocytes and macrophages being central to the development 
of inflammation within the tissue. The chronic low-grade proinflammatory 
environment within obese adipose tissue has been reported to have a negative 
effect on whole body insulin sensitivity, with elevated levels of proinflammatory 
mediators in obese WAT associated with insulin resistance (Shoelson, Herrero, and 
Naaz 2007).  
5.1.2 Consequences of AMPK-mediated inhibition of inflammation 
In addition to inhibition of proinflammatory signalling pathway intermediates, 
AMPK activation has also been reported to influence cytokine production in a 
variety of cell types, including inhibition of TNF-, IL-1 and IL-6 synthesis in 
macrophages (Yang et al. 2010, Sag et al. 2008, Jeong et al. 2009). AICAR-
mediated AMPK activation was reported to stimulate an increase in adiponectin 
gene expression in human SCAT cultured ex vivo (Lihn et al. 2004). Furthermore, 
AMPK has been proposed to promote macrophage polarisation towards an anti-
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inflammatory, M2 phenotype; a key study by Sag and co-workers utilised RNA 
interference and viruses expressing a constitutively active or dominant negative 
AMPK mutant in order to demonstrate that macrophages displayed an M1 
phenotype and produced proinflammatory cytokines in the absence of AMPK, 
which was reversed when AMPK was constitutively active (Sag et al. 2008). It is 
well established that inflammation in obese adipose tissue is associated with 
insulin resistance (Guilherme et al. 2008, Schenk, Saberi, and Olefsky 2008), while 
AMPK activation has been suggested to improve insulin sensitivity in skeletal 
muscle and liver, with reduced  AMPK activity or impaired AMPK activation being 
reported in skeletal muscle of obese, insulin resistant individuals (Bandyopadhyay 
et al. 2006, Sriwijitkamol et al. 2007). Furthermore, muscle-specific transgenic 
mice expressing an inactive form of the AMPK2 catalytic subunit exhibited 
exacerbated HFD-induced insulin resistance compared to the wild-type control 
(Fujii et al. 2008). In adipocytes, however, AMPK has been reported to exert 
opposing effects, with Salt and co-workers demonstrating an inhibition of insulin-
stimulated glucose uptake in 3T3-L1 adipocytes in response to AICAR (Salt, 
Connell, and Gould 2000). To our knowledge, there have been no reports 
elucidating the impact of AMPK activation on inflammation-mediated insulin 
resistance in adipocytes. 
5.1.3 Aims 
While it has been established in the current study that activation of AMPK in 
adipocytes inhibited phosphorylation and activation of several components of the 
NFB, MAPK and JAK/STAT pathways in response to proinflammatory cytokines 
TNF-, IL-1 and IL-6, it was of interest to examine the functional effects of AMPK 
activation on proinflammatory signalling. In the current study the effect of AMPK 
on cytokine and chemokine production in 3T3-L1 adipocytes and macrophages was 
assessed. Furthermore, the effect of individual proinflammatory cytokines or 
conditioned medium from activated macrophages on insulin-stimulated glucose 
uptake in 3T3-L1 adipocytes was determined. Finally, adipose tissue from AMPK1-
/- and litter-matched wild-type mice was examined to assess adipocyte cell size. 
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5.2 Results 
5.2.1 Downstream effects of AMPK on the IL-6 signalling pathway 
Suppressor of Cytokine Signalling-3 (SOCS3) is induced by IL-6 and acts as a 
negative regulator of the IL-6 signalling pathway, while another protein reported 
to be upregulated as a result of IL-6 signalling in many tissues is the transcription 
factor C/EBP, which plays a role in adipogenesis and immune functions; therefore 
it was of interest to investigate whether activation of AMPK affected expression 
of these downstream proteins. To examine whether AMPK altered IL-6-stimulated 
SOCS3 or C/EBP expression in 3T3-L1 adipocytes, cells were incubated with IL-
6/sIL-6R in the presence or absence of A769662 following treatment with the 
proteasome inhibitor MG132. MG132 was utilised to reduce degradation of SOCS3 
and C/EBP by the proteasome. The extent of SOCS3 or C/EBP protein expression 
was determined by western blotting analysis of 3T3-L1 adipocyte lysates. 
Incubation of 3T3-L1 adipocytes with IL-6/sIL-6R in the absence of A769662 
caused a significant (p < 0.01) increase, compared to the basal level, in SOCS3 
expression (Fig. 5.1A). Preincubation with A769662 had no effect on SOCS3 
expression, relative to IL-6/sIL-6R treatment alone (Fig. 5.1A). Incubation of 
3T3-L1 adipocytes with IL-6/sIL-6R did not significantly increase expression of 
C/EBP relative to the basal level (Fig. 5.1B). Similarly, preincubation with 
A769662 had no effect on C/EBP expression, relative to IL-6/sIL-6R treatment 
alone (Fig. 5.1B). 
5.2.2 Effect of AMPK on cytokine-stimulated MCP-1 gene 
expression in 3T3-L1 adipocytes 
To determine whether AMPK activation influenced the induction of MCP-1 gene 
expression by proinflammatory stimuli, RNA extracted from 3T3-L1 adipocytes 
incubated with TNF- or IL-6/sIL-6R in the presence or absence of A769662 was 
reverse transcribed, and the extent of MCP-1 expression examined by semi-
quantitative PCR using murine MCP-1 primers. 
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Figure 5-1: Effect of AMPK on IL-6-stimulated SOCS3 and C/EBP expression 
in 3T3-L1 adipocytes 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) in the 
presence or absence of MG132 (6 M) for 6 h following preincubation for 30 min 
in the presence or absence of A769662 (300 M) and lysates prepared. Lysates 
were resolved by SDS-PAGE and subjected to immunoblotting with the antibodies 
indicated.  (A) Quantification of SOCS3 expression relative to GAPDH was 
determined using densitometric analysis. Data shown represent the mean  SEM 
% maximum SOCS3 expression of three independent experiments. **p < 0.01 (one-
way ANOVA), increase in SOCS3 expression, relative to absence of IL-6. (B) 
Quantification of C/EBP expression relative to GAPDH was determined using 
densitometric analysis. Data shown represent the mean  SEM % maximum C/EBP  
expression of three independent experiments. (C) Representative western blot. 
A B 
C 
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Incubation of 3T3-L1 adipocytes with TNF- (6 h) in the absence of A769662 
stimulated a significant (p < 0.001) increase compared to the basal level, in MCP-
1 gene expression (Fig. 5.2A). Preincubation with A769662 caused a significant (p 
< 0.01) reduction in MCP-1 gene expression, compared to TNF- treatment alone 
(Fig. 5.2A). 
Incubation of 3T3-L1 adipocytes with IL-6/sIL-6R (6 h) in the absence of A769662 
caused a significant (p < 0.05) increase compared to the basal level, in MCP-1 gene 
expression (Fig. 5.2C). MCP-1 gene expression was significantly (p < 0.01) reduced 
following preincubation with A769662, compared to IL-6/sIL-6R treatment alone 
(Fig. 5.2C). 
5.2.3 Effect of AMPK on endogenous macrophage marker gene 
expression in murine adipose tissue 
To examine the role of AMPK on the basal gene expression of markers of 
macrophage activation in adipose tissue, gonadal and subcutaneous adipose tissue 
was collected from female AMPK1-/- and litter-matched wild-type sv129 mice. 
The extent of TNF- and NOS2 (nitric oxide synthase 2) gene expression were 
assessed as markers of M1 macrophage activation and ARG1 (arginase 1), RELM- 
(resistin like-) and CHI313 (chitinase like lectin) gene expression were assessed 
as markers of M2 macrophage activation using quantitative PCR. Data is presented 
as fold change values (2-CT) with expression relative to an endogenous control 
(TBP) and wild-type gonadal adipose. These data were generated and analysed by 
Dr Anna White (University of Glasgow). Subcutaneous or gonadal adipose tissue 
expression of TNF- (Fig. 5.3A, 5.3B), NOS2 (Fig. 5.3C, 5.3D), ARG1 (Fig. 5.3E, 
5.3F), RELM- (Fig. 5.3G, 5.3H) and CHI313 (Fig. 5.3I, 5.3J) in AMPK1-/- adipose 
tissue were not significantly altered compared to expression levels in wild-type 
adipose tissue. 
Sarah Mancini, 2014   Chapter 5, 213 
  
  
 
 
   
 
Figure 5-2: Effect of A769662 on TNF- or IL-6-stimulated MCP-1 gene 
expression 
3T3-L1 adipocytes were incubated with (A & B) TNF- (10 ng/ml) or (C & D) IL-
6/sIL-6R (5 ng/ml; 25 ng/ml) for 3 or 6 h following preincubation for 30 min in 
the presence or absence of A769662 (300 M) and RNA prepared. RNA was reverse 
transcribed, with subsequent cDNA amplified by PCR using MCP-1 primers and 
resolved by agarose gel electrophoresis. (A & C) Quantification of MCP-1 
expression was determined relative to 18S using densitometric analysis. (A) Data 
shown represent the mean  SEM % 6h TNF--stimulated MCP-1 expression of 
three independent experiments. †††p < 0.001 (one-way ANOVA), increase in MCP-
1 expression, relative to vehicle.  **p < 0.01 (one-way ANOVA), reduction in MCP-
1 expression, relative to the absence of A769662. (B) Representative agarose gel 
image. RT, reverse transcriptase. (C) Data shown represent the mean  SEM % 6h 
IL-6-stimulated MCP-1 expression of four independent experiments. †p < 0.05 
(one-way ANOVA), increase in MCP-1 expression, relative to vehicle. **p < 0.01 
(one-way ANOVA), reduction in MCP-1 expression, relative to the absence of 
A769662. (B) Representative agarose gel image. 
C 
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Figure 5-3: Effect of AMPK1-/- on basal macrophage marker gene expression 
in mouse adipose tissue 
Adipose tissue was obtained from AMPK1-/- and wild-type mice and RNA 
prepared. RNA was reverse transcribed, with subsequent cDNA amplified by qPCR 
using macrophage marker primers. Data shown represent the mean   SEM fold 
change (A) TNF-, (C) NOS2, (E) ARG1, (G) RELM-, (I) CHI313 expression in 
subcutaneous adipose tissue of five wild-type and 3 AMPK1-/- mice and (B) TNF-
, (D) NOS2, (F) ARG1, (H) RELM-, (J) Chi313 expression in gonadal adipose tissue 
of five wild-type and three AMPK1-/- mice. Macrophage marker expression was 
normalised to TBP and quantification determined relative to mean wild-type 
gonadal adipose. Data generated and analysed by Dr Anna White (University of 
Glasgow). 
I J 
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5.2.4 Effect of AMPK and proinflammatory cytokines on protein 
secretion 
5.2.4.1 Adiponectin secretion in 3T3-L1 adipocytes 
In order to investigate the effect of AMPK activation or proinflammatory cytokine 
stimulation on secretion of adiponectin, 3T3-L1 adipocytes were incubated with 
TNF- or IL-6/sIL-6R in the presence or absence of A769662, and secretory 
proteins precipitated. The extent of adiponectin secretion was assessed by 
western blotting. 
Incubation of 3T3-L1 adipocytes with A769662 caused a subtle, but significant (p 
< 0.05; two-tail t-test) increase, compared to the basal level, in adiponectin 
secretion (Fig. 5.4A). When analysed together with the entire data set (one-way 
ANOVA), this significance was lost (Fig. 5.4B). Incubation with TNF- caused a 
subtle reduction in adiponectin secretion, compared to the basal level, which 
appeared to be increased following preincubation with A769662 (p < 0.05; two-
tail t-test); however this did not reach significance when analysed using one-way 
ANOVA (Fig. 5.4B). Incubation with IL-6/sIL-6R did not alter adiponectin 
secretion (Fig. 5.4B). 
5.2.4.2 Proinflammatory cytokine and chemokine production 
This study has thus far demonstrated that AMPK activation in 3T3-L1 adipocytes 
ameliorated phosphorylation of cytokine-stimulated NFB, MAPK and JAK/STAT 
signalling pathway intermediates, NFB nuclear translocation and MCP-1 gene 
expression. It was of interest, therefore, to investigate the effect of A769662-
mediated AMPK activation on the secretion of chemokines and cytokines. 
Concentrations of the chemokines IP-10 (CXCL10), KC (CXCL1), MCP-1 (CCL2), MIG 
(CXCL9), MIP-1α (CCL3) and the cytokines basic-FGF, GM-CSF, IFN-, IL-1, IL-1, 
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IL-13, IL-17, TNF- and VEGF were 
assessed in 3T3-L1 CAR adipocytes infected with an empty vector or RAW 264.7 
macrophages following proinflammatory stimulation using a murine 
cytokine/chemokine multiplex bead immunoassay and a Luminex® 100™ 
detection system (see 2.2.15). 
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Figure 5-4: Effect of A769662, TNF- or IL-6 on adiponectin secretion 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) or TNF-
 (10 ng/ml) for 6 h following preincubation for 30 min in the presence or absence 
of A769662 (300 M) and secreted proteins precipitated from incubation media 
as described in section 2.2.16. Secreted proteins were resolved by SDS-PAGE and 
subjected to immunoblotting with anti-Acrp30. (A & B) Quantification of 
adiponectin secretion was determined using densitometric analysis. Data shown 
represent the mean  SEM % A769662-stimulated adiponectin secretion of three 
independent experiments.  *p < 0.05 (two-tail t-test), increase in adiponectin 
secretion, relative to absence of A769662. (C) Representative western blot. 
A 
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3T3-L1 adipocytes were incubated with IL-1 or IL-6/sIL-6R in the presence or 
absence of A769662 in order to determine the extent of cytokine/chemokine 
production. Analysis of cytokine/chemokine secretion showed that unstimulated 
or IL-6-stimulated 3T3-L1 CAR adipocytes did not produce measurable levels of 
any of the cytokine or chemokines listed above; however IP-10, KC and MCP-1 
were found to be secreted at levels within the detection limits of the assay by 
3T3-L1 adipocytes in response to IL-1 stimulation. IP-10 secretion was in the 
range of 52-398 pg/h/106 cells, KC secretion was in the range of 16-287 pg/h/106 
cells and MCP-1 secretion was in the range of 16-30 pg/h/106 cells. IL-1 caused 
a significant (p < 0.001) increase in IP-10, KC and MCP-1 secretion in 3T3-L1 
adipocytes, relative to the basal level (Fig. 5.5A, 5.5B and 5.5C, respectively). 
Preincubation with A769662 abolished secretion of IP-10, KC and MCP-1 (p < 0.001) 
(Fig. 5.5A, 5.5B and 5.5C, respectively). Furthermore, IL-1 and IL-6 were 
undetectable in the supernatant, indicating the stimuli were sufficiently washed 
away prior to the collection of the conditioned medium. 
In order to determine the effect of AMPK on the extent of cytokine/chemokine 
production in activated macrophages, RAW 264.7 macrophages were incubated 
with LPS in the presence or absence of A769662. Analysis of cytokine/chemokine 
secretion showed that macrophages secreted measurable levels of IL-5 (152-520 
pg/h/10 cm diameter dish), TNF- (160-1916 pg/h/10 cm diameter dish), MCP-1 
(602-2415 pg/h/10 cm diameter dish) and MIP-1 (3056-22124 pg/h/10 cm 
diameter dish). Levels of the other cytokines and chemokines detailed above were 
not detected within the limits of the assay. LPS caused a significant (p < 0.001) 
increase in IL-5, MCP-1 and MIP-1 secretion in macrophages, relative to the basal 
level (Fig. 5.6A, 5.6B and 5.6C, respectively). Preincubation with A769662 
significantly (p < 0.01) reduced both IL-5 (60  14.7 %) and MCP-1 (47  17.1 %) 
secretion relative to LPS treatment alone (Fig. 5.6A and 5.6B, respectively). 
Preincubation with A769662 caused a subtle (33  17.9 %) reduction in LPS-
stimulated MIP-1 secretion; however this did not reach significance (Fig. 5.6C). 
LPS treatment induced a significant (p < 0.001) increase in TNF- secretion 
relative to absence of LPS when analysed using a two-tail t-test; however this 
significance was lost upon one-way ANOVA analysis (Fig. 5.6D). Preincubation with 
A769662 did not significantly alter TNF- secretion relative to absence of A769662 
(Fig. 5.6D).
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Figure 5-5: Effect of AMPK on 3T3-L1 adipocyte cytokine/chemokine 
secretion 
3T3-L1 CAR adipocytes were stimulated with IL-1 (10 ng/ml) or IL-6/sIL-6R (5 
ng/ml; 25 ng/ml) for 6 h following preincubation for 30 min in the presence or 
absence of A769662 (300 M). Thereafter, cells were thoroughly washed and 
incubated in SF-DMEM for 1 h and conditioned medium collected for chemokine 
analysis using a multiplex bead immunoassay and a Luminex® 100™ detection 
system. Data shown represent the mean  SEM % IL-1-stimulated (A) IP-10, (B) 
KC or (C) MCP-1 secretion of three independent experiments. †††p < 0.001 (one-
way ANOVA), increase in secretion, relative to vehicle.  ***p < 0.001 (one-way 
ANOVA), reduction in secretion, relative to absence of A769662. 
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Figure 5-6: Effect of AMPK on macrophage cytokine/chemokine secretion 
(continued overleaf) 
A 
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C 
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Figure 5-6: Effect of AMPK on macrophage cytokine/chemokine secretion 
RAW 264.7 macrophages were incubated with LPS (1 g/ml) for 6 h following 
preincubation for 30 min in the presence or absence of A769662 (100 M). 
Thereafter, cells were thoroughly washed and incubated in SF-RPMI for 1 h and 
conditioned medium collected for chemokine analysis using a multiplex bead 
immunoassay and a Luminex® 100™ detection system. Data shown represent the 
mean  SEM % LPS-stimulated (A) IL-5, (B) MCP-1 or (C) MIP-1 secretion of four 
independent experiments. †††p < 0.001 (one-way ANOVA), increase in secretion, 
relative to vehicle.  **p < 0.01 (one-way ANOVA), reduction in secretion, relative 
to absence of A769662. (D) Data shown represents the mean  SEM % LPS-
stimulated TNF- secretion of three independent experiments.
D 
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5.2.5 Effect of inflammation on 3T3-L1 adipocyte insulin 
sensitivity 
5.2.5.1 Effect of cytokines on 3T3-L1 adipocyte glucose uptake 
Proinflammatory cytokines and chemokines in adipose tissue have been proposed 
to play a key role in the development of obesity-associated insulin resistance. It 
was of interest, therefore, to investigate whether incubation with individual 
cytokines could suppress insulin-stimulated glucose transport in 3T3-L1 
adipocytes. To determine whether individual cytokines reduce insulin sensitivity 
in adipocytes, 3T3-L1 adipocytes were stimulated with TNF-, IL-1 or IL-6 for 
various durations. The extent of insulin-stimulated glucose uptake was assessed 
as a measure of incorporation of radiolabelled glucose. 
In separate experiments, 3T3-L1 adipocytes were incubated with IL-6/sIL-6R for 
1, 6, 24 or 72 h prior to insulin-stimulated glucose uptake being assessed. The raw 
data indicated that incubation with IL-6/sIL-6R did not alter insulin-stimulated 
glucose transport, compared to the vehicle control; however, basal glucose uptake 
was increased following 6, 24 and 72 h IL-6/sIL-6R incubation (Fig. 5.7C, 5.7E 
and 5.7G, respectively). Thus, analysis of the fold change in insulin-stimulated 
glucose uptake demonstrated that incubation with IL-6/sIL-6R caused a 
reduction in insulin-stimulated glucose uptake following 6 h (30 %), 24 h (88 %) 
and 72 h (50 %) treatment (Fig. 5.7D, 5.7F and 5.7H, respectively). A slight 
increase in insulin-stimulated glucose uptake was observed following incubation 
with IL-6/sIL-6R for 1h (Fig. 5.7B). 
Similarly, 3T3-L1 adipocytes were incubated with IL-1 for 1 h or TNF- for 1 or 6 
h prior to insulin-stimulated glucose uptake being assessed. Analysis of the fold 
change in insulin-stimulated glucose uptake demonstrated that incubation with 
TNF- caused a 50 % reduction in insulin-stimulated glucose uptake following 6 h 
treatment (Fig. 5.8D), and incubation with IL-1 caused a 48 % reduction in insulin-
stimulated glucose uptake following 1 h treatment (Fig. 5.8F). 
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Figure 5-7: Effect of IL-6 on 3T3-L1 insulin-stimulated glucose uptake (legend 
overleaf) 
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Figure 5-7: Effect of IL-6 on 3T3-L1 insulin-stimulated glucose uptake 
3T3-L1 adipocytes were incubated with IL-6/sIL-6R (5 ng/ml; 25 ng/ml) for 
various durations prior to stimulation with insulin (10 nM) for 15 min. Glucose 
transport was initiated by the addition of 2-[3H]-deoxy-D-glucose, and terminated 
after 3 min. (A, C, E, G) Data shown represent 2-[3H]-deoxy-D-glucose uptake 
(pmol/min/well) of single experiments conducted independently of each other. 
(B, D, F, H) Data shown represent the fold change in insulin stimulated glucose 
uptake relative to vehicle of single experiments conducted independently of each 
other. 
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Figure 5-8: Effect of TNF- or IL-1 on 3T3-L1 insulin-stimulated glucose 
uptake 
3T3-L1 adipocytes were incubated with (A-D) TNF- (10 ng/ml) or (E-F) IL-1 (10 
ng/ml) for various durations prior to stimulation with insulin (10 nM) for 15 min. 
Glucose transport was initiated by the addition of 2-[3H]-deoxy-D-glucose, and 
terminated after 3 min. (A), (C) and (E) Data shown represent 2-[3H]-deoxy-D-
glucose uptake (pmol/min/well) of single experiments conducted independently 
of each other. (B), (D) and (F) Data shown represent the fold change in insulin 
stimulated glucose uptake relative to vehicle of single experiments conducted 
independently of each other. 
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5.2.5.2 Effect of conditioned medium from activated macrophages 
on 3T3-L1 adipocyte glucose uptake 
Interplay between adipocytes and macrophages in adipose tissue is key to the 
development of a sustained proinflammatory profile within the tissue; therefore 
it was of interest to investigate the effect of activated macrophage secretory 
products on adipocyte insulin sensitivity. Murine RAW 264.7 macrophages were 
stimulated with LPS to induce a shift in their polarity towards an M1 classically 
activated phenotype, and conditioned medium collected. 3T3-L1 adipocytes were 
incubated in this conditioned medium prior to glucose uptake being measured. 
3T3-L1 adipocytes incubated in conditioned medium from macrophages stimulated 
for 6 h with LPS displayed a significant (p < 0.05) 55.2  12.1 % reduction in insulin-
stimulated glucose uptake, relative to incubation with conditioned medium from 
untreated macrophages, as determined by the fold change (Fig. 5.9). Similarly, 
incubation with conditioned medium collected from macrophages stimulated with 
LPS for 1 h caused a 29  11.2 %  reduction in 3T3-L1 adipocyte glucose uptake, 
relative to the basal level (p = 0.06; two-tail t-test) (Fig. 5.9). 
In a similar, but separate, set of experiments, conditioned medium was collected 
from macrophages stimulated with LPS in the presence or absence of A769662. 
3T3-L1 adipocytes were incubated in this conditioned medium and glucose uptake 
was measured to assess whether prior A769662-mediated AMPK activation in 
macrophages could rescue the LPS-induced reduction in glucose uptake observed 
in Figure 5.9. 3T3-L1 adipocytes incubated in conditioned medium from 
macrophages treated with A769662 alone exhibited a 44.3  21 % (p = 0.1; two-
tail t-test) increase in insulin-stimulated glucose uptake relative to incubation 
with conditioned medium from untreated macrophages (Fig. 5.10). While this did 
not reach significance with one-way ANOVA, it may indicate a tendency toward 
AMPK activation in macrophages improving adipocyte insulin sensitivity. In 
contrast to the set of experiments described in Figure 5.9, conditioned medium 
from macrophages stimulated with LPS did not significantly reduce adipocyte 
glucose uptake relative to the basal level. However, glucose uptake was 
significantly (p < 0.05) blunted in adipocytes incubated with conditioned medium 
from macrophages stimulated with LPS in the presence of A769662, relative to the 
absence of LPS (Fig. 5.10).
Sarah Mancini, 2014   Chapter 5, 227 
 
 
Figure 5-9: Effect of activated macrophage conditioned medium on 3T3-L1 
insulin-stimulated glucose uptake 
RAW 264.7 macrophages were stimulated with LPS (1 g/ml) for 1 or 6 h. 
Thereafter, cells were thoroughly washed and incubated in SF-RPMI for 1 h and 
conditioned medium collected. 3T3-L1 adipocytes were incubated with 
conditioned medium for 6 h prior to stimulation with insulin (10 nM) for 15 min. 
Glucose transport was initiated by the addition of 2-[3H]-deoxy-D-glucose, and 
terminated after 3 min. Data shown represent the mean  SEM % fold change in 
insulin stimulated 2-[3H]-deoxy-D-glucose uptake relative to vehicle of three 
independent experiments. *p < 0.05 (one-way ANOVA), reduction in insulin-
stimulated glucose uptake, relative to vehicle. 
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Figure 5-10: Effect of activated macrophage conditioned medium on 3T3-L1 
insulin-stimulated glucose uptake 
RAW 264.7 macrophages were stimulated with LPS (1 g/ml) for 6 h following 
preincubation for 30 min in the presence or absence of A769662 (100 M). 
Thereafter, cells were thoroughly washed and incubated in SF-RPMI for 1 h and 
conditioned medium collected. 3T3-L1 adipocytes were incubated with 
conditioned medium for 6 h prior to stimulation with insulin (10 nM) for 15 min. 
Glucose transport was initiated by the addition of 2-[3H]-deoxy-D-glucose, and 
terminated after 3 min. Data shown represent the mean  SEM % fold change in 
insulin stimulated 2-[3H]-deoxy-D-glucose uptake relative to vehicle of three 
independent experiments. *p < 0.05 (one-way ANOVA), reduction in insulin-
stimulated glucose uptake, relative to absence of LPS. 
Sarah Mancini, 2014   Chapter 5, 229 
5.2.6 Effect of AMPK on adipocyte morphology and 
differentiation 
5.2.6.1 Effect of A769662 on adipogenesis 
Activation of AMPK by AICAR has been demonstrated to inhibit adipogenesis 
(Habinowski and Witters 2001) via a currently unknown mechanism, while it has 
also been reported that JAK2/STAT3 pathway activation is critical for adipogenesis 
to proceed (Wang, Zhou, et al. 2010). In order to investigate whether AMPK 
inhibited adipogenesis via regulation of STAT3, 3T3-L1 adipocytes were 
differentiated in the presence or absence of A769662 and lysates obtained at 
various intervals post-differentiation. The extent of ACC S79 and STAT3 Y705 
phosphorylation, in addition to the expression of adipogenic markers: C/EBP, 
C/EBP, C/EBP and PPAR, was determined by western blotting analysis of 3T3-
L1 adipocyte lysates.  
Figure 5.11A demonstrates that expression of C/EBP is not increased, compared 
to undifferentiated fibroblasts, until day 8 post-differentiation, where it appears 
to be modestly reduced upon preincubation with A769662. C/EBP expression was 
not detected until day 4, and continued to be expressed until day 8 post-
differentiation; however this appeared to be unaffected by preincubation with 
A769662 (Fig. 5.11A). Expression of C/EBP could be observed from day 2 post-
differentiation; preincubation with A769662 reduced C/EBP expression at day 4 
and day 6, but not day 8 (Fig. 5.11A). PPAR expression was detected from day 4; 
however it remained unaffected by preincubation with A769662 (Fig. 5.11A).  
STAT3 Y705 phosphorylation was rapidly induced at 24 h post-differentiation and 
disappeared after 48 h; preincubation with A769662 clearly reduced STAT3 Y705 
phosphorylation, relative to the absence of A769662 (Fig. 5.11A). In a separate 
experiment, the effect of A769662 on lipid accumulation in 3T3-L1 adipocytes 
during adipogenesis was examined by staining adipocytes with oil red O at various 
intervals post-differentiation. 3T3-L1 adipocytes differentiated in the presence of 
A769662 demonstrated a slightly reduced lipid accumulation at day 4 post 
differentiation, compared to the control cells (Fig. 5.11B). At day 8 post 
differentiation the control 3T3-L1 adipocytes displayed an abundance of lipid as 
detected by oil red O staining; by comparison, lipid accumulation was clearly 
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reduced in 3T3-L1 adipocytes differentiated in the presence of A769662 (Fig. 
5.11B). 
5.2.6.2 Effect of AMPK1 on adipocyte cell size 
In order to assess the consequences of a lack of AMPK1 on adipocyte cell size, 
omental and subcutaneous adipose tissue were extracted from AMPK1-/- and 
litter-matched wild-type mice and adipocyte cell size observed following H&E 
staining of the sectioned tissue. Adipocytes in omental adipose tissue from 
AMPK1-/- mice appeared to be greatly reduced in size compared to omental 
adipocytes from wild-type adipose tissue (Fig. 5.12). A difference in size between 
adipocytes from AMPK1-/- or wild-type subcutaneous adipose tissue was less 
clear; however there does appear to be a slight reduction in size in subcutaneous 
adipocytes from AMPK1-/- mice compared to the wild-type (Fig. 5.12). 
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Figure 5-11: Effect of A769662 on adipogenesis 
3T3-L1 adipocytes were differentiated (A) in the presence of troglitazone or (B) 
in the absence of troglitazone for various durations in the presence of A769662 
(300 M) or DMSO. (A) Lysates were prepared at various intervals post-
differentiation and resolved by SDS-PAGE before being subjected to 
immunoblotting with the antibodies indicated. Western blot from a single 
experiment. (B) Cells were fixed and stained with oil red O at various intervals 
post differentiation. Representative microscope images from a single 
experiment. Scale bar = 50 m. 
A 
B 
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Figure 5-12: Effect of AMPK1 on adipocyte cell size 
Omental and subcutaneous adipose tissue harvested from AMPK1-/- and litter-
matched wild-type mice were embedded in paraffin and sections stained with 
haemotoxylin and eosin. Representative microscope images from a single 
experiment. Scale bar = 50 m. 
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5.3 Discussion 
The key findings of this chapter are that A769662 suppressed many downstream 
functional effects of cytokine-stimulated proinflammatory signalling pathways, 
including TNF- and IL-6-stimulated MCP-1 gene expression, and IL-1-stimulated 
MCP-1, KC and IP-10 secretion in 3T3-L1 adipocytes. Furthermore, A769662 
reduced LPS-stimulated secretion of IL-5, MCP-1 and MIP-1, but not TNF- from 
macrophages. Preliminary data suggested that sustained, but not acute, IL-6 
treatment may reduce insulin sensitivity in 3T3-L1 adipocytes, while acute 
stimulation with TNF- or IL-1 may suppress insulin-stimulated glucose uptake. 
Secretory products from M1-activated macrophages rendered 3T3-L1 adipocytes 
insulin resistant, while conditioned medium from macrophages treated with 
A769662 alone appeared to enhance adipocyte glucose uptake; however it is 
unclear whether prior A769662-mediated AMPK activation in macrophages is 
sufficient to reduce secretion of proinflammatory mediators to the extent that 
3T3-L1 insulin sensitivity is restored. Finally, mouse AMPK1-/- gonadal and 
subcutaneous adipocytes appeared to be reduced in size compared to wild-type, 
while A769662 suppressed 3T3-L1 adipocyte differentiation and reduced early 
STAT3 phosphorylation which is thought to be crucial in the development of 
adipogenesis. 
A key target of the IL-6-stimulated JAK/STAT pathway is SOCS3. SOCS3 is induced 
upon cytokine stimulation and functions as a negative regulator of the pathway 
via binding to phosphotyrosine residues on the intracellular domain of gp130 and 
inhibiting JAK activity (Kubo, Hanada, and Yoshimura 2003, Murray 2007). Both in 
vitro and in vivo studies have reported an increase in IL-6-induced SOCS3 
expression in 3T3-L1 adipocytes (Fasshauer, Kralisch, et al. 2004, Lagathu et al. 
2003) and in various tissues, including adipose (Carey et al. 2006, Shi et al. 2004). 
Elevated SOCS3 expression in adipocytes has been reported to be associated with 
a reduction in IRS expression and perturbed insulin signalling, leading to localised 
insulin resistance and impaired glucose tolerance (Shi et al. 2004, Shi, Cave, et 
al. 2006). Furthermore, skeletal muscle-specific SOCS3-/- mice were protected 
from HFD-induced insulin resistance due to enhanced phosphorylation of the 
insulin signalling pathway and elevated skeletal muscle glucose uptake (Jorgensen 
et al. 2013). It was of interest to investigate the effect of AMPK activation on 
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SOCS3 expression, which prior to beginning this study was previously unknown. 
3T3-L1 adipocytes were incubated with the proteasome inhibitor MG132 to 
prevent degradation of the protein. Figure 5.1A demonstrated a significant 
increase in SOCS3 protein expression in response to IL-6 stimulation, which 
supports previous reports; however activation of AMPK had no effect on expression 
of SOCS3 (Fig. 5.1A). These data support a recent study which reported AICAR-
mediated AMPK activation did not alter SOCS3 expression in HepG2 cells also 
following 6 h incubation (Nerstedt et al. 2013). In contrast, there is evidence for 
the AMPK-mediated reduction in SOCS3 production in the liver following acute (1 
h) stimulation. Nerstedt and co-workers found that AICAR reduced IL-6-stimulated 
SOCS3 mRNA expression in mouse liver and HepG2 cells (Nerstedt et al. 2013), 
while Kim and co-workers reported that AMPK activation via metformin or 
constitutively active adenoviral infection suppressed IL-6-stimulated SOCS3 
induction in rat primary hepatocytes (Kim et al. 2012). Conversely, inhibition of 
IL-6-induced SOCS3 expression was ablated upon downregulation of AMPK via 
adenovirus-mediated infection in hepatocytes (Kim et al. 2012). As these contrary 
findings were all observed in the liver or liver cells, it is possible that the effects 
of AMPK activation on SOCS3 induction could be cell or tissue-specific. Moreover, 
to our knowledge, these data are the first to demonstrate the effect of AMPK 
activation on SOCS3 induction in adipocytes. 
Another protein upregulated as a result of IL-6 signalling is the transcription factor 
C/EBP (CCAAT/enhancer binding protein-), which is involved in cellular 
differentiation and inflammatory responses (Lekstrom-Himes and Xanthopoulos 
1998) and is activated via the ERK arm of the IL-6 signalling pathway (Hu et al. 
2001). Figure 5.1B demonstrated that IL-6 or AMPK activation had no effect 
C/EBP protein expression in 3T3-L1 adipocytes; furthermore, A769662 had no 
effect on C/EBP expression during adipogenesis (Fig. 5.11A). These data are not 
surprising, given that C/EBP is induced via the Ras/Raf/ERK pathway, and Figure 
4.3 showed no evidence of IL-6-stimulated ERK1/2 activation. There is conflicting 
evidence in the literature as to the effect of AMPK on C/EBP expression; AICAR 
was reported to elevate basal C/EBP expression in preadipocytes (Arai et al. 
2007), while AICAR or constitutively active AMPK was reported to reduce ER stress-
induced C/EBP expression in FAO hepatoma cells, which conversely was blocked 
following expression of a dominant-negative AMPK (Choudhury et al. 2011). It is 
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therefore possible that AMPK could exert differential effects on C/EBP expression 
depending on the cell type and stimuli. 
AMPK activation has been widely reported to suppress the synthesis of 
proinflammatory cytokines including TNF-, IL-1 and IL-6 in macrophages (Yang 
et al. 2010, Galic et al. 2011, Sag et al. 2008, Jeong et al. 2009); however, the 
effect of AMPK on the production of many other proinflammatory cytokines and 
chemokines, particularly in adipocytes, is currently poorly characterised. The two 
major families of chemokines are the C-C family, characterised by two adjacent 
cysteine residues near the amino terminus, and C-X-C family, whereby the amino 
terminal cysteine residues are separated by one amino acid (Ono et al. 2003). 
MCP-1 (CCL2) is a well-characterised chemokine produced in response to 
proinflammatory mediators, and stimulates the migration of monocytes to sites of 
inflammation where they then become macrophages (Ono et al. 2003). 
Furthermore, MCP-1 also stimulates chemotaxis and activation of T-cells; Wu and 
co-workers reported an increased infiltration of activated T-cells in adipose tissue 
from DIO mice (Wu et al. 2007), suggesting an accumulation of T-cells in obese 
adipose tissue may contribute to the immune dysfunction observed in obesity. In 
contrast, other groups have proposed inflammatory M1 activated macrophages to 
be central to the development of an inflammatory environment within the tissue 
(Galic et al. 2011, Weng and Schuppan 2013). In the current study, A769662 
suppressed TNF- or IL-6-stimulated MCP-1 gene expression in 3T3-L1 adipocytes 
(Fig. 5.2A and 5.2C, respectively). These data support similar observations 
reported in endothelial cells, where metformin or AICAR-mediated AMPK 
activation ameliorated TNF--stimulated MCP-1 expression (Hattori et al. 2006). 
Likewise, berberine has been reported to reduce elevated MCP-1 expression 
observed in obese db/db mice (Jeong et al. 2009). Moreover, secretion of MCP-1 
was found to be elevated in 3T3-L1 adipocytes in response to IL-1 (Fig. 5.5C) and 
RAW 264.7 macrophages in response to LPS (Fig. 5.6B); this was significantly 
attenuated in both cell types following preincubation with A769662 (Fig. 5.5C and 
5.6B). These data correlate with the suppression of cytokine-stimulated gene 
expression of MCP-1 observed in 3T3-L1 adipocytes (Fig. 5.2A), and are also 
consistent with a previous study in human endothelial cells conducted in this 
laboratory, which reported an inhibition of TNF--stimulated MCP-1 secretion by 
AICAR (Ewart, Kohlhaas, and Salt 2008). Similarly, an increase in serum MCP-1 was 
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reported in HFD-fed mice with hematopoietic deletion of AMPK1 (Galic et al. 
2011), thus demonstrating the potential importance of AMPK in the suppression of 
MCP-1. 
Secretion of several cytokines and chemokines from 3T3-L1 adipocytes or 
macrophages in response to proinflammatory mediatiors were analysed in the 
current study; however most were found to be at levels below the sensitivity of 
the assay. Interestingly, IL-6 failed to stimulate secretion of any of the chemokines 
or cytokines in the panel (IP-10 (CXCL10), KC (CXCL1), MCP-1 (CCL2), MIG (CCL9), 
MIP-1α (CCL3), FGF-basic, GM-CSF, IFN-γ, IL-1α, IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, 
IL-12 (p40/p70), IL-13, IL-17, TNF-α and VEGF). Given that IL-6 was demonstrated 
to induce MCP-1 gene expression (Fig. 5.2C), it is possible that incubation with IL-
6 for 6 h may be sufficient to induce gene expression but not detectable protein 
production and secretion. The chemokines IP-10 and KC were found to be secreted 
from 3T3-L1 adipocytes in response to IL-1 stimulation, with levels markedly 
reduced following preincubation with A769662 (Fig. 5.5A and 5.5B, respectively). 
KC and IP-10 have not been as well characterized as MCP-1 in terms of the effect 
of AMPK; however these data support one recent study reporting a reduction in 
murine serum KC levels in response to resveratrol (Baron et al. 2014). As KC and 
IP-10 are members of the CXC chemokine family, they induce neutrophil 
chemotaxis (Ono et al. 2003). Neutrophils are generally recruited during the acute 
phase of inflammation, while macrophage infiltration of murine adipose tissue has 
not been observed until 8 weeks of HFD feeding (Strissel et al. 2007). Transient 
neutrophil infiltration which precedes macrophage infiltration has been reported 
in adipose tissue of HFD-fed mice (Elgazar-Carmon et al. 2008); in line with this, 
a clinical study demonstrated that circulating neutrophils are activated to a 
greater extent in morbidly obese subjects compared to lean individuals (Nijhuis 
et al. 2009). Considering neutrophils have a short life span and are primarily 
involved in acute inflammation, these studies imply that the chronic inflammatory 
profile associated with morbid obesity could be, in part, the result of a continuous 
activation of the innate immune system. The secretion of multiple chemokines 
from inflamed adipocytes demonstrates the complexity of the proinflammatory 
profile of adipose tissue, and the potential ability of A769662 to inhibit both 
macrophage recruitment via MCP-1, and neutrophil recruitment via KC and IP-10, 
indicates the pleiotropic nature of AMPK. 
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In addition to MCP-1, classically activated macrophages were found to secrete IL-
5, MIP-1 and TNF- (Fig. 5.6). IL-5 (interleukin-5) is predominantly produced by 
Th2 (T helper 2) cells and is involved in the differentiation of activated B cells and 
the maturation of eosinophils (Kouro and Takatsu 2009); thus it is a key factor in 
the development of allergic diseases which are characterised by inflammation. 
A769662-mediated AMPK activation significantly reduced IL-5 secretion from LPS-
stimulated macrophages (Fig. 5.6A). To our knowledge, a link between AMPK and 
IL-5 has never been suggested, and the relevance of these data in terms of obesity-
associated inflammation and insulin resistance is unknown; however it may 
suggest that AMPK activation could play a role in the suppression of the 
exaggerated immune response associated with allergy. Similarly to MCP-1, MIP-1 
(macrophage inflammatory protein-1) (CCL3) is a chemokine which induces 
synthesis of proinflammatory mediators and is a macrophage chemoattractant 
(Fahey et al. 1992). In the current study, activated macrophages exhibited an 
increase in MIP-1 secretion compared to an absence of LPS; however in contrast 
to MCP-1, preincubation with A769662 induced only a subtle reduction in MIP-1 
secretion (Fig. 5.6C). Activated macrophages displayed an increase in TNF- 
secretion relative to the basal level; however this did not reach significance using 
one-way ANOVA analysis (Fig. 5.6D). This is likely due to the high degree of 
variability across experimental replicates. Unexpectedly, preincubation with 
A769662 failed to reduce TNF- secretion (Fig. 5.6D). These data are in direct 
contrast to the findings of several different groups: Sag and co-workers reported 
an inhibition of LPS-stimulated TNF- secretion in macrophages expressing 
constitutively active AMPK, while conversely, expression of a dominant negative 
AMPK enhanced TNF- secretion (Sag et al. 2008). Similarly, TNF- secretion was 
reported to be elevated in macrophages deficient in AMPK1 (Galic et al. 2011). 
Furthermore, AICAR or berberine-mediated AMPK activation has been reported to 
suppress TNF- expression in macrophages (Yang et al. 2010, Jeong et al. 2009). 
This intruiging result is most likely due to the high degree of variability across 
experimental replicates; however it is possible that A769662-mediated AMPK 
activation may not have any effect on TNF- secretion from macrophages. 
Crucially, proinflammatory cytokine-induced transcription factors NFB and AP-1 
have been reported to regulate transcription of the chemokines IP-10 (Ohmori and 
Hamilton 1993), KC (Ohmori, Fukumoto, and Hamilton 1995), MCP-1 (Martin et al. 
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1997), MIP-1 (Grove and Plumb 1993) and the cytokines TNF- (Shakhov et al. 
1990) and IL-5 (Lee et al. 1995). Thus, with the exception of TNF-, the finding 
that A769662 suppresses secretion of these proinflammatory proteins from 3T3-L1 
adipocytes and RAW 264.7 macrophages correlates with the earlier findings in this 
study that A769662 inhibited MAPK and NFB proinflammatory signalling and NFB 
nuclear translocation (Fig. 3.2-3.7, 3.15-3.20). 
To explore the importance of AMPK on the activation state of macrophages in 
adipose tissue, the basal gene transcription of markers associated with M1 and M2 
activation states were assessed in subcutaneous and gonadal adipose tissue depots 
obtained from AMPK1-/- and genetically matched wild-type mice. TNF- and 
NOS2 (iNOS) are classical markers of M1 activation, while M2 macrophages are 
characterised by the expression of ARG1, RELM- and CHI313. NOS2 is a 
proinflammatory gene induced by activation of MAPK/NFB signalling pathways, 
and catalyses the production of NO and citrulline from arginine. The high levels 
of NO produced in response to inflammatory signalling pathways can react with 
the free radical superoxide, producing peroxynitrite, an oxidant which reacts with 
biological molecules (Pacher, Beckman, and Liaudet 2007). In contrast, the M2 
marker ARG1 catalyses the hydrolysis of arginine, thus reducing its availability as 
a substrate for NOS (Pacher, Beckman, and Liaudet 2007). RELM- and CHI313 
mediate the Th2 cell-driven inflammatory response (Pesce et al. 2009, Elias et al. 
2005). There was no clear difference in expression of M1 marker genes TNF- (Fig. 
5.3A, 5.3B) and NOS2 (Fig. 5.3C, 5.3D), or M2 marker genes ARG1 (Fig. 5.3E, 5.3F), 
RELM- (Fig. 5.3G, 5.3H) and CHI313 (Fig. 5.3I, 5.3J) between AMPK1-/- and wild-
type in subcutaneous or gonadal adipose tissue, respectively. These data would 
suggest that there was no alteration in the M1/M2 ratio in adipose tissue in the 
presence or absence of AMPK1. This is intriguing, as lysates prepared from the 
same samples yielded results suggesting an increase in basal inflammation existed 
within AMPK1-/- tissue relative to wild-type, as demonstrated by elevated 
phosphorylation of JNK (Fig. 3.10A) and STAT3 (Fig. 4.7). Taken together, these 
data imply that as the macrophages within AMPK1-/- adipose tissue do not appear 
to be predominantly polarised towards an M1 activation state, then the increased 
proinflammatory signalling observed may be coming from other cells within the 
tissue, such as adipocytes or possibly vascular cells. AMPK activation has been 
reported to promote the anti-inflammatory polarisation of macrophages to M2; 
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while conversely, AMPK1-/- mice have been reported to exhibit increased 
systemic inflammation and M1 macrophage infiltration in adipose tissue and liver 
(Galic et al. 2011, Weng and Schuppan 2013). While these reports, in contrast to 
the current study, indicate that loss of AMPK function drives the proinflammatory 
polarisation of macrophages, it is important to note that this was observed 
following HFD-feeding (Galic et al. 2011, Weng and Schuppan 2013). The  AMPK1-
/- and wild-type mice analysed for M1 macrophage activation in the current study 
were fed a normal chow diet, therefore suggesting that while loss of AMPK alone 
may be sufficient to induce basal phosphorylation of proinflammatory mediators 
(Fig. 3.10A and Fig. 4.7), a shift in macrophage polarisation may require an 
additional inflammatory insult. 
Lastly, the effect of AMPK activation, TNF- or IL-6 stimulation on the secretion 
of the adipocytokine adiponectin was assessed via protein precipitation. It is well 
established that adiponectin can stimulate AMPK activation in liver and muscle 
both in vitro and in vivo (Yamauchi et al. 2002), and in rat primary adipocytes 
(Wu et al. 2003); however the effect of AMPK activation on adiponectin production 
is less clear. In the current study A769662 appeared to stimulate secretion of 
adiponectin in 3T3-L1 adipocytes compared to both the basal level and incubation 
with TNF-, although it had no effect in the presence of IL-6 (Fig. 5.4). These data 
support a study by Lihn and co-workers, who reported an AICAR-mediated increase 
in adiponectin gene expression in human SCAT cultured ex vivo (Lihn et al. 2004). 
The opposite has also been reported, however; AICAR or metformin-mediated 
AMPK activation has been proposed to suppress adiponectin expression in 3T3-L1 
adipocytes (Huypens, Quartier, et al. 2005). Furthermore, it has been suggested 
that proinflammatory cytokines may negatively regulate adiponectin production, 
which may explain the negative correlation of adiponectin plasma and mRNA 
levels with adiposity (Cnop et al. 2003). TNF- has been reported to suppress 
adiponectin gene transcription (Maeda et al. 2001); however in this study only a 
very modest reduction in adiponectin secretion following TNF- stimulation was 
observed; however preincubation with A769662 did appear to elevate adiponectin 
secretion compared to the absence of A769662 (Fig. 5.4). These data could 
indicate that while TNF- alone did not have a substantial effect on adiponectin 
production in 3T3-L1 adipocytes, it did not ablate the A769662-mediated elevation 
of adiponectin secretion. Similarly, our observation that IL-6 did not alter 
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adiponectin secretion (Fig. 5.4) is in contrast to a study by Fasshauer and co-
workers, which reported an inhibition of adiponectin gene expression and protein 
secretion in response to IL-6 in 3T3-L1 adipocytes (Fasshauer et al. 2003). In 
contrast to observations with TNF-, however, the presence of IL-6 appeared to 
ablate any A769662-mediated increase in adiponectin secretion (Fig. 5.4); thus IL-
6 may not directly reduce adiponectin secretion, but may preclude an increase by 
AMPK activation. 
Taken together, these data demonstrate for the first time in adipocytes that 
A769662 suppresses cytokine-stimulated secretion of the chemokines MCP-1, IP-
10 and KC, and gene expression of MCP-1. Furthermore, A769662 has been shown 
to reduce MCP-1, IL-5 and MIP-1, but not TNF- secretion from macrophages. 
These data further support previous observations made in this study, and provides 
further evidence in support of AMPK as an anti-inflammatory protein; in addition 
to inhibition of proinflammatory signalling pathway intermediates, it has also been 
demonstrated to suppress proinflammatory gene transcription and protein 
secretion. 
Preliminary observations were made in this study regarding the effect of individual 
proinflammatory cytokines on insulin-stimulated glucose uptake in 3T3-L1 
adipocytes. A consistent observation was that exposure of 3T3-L1 adipocytes to a 
proinflammatory stimulus caused an elevation in basal glucose uptake, without 
any concomitant increase in insulin-stimulated glucose uptake; therefore the data 
were analysed using the fold change in insulin-stimulated glucose uptake (Fig. 5.7 
– 5.10). The increased basal glucose uptake was likely to be GLUT1-mediated, as 
reported by Lumeng and co-workers (Lumeng, Deyoung, and Saltiel 2007). Figure 
5.7 demonstrated that acute (1 h) stimulation with IL-6 appeared to slightly 
increase the fold change insulin-stimulated glucose uptake, while this was clearly 
reduced upon chronic IL-6 exposure (Fig. 5.7D, 5.7F, 5.7H), with 24 h IL-6 causing 
the most pronounced inhibition (5.7F). These preliminary observations correlate 
with studies suggesting acute IL-6 exposure (as observed in muscle following 
exercise) has a positive effect on insulin sensitivity (Carey et al. 2006), while 
chronic IL-6 exposure (as reported in obesity) is associated with insulin resistance 
(Rotter, Nagaev, and Smith 2003). Furthermore, these observations would indicate 
that IL-6 is unlikely to perturb insulin signalling via inhibitory phosphorylation of 
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signalling pathway components, as this would promote a rapid inhibition of glucose 
uptake. It is more likely IL-6-mediated insulin resistance is the result of the 
negative regulation of longer term processes, such as the transcription of genes 
involved in the insulin signalling pathway. Indeed, these observations are 
supported by a study by Rotter and co-workers, who reported that acute IL-6 
stimulation had no effect on phosphorylation of IRS-1 at Ser307 (Rotter, Nagaev, 
and Smith 2003); a site which if phosphorylated impairs tyrosine phosphorylation 
of IRS-1 and subsequent downstream signalling. Moreover, chronic (24 h) IL-6 
stimulation has been reported to induce a marked reduction in gene expression of 
IRS-1 and GLUT4, with a concomitant inhibition of 3T3-L1 adipocyte insulin-
stimulated glucose uptake independent of TNF- (Rotter, Nagaev, and Smith 
2003). In contrast, IL-6 has been reported to induce insulin resistance in the liver 
in an acute manner via the transient upregulation of SOCS3, which was proposed 
to be associated with inhibition of IRS-1 tyrosine phosphorylation, p85 binding and 
subsequent phosphorylation of PKB (Senn et al. 2003). 
Further preliminary observations suggested that acute stimulation with cytokines 
which signal via the MAPK/NFB pathways was sufficient to suppress insulin 
sensitivity in 3T3-L1 adipocytes, with IL-1 and TNF- inducing a reduction in the 
fold change in insulin-stimulated glucose uptake after 1 h and 6 h, respectively 
(Fig. 5.8F and 5.8D). Unexpectedly, TNF- stimulation appeared to have no effect 
on insulin-stimulated glucose uptake after 1 h (Fig. 5.8B); however these data are 
merely a preliminary observation. Several studies have suggested the mechanism 
by which TNF- or IL-1 induce insulin resistance is via the inhibitory 
phopshorylation of components of the insulin signalling pathway, which would 
correlate with acute, rather than chronic, exposure of these cytokines inhibiting 
insulin-stimulated glucose uptake. TNF- has been proposed to stimulate the 
inhibitory phosphorylation of IRS-1 Ser307 via JNK (Rotter, Nagaev, and Smith 
2003, Aguirre et al. 2000, Hotamisligil et al. 1996) or IKK (Gao et al. 2002). Less 
is known about the mechanism by which IL-1 may acutely suppress insulin-
stimulated glucose uptake in adipocytes; however it is likely to also occur via 
JNK/IKK-mediated inhibitory phosphorylation of IRS-1. Interestingly, chronic 
TNF- stimulation has also been proposed to suppress IRS-1 and GLUT4 gene 
expression in 3T3-L1 adipocytes (Rotter, Nagaev, and Smith 2003), while chronic 
exposure to IL-1 in 3T3-L1 adipocytes has been reported to downregulate IRS-1 
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expression in an ERK-dependent manner (Jager et al. 2007). Taken together, TNF-
 and IL-1 appear to acutely regulate insulin signalling via phosphorylation of key 
insulin signalling pathway components, and elicit longer term effects via inhibition 
of gene transcription. 
When assessing the effects of chronic stimulation with an individual cytokine, it 
can be difficult to delineate whether a reduction in insulin sensitivity is due to 
that particular cytokine, or if it is the result of any number of other 
proinflammatory factors whose transcription has been induced by the cytokine in 
question. Moreover, when considering inflammation-mediated insulin resistance 
in obese adipose tissue, it is not likely to be mediated predominantly by a single 
cytokine; rather a combination of various proinflammatory factors secreted from 
macrophages as well as adipocytes. Indeed, while hypertrophic adipocytes do 
synthesise and secrete proinflammatory mediators, it is well established that the 
majority within adipose tissue originate from M1 activated macrophages. 
Furthermore, infiltration of macrophages into adipose tissue has been proposed 
to crucial to the development of obesity-related insulin resistance; mice deficient 
in factors related to macrophage recruitment such as MCP-1 or CCR2 (MCP-1 
receptor) were reported to have reduced adipose tissue macrophage accumulation 
and were protected from HFD-induced insulin resistance (Kanda et al. 2006, 
Weisberg et al. 2006). TNF- was originally considered to be the primary cytokine 
involved in the development of insulin resistance; obesity is associated with 
increased TNF-, and a plethora of studies exist proposing its absence was 
sufficient to restore insulin sensitivity in vitro and in vivo (Hotamisligil, Shargill, 
and Spiegelman 1993, Uysal et al. 1997, Kern et al. 1995, Dandona et al. 1998). 
Interestingly, recent clinical studies targeting TNF- individually with neutralising 
antibodies or chemical inhibitors proved unsuccessful in improving insulin 
sensitivity in humans (Ofei et al. 1996, Wascher et al. 2011, Ferraz-Amaro et al. 
2011), thus indicating the clinical importance of proinflammatory cytokines other 
than TNF-. Rather than examine the effect of individual cytokines, it would be 
more relevant to investigate the effect of M1 activated macrophage secretory 
products on adipocyte insulin sensitivity. 
In this study, murine RAW 264.7 macrophages were exposed to LPS in order to 
promote a shift in polarisation towards M1, and therefore stimulate the secretion 
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of proinflammatory mediators. This conditioned medium was then applied to 3T3-
L1 adipocytes to investigate the effect of macrophage secretory products on 
adipocyte insulin-stimulated glucose uptake utilising an indirect co-culture 
technique. Figure 5.9 demonstrated that macrophages stimulated for 6 h with LPS 
secreted proinflammatory factors which significantly reduced 3T3-L1 adipocyte 
insulin sensitivity upon exposure. These data suggest the existence of a paracrine 
interaction between macrophages and adipocytes. In a similar study, Lumeng and 
co-workers also reported a reduction in the fold change in insulin-stimulated 
glucose uptake in response to exposure of conditioned medium from LPS-activated 
macrophages (Lumeng, Deyoung, and Saltiel 2007).  Furthermore, the group 
reported a reduction in IRS-1 protein expression and tyrosine phosphorylation, 
while no difference in IRS-1 Ser307 or JNK phosphorylation was observed following 
treatment with macrophage conditioned medium (Lumeng, Deyoung, and Saltiel 
2007).  
We hypothesised that activation of macrophage AMPK with A769662 would limit 
the secretion of LPS-stimulated proinflammatory mediators, and subsequently 
improve the reduced 3T3-L1 adipocyte insulin sensitivity observed in Figure 5.9. 
Interestingly, exposure of A769662-treated macrophage conditioned medium 
appeared to cause a subtle increase in 3T3-L1 glucose uptake, which was 
significantly ablated when macrophages had been exposed to LPS (Fig. 5.10). 
These data suggest that AMPK activation in macrophages may induce the 
production of anti-inflammatory, insulin-sensitising factors; however this may not 
be sufficient to restore the insulin resistance caused by the plethora of 
proinflammatory factors secreted by activated macrophages. Taken together with 
the data shown in Figure 5.6, which demonstrated that A769662 was able to 
suppress LPS-stimulated MCP-1, IL-5, and possibly MIP-1, but not TNF-, these 
data suggest it is possible that the elevated TNF- secreted from these activated 
macrophages even in the presence of A769662 could explain the reduction in 
insulin-stimulated glucose uptake upon exposure of 3T3-L1 adipocytes to 
conditioned medium from these macrophages. This speculation would correlate 
well with other studies which have suggested TNF- to be the key cytokine 
contributing to inflammation-associated insulin resistance in vitro (Hotamisligil, 
Shargill, and Spiegelman 1993, Nieto-Vazquez et al. 2008). 
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To our knowledge, no study has directly evaluated whether an AMPK-mediated 
reduction in inflammation corresponds to an improvement in adipocyte insulin 
sensitivity; however, a few studies have alluded to this possibility. Galic and co-
workers reported that the hematopoietic deletion of AMPK1 in mice resulted in 
the infiltration of activated macrophages into liver and adipose tissue, and the 
subsequent development of hepatic insulin resistance (Galic et al. 2011). 
Furthermore, a clinical study proposed that the diminished AMPK activity in obese 
individuals was the cause of the increased adipose tissue inflammation and whole 
body insulin resistance observed (Gauthier et al. 2011). Taken together, this these 
data suggest both individual cytokines and M1 activated macrophage secretory 
products can induce insulin resistance in 3T3-L1 adipocytes; however A769662-
mediated AMPK activation may not be sufficient to restore insulin sensitivity in 
vitro while macrophage TNF- secretion remains elevated. 
AMPK, adipocyte morphology and adipogenesis 
Adipogenesis is an anabolic process, and is described in more detail in section 
1.4.2. AMPK has been suggested to inhibit it in the MCE phase, with reduced 
expression of C/EBP (which is essential for initiation of the adipogenic 
transcriptional cascade), and subsequent inhibition of PPAR, C/EBP and late 
adipogenic markers (Habinowski and Witters 2001). The mechanism by which AMPK 
inhibits adipogenesis is currently unknown. 
Separately, the JAK2-STAT3 pathway has been suggested to be important in the 
differentiation process, with several studies postulating that STAT 
phosphorylation in the MCE phase is essential for adipocyte differentiation 
(Stewart et al. 1999, Shang and Waters 2003). Indeed, selective pharmacological 
inhibitors, STAT3 siRNA and a dominant-negative STAT3 all inhibited adipogenesis 
in 3T3-L1 adipocytes (Wang, Zhou, et al. 2010). Taken together, it appears that 
AMPK inhibits adipocyte differentiation at the MCE, at a temporally similar manner 
to when STAT3 phosphorylation and activation is critical for differentiation to 
proceed. It was therefore of interest to investigate whether AMPK could inhibit 
adipogenesis via regulation of STAT3.  
Figure 5.11A demonstrated that STAT3 was phosphorylated 24-48h post-
differentiation; a finding which supports a study by Wang and co-workers 
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indicating STAT3 phosphorylation is rapidly and transiently elevated during 
adipogenesis (Wang, Zhou, et al. 2010). Basal ACC phosphorylation appeared 
increased from day 4 post-induction of differentiation (Fig. 5.11A), an observation 
also reported by Zhou and co-workers (Zhou, Wang, et al. 2009). This suggests 
that while AMPK activation during the MCE phase is detrimental to adipogenesis, 
it may be required during the later phase. Importantly, activation of AMPK with 
A769662 was found to inhibit this induction of STAT3 phosphorylation (Fig. 5.11A). 
It is unclear from these data whether differentiation was suppressed in response 
to AMPK activation, as despite a reduction in expression of the late adipogenic 
marker C/EBP at day 4 post-differentiation, expression of C/EBP and PPAR was 
still maintained at day 8. It is likely that this could have been due to the presence 
of troglitazone, a PPAR agonist, in the differentiation cocktail; this is not 
essential for differentiation but is often utilised to improve accumulation of lipid 
droplets within the cells. Indeed, Wang and co-workers reported progression of 
3T3-L1 adipogenesis in the presence of troglitazone, despite pharmacological or 
RNAi-mediated inhibition of STAT3 (Wang, Zhou, et al. 2010). As troglitazone did 
not alter pharmacological downregulation of STAT3 activation, it was postulated 
that PPAR may regulate adipogenesis downstream of STAT3 (Wang, Zhou, et al. 
2010). Separately, 3T3-L1 adipocytes differentiated in the absence of troglitazone 
were incubated with and without A769662 prior to staining with Oil red O; 
observation of lipid accumulation via staining provided a clear indication of the 
progression of adipogenesis. Figure 5.11B demonstrated substantial lipid 
accumulation in vehicle 3T3-L1 adipocytes on day 8 post-differentiation as 
demonstrated by the presence of red staining, which was abolished with A769662-
mediated AMPK activation. Taken together, these preliminary data showed for the 
first time that A769662 inhibited adipogenesis-induced STAT3 phosphorylation in 
3T3-L1 adipocytes and suppressed the lipid accumulation characteristic of 
adipogenesis. The mechanism by which AMPK activation inhibits adipocyte 
differentiation may be via inhibition of STAT3 phosphorylation at the MCE phase 
of adipogenesis, however further investigation is required. 
In order to evaluate whether AMPK1 influenced adipocyte cell size, omental and 
subcutaneous adipose tissue from AMPK1-/- and genetically matched wild-type 
mice fed a chow diet were obtained. The size of the adipocytes appeared reduced 
in AMPK1-/- tissue relative to wild-type in both adipose depots, with a more 
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striking contrast observed in the omental adipose (Fig. 5.12). These observations 
support a study by Daval and co-workers, who reported smaller adipocytes in mice 
lacking AMPK1 (Daval et al. 2005). On the other hand, an increase in adipocyte 
hypertrophy was reported in AMPK2-/- mice; however this occurred in response 
to HFD feeding (Villena et al. 2004). Moreover, AMPK activity in adipocytes is 
mainly represented by the 1 isoform (Daval et al. 2005). Smaller adipocytes in 
the absence of AMPK1 could be attributed to an increase in lipolysis; 
furthermore, enhanced lipolysis would be reflected by an increase in serum FA, 
which can be proinflammatory (Shi, Kokoeva, et al. 2006). It could be speculated 
that the basal phosphorylation of proinflammatory cytokines JNK (Fig. 3.10A) and 
STAT3 (Fig. 4.7) in AMPK1-/- adipose tissue could be linked to an increase in 
serum FA, as Figure 5.3 suggests there to be no shift in macrophage polarisation 
to M1 in the AMPK1-/- adipose tissue. 
Overall, this current work demonstrates for the first time in adipocytes that 
A769662 suppresses cytokine-stimulated chemokine expression and secretion, and 
suppresses IL-5, MCP-1 and MIP-1, but not TNF- secretion from activated 
macrophages. Furthermore, proinflammatory factors secreted from M1 activated 
macrophages suppress insulin-stimulated glucose uptake in adipocytes which could 
not be rescued by A769662, possibly due to the presence of TNF-. Lastly, we 
observed no difference between M1/M2 activation state of macrophages in 
AMPK1-/- and wild-type adipose tissue, while AMPK1-/- is associated with 
comparatively small adipocytes. 
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 Chapter 6 - Final Discussion 
This study has demonstrated for the first time that AMPK activation in adipocytes 
is associated with inhibition of multiple distinct proinflammatory signalling 
pathways, and the subsequent inhibition of chemokine gene expression and 
chemokine and cytokine secretion. Furthermore, some of the mechanisms by 
which this occurs have also been characterised. 
Work in this current study showed that the direct AMPK activator A769662 
suppressed phosphorylation and activation of multiple proinflammatory signalling 
pathway intermediates in response to proinflammatory cytokine stimulation in 
3T3-L1 adipocytes. As described (1.2.2.1), cytokines such as TNF- and IL-1 
simultaneously activate the NFB pathway and MAPK cascade, regulating 
transcription of proinflammatory genes in the nucleus. In this study, AMPK 
activation suppressed phosphorylation of JNK, ERK1/2 and p38 MAPK, supporting 
similar findings by Jeong and co-workers in macrophages in response to berberine 
(Jeong et al. 2009). In addition, elevated JNK phosphorylation was reported in 
macrophages and endothelial cells of mice deficient in AMPK1 or AMPK2, 
respectively (Galic et al. 2011, Dong et al. 2010). Furthermore, A769662 or 
adenoviral upregulation of a constitutively active AMPK mutant ablated nuclear 
translocation of the transcription factor NFB; conversely, downregulation of 
AMPK activation suppressed the A769662-mediated inhibition of NFB nuclear 
translocation. Thus, these data demonstrated that A769662 inhibited nuclear 
translocation in an AMPK-dependent manner. In line with this, AMPK activation 
ameliorated phosphorylation of upstream IB and IKK. These data support previous 
findings that there was an increase in NFB present in the nuclear fraction of 
endothelial cells deficient in AMPK2 (Wang, Zhang, et al. 2010). Concomitantly, 
A769662 suppressed TNF--stimulated MCP-1 gene expression and IL-1-
stimulated secretion of chemokines MCP-1, IP-10 and KC from 3T3-L1 adipocytes; 
as these proteins are transcriptionally regulated by NFB and/or AP-1, these data 
correlate with inhibition of NFB nuclear translocation by AMPK. Furthermore, 
these data support previous reports that AMPK inhibits TNF--stimulated MCP-1 
expression and secretion in endothelial cells (Ewart, Kohlhaas, and Salt 2008). 
Taken together, this study has demonstrated for the first time in adipocytes that
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A769662-mediated AMPK activation simultaneously suppresses cytokine-
stimulated phosphorylation of MAPKs and NFB signalling pathway intermediates, 
and the downstream transcription and subsequent secretion of proinflammatory 
chemokines. 
While AMPK has previously been reported to phosphorylate and activate eNOS 
(Morrow et al. 2003), results from the current study indicated that the mechanism 
by which AMPK produces its anti-inflammatory effects is likely to be independent 
of NO production. Thus, the molecular mechanism(s) by which AMPK elicits the 
inhibition of MAPK and NFB signalling pathways remains to be determined, but 
occur at a site upstream of MAPK and IKK. A potential target of AMPK could be 
TAK1; as TNF- and IL-1 engage different signalling pathways upstream of TAK1 
activation, it is possible that the coordinated inhibition of JNK, p38 and IKK 
phosphorylation by AMPK in response to both TNF- and IL-1 reflects targets 
common to both pathways. Several mechanisms have recently been proposed for 
the AMPK-mediated inhibition of NFB signalling. Zhang and co-workers reported 
in cultured endothelial cells that constitutively active AMPK or long-term AICAR 
treatment phosphorylated the transcriptional co-activator p300, subsequently 
blocking acetylation of NFB p65, and in turn inhibited TNF--stimulated NFB 
DNA binding (Zhang et al. 2011). Similarly,  it has been reported that AMPK may 
inhibit NFB-mediated gene transcription via activation of the deacetylase SIRT1 
which was demonstrated to deacetylate Lys310 of p65, stimulating Ser9-mediated 
methylation of Lys314/315 (Yang, Tajkhorshid, and Chen 2010). This leads to the 
polyubiquitination and subsequent proteasomal degradation of p65, thus ablating 
transcription of NFB target genes. However, due to the rapid nature of AMPK-
mediated inhibition of the NFB pathway in 3T3-L1 adipocytes observed in the 
current study, it seems unlikely to be due to the suppression of p300 histone 
acetyltransferase activity. Lastly, another group reported that 
hyperphosphorylation of IKK by constitutively active AMPK blocked subsequent 
phosphorylation of IB and p65, and in turn suppressed NFB-mediated gene 
transcription in response to TNF- I COS-7 cells (Bess et al. 2011). This is in direct 
contrast to the findings in the current study, whereby the rapid inhibition of IKK 
phosphorylation and subsequent downstream NFB signalling further suggests 
TAK1 may be a potential target of AMPK in adipocytes to suppress downstream 
signalling. 
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The current study also investigated the effect of A769662-mediated AMPK 
activation on the IL-6 proinflammatory signalling pathway in adipocytes. A769662 
suppressed IL-6-stimulated STAT3 phosphorylation and subsequent MCP-1 gene 
expression in 3T3-L1 adipocytes; in contrast, IL-6 did not appear to induce 
chemokine or cytokine secretion. This could indicate that while IL-6 stimulates 
chemokine gene expression, it is possible that secreted products were produced 
at too low a level to be observed. IL-6 was not found to stimulate ERK1/2 
phosphorylation in these cells; consistent with this, no stimulation of C/EBP 
protein expression was observed. The mechanism by which AMPK inhibited IL-6-
stimulated STAT3 phosphorylation was also investigated in this study. AMPK was 
not found to inhibit IL-6-stimulated STAT3 phosphorylation via the action of a 
phosphatase; however genetic manipulation of JAK2 in HEK-293 and HeLa cells 
suggested JAK may be a possible target for AMPK, as A769662-mediated inhibition 
of STAT3 phosphorylation was ablated following transfection with a constitutively 
active JAK2 mutant. Furthermore, this study demonstrated that pharmacological 
inhibition of mTORC1 and mTORC2 suppressed STAT3 phosphorylation in 3T3-L1 
adipocytes, potentially via the action of the phosphatase TC-PTP. Prior to the 
beginning of the current study, the effect of AMPK on IL-6-stimulated STAT3 
phosphorylation had, to our knowledge, never been reported in any cell type. 
During the course of this study, only a small number of groups have reported an 
AMPK-mediated reduction in IL-6-stimulated STAT3 phosphorylation (Nerstedt et 
al. 2010, Nerstedt et al. 2013, Kim et al. 2012); however these studies were all 
conducted in liver-derived cells. In contrast to adipocytes, and indeed the 
majority of cells, hepatocytes do not require the presence of a soluble IL-6 
receptor as they possess membrane-bound IL-6 receptors. Trans-signalling, 
requiring the soluble IL-6 receptor, is proposed to be more proinflammatory than 
classical IL-6 signalling involving the membrane-bound receptor (Rose-John 2012); 
thus the consequences of IL-6 signalling in liver cells are likely to be different 
compared to adipocytes. 
Collectively, these results demonstrate for the first time in adipocytes that 
A769662 inhibits IL-6-stimulated STAT3 phosphorylation independently of 
phosphatases and potentially via regulation of upstream JAK. Furthermore, mTOR 
inhibition suppresses STAT3 phosphorylation via a mutually exclusive mechanism, 
potentially mediated by TC-PTP. While IL-6 did not stimulate observable secretion 
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of proinflammatory mediators in this study, the upregulation of MCP-1 gene 
expression was suppressed by A769662, thereby indicating A769662-mediated 
AMPK activation inhibits a functional consequence of IL-6 signalling in 3T3-L1 
adipocytes. The potential regulation of IL-6-stimulated JAK/STAT pathway is 
summarised below: 
 
 
Figure 6-1: Potential regulation of IL-6-stimulated proinflammatory signalling 
by AMPK and mTOR in 3T3-L1 adipocytes 
 
Macrophage recruitment and M1 activation in obese adipose tissue is critical for 
the development of a sustained proinflammatory environment, contributing to 
insulin resistance in metabolic tissues. In the current study A769662 suppressed 
secretion of MCP-1, MIP-1 and IL-5, but not TNF- from activated RAW 264.7 
macrophages; however the reduction in 3T3-L1 adipocyte glucose uptake following 
exposure to activated macrophage secreted products was not rescued upon prior 
AMPK activation in macrophages. This could be potentially due to the continued 
presence of TNF- in the conditioned medium. Furthermore, preliminary data 
suggested that acute TNF- or IL-1 and chronic IL-6 stimulation may ameliorate 
insulin-stimulated glucose uptake in 3T3-L1 adipocytes. Taken together, these 
data indicate that both individual cytokines and activated macrophage secreted 
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products suppress adipocyte insulin-stimulated glucose uptake; however, although 
A769662 inhibited secretion of several proinflammatory mediators from 
macrophages, the continued presence of TNF- in the macrophage conditioned 
medium may have been sufficient to induce insulin resistance. 
The basal proinflammatory profile of adipose tissue from AMPK1-/- mice was 
examined for the first time in this study. Basal phosphorylation of JNK and STAT3 
was elevated in AMPK1-/- adipose tissue compared to wild-type. While this study 
provided evidence suggesting this may have been independent of alterations in 
macrophage M1/M2 ratio, FACS (fluorescence-activated cell sorting) analysis 
should be performed to fully address this. Overall, these results suggest that cells 
other than macrophages, such as adipocytes or endothelial cells, may have been 
the source of inflammation observed in AMPK1-/- adipose tissue. Alternatively, 
the smaller adipocytes observed in AMPK1-/- adipose tissue could be the result of 
an increase in lipolysis; thus the subsequent increase in serum FA could stimulate 
JNK and STAT3 phosphorylation in adipose tissue. As the mice are global AMPK1 
deficient, however, there is the potential for this to be a secondary, indirect 
effect due to the down-regulation of AMPK1 in other tissues. Thus, there is an 
urgent need for the generation of animals with a tissue-specific AMPK ablation in 
order to truly characterise the role of AMPK in adipose. 
AMPK has been reported to suppress NFB and MAPK inflammatory signalling in 
cells that constitute adipose tissue, including endothelial cells and macrophages 
(Wang, Zhang, et al. 2010, Dong et al. 2010, Ewart, Kohlhaas, and Salt 2008, Jeong 
et al. 2009, Galic et al. 2011, Sag et al. 2008); however, the effect of AMPK 
activation on NFB, MAPK and JAK/STAT signalling in adipocytes and the molecular 
mechanisms by which AMPK elicits its anti-inflammatory effects had never been 
examined. Overall, this study demonstrated for the first time that the AMPK 
activator A769662 inhibited multiple, distinct, proinflammatory signalling 
pathways in adipocytes, leading to the suppression of subsequent proinflammatory 
gene expression and chemokine secretion. Furthermore, AMPK1-/- mouse adipose 
tissue exhibited increased activation of proinflammatory signalling intermediates, 
despite no obvious alteration in the M1/M2 ratio as assessed by analysis of M1 and 
M2 marker mRNA. Finally, A769662 inhibited proinflammatory protein secretion 
from macrophages; however the ability of AMPK activation to rescue 
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inflammation-induced insulin resistance remains to be determined. Very few 
studies have investigated adipose tissue AMPK and inflammation; those that have 
found AMPK activation suppressed expression of proinflammatory cytokines in 
adipose tissue of obese db/db mice (Jeong et al. 2009) and TNF- and IL-6 
secretion from human SCAT cultured ex vivo (Lihn et al. 2008). Human in vivo 
studies revealed that AMPK expression and activity was lower in VAT compared 
with SCAT in morbidly obese individuals (Gauthier et al. 2011, Martínez-Agustin et 
al. 2010). Moreover, AMPK activity was further reduced in adipose tissue of insulin 
resistant volunteers compared with BMI (body mass index)-matched insulin 
sensitive controls (Gauthier et al. 2011, Martínez-Agustin et al. 2010).  A 
schematic overview outlining the potential inhibition of adipose inflammation by 
AMPK is depicted below: 
 
Figure 6-2: Regulation of adipose tissue inflammation by AMPK 
 
This study suggests that activation of AMPK in adipocytes and macrophages may 
reduce the proinflammatory profile of adipose tissue which is associated with 
obesity and insulin resistance. The small number of studies examining AMPK 
activation in human adipose tissue have suggested that AMPK activation in adipose 
tissue could be both feasible and beneficial. Metformin is a widely-used anti-
diabetic drug which promotes insulin-stimulated glucose uptake in muscle and 
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suppresses hepatic glucose output, while also lowering plasma TG; however the 
extent to which indirect AMPK activation by metformin underlies some of its 
effects, such as the ability to suppress hepatic glucose output (Foretz et al. 2010) 
is currently debated. Recent work in our laboratory has shown that metformin 
stimulated AMPK activity in SCAT of individuals with Type 2 diabetes in a 
randomised glycaemia-controlled cross-over study (Boyle et al. 2011). 
Furthermore, metformin was reported to reduce serum TNF- in obese insulin 
resistant patients in a randomised clinical trial (Evia-Viscarra et al. 2012), 
therefore suggesting clinical anti-inflammatory effects of the drug. The 
thiazolidinedione class of anti-diabetic drugs, including rosiglitazone, also 
stimulate AMPK activation. Moreover, rosiglitazone was reported to suppress 
expression of proinflammatory genes in adipose tissue of patients with Type 2 
diabetes (Kolak et al. 2007); however, as with metformin, the extent to which 
AMPK underlies their clinical action remains uncertain. 
More recently, salicylate, the pharmacologically active breakdown product of 
aspirin and salsalate in vivo, has been reported to bind and allosterically activate 
1-containing AMPK complexes in a similar manner to A769662 (Hawley et al. 
2012). Salicylate has been shown to stimulate hepatocyte ACC phosphorylation 
and FA oxidation in vitro and fat utilisation in vivo in an AMPK-dependent manner 
(Hawley et al. 2012). Moreover, salicylates have also been reported to improve 
the proinflammatory profile and glucose tolerance in patients with Type 2 
diabetes (Hundal et al. 2002). Salicylate has long been proposed to exert its anti-
inflammatory actions via inhibition of NFB activation (Kopp and Ghosh 1994, Kiss 
et al. 2004); thus findings in the current study suggest that salicylate may suppress 
NFB activation via AMPK, although this has yet to be directly investigated. 
The widespread use of metformin, thiazolidinediones and salicylate suggests that 
AMPK-activating drugs could be relatively safe for the long-term management of 
chronic inflammatory conditions. As the activators salicylate and A769662 
selectively target 1-containing AMPK complexes, this indicates that it may be 
feasible to design AMPK activators that are targeted to specific tissues by 
exploiting tissue-specific variation of subunit isoforms. Furthermore, the different 
 subunit isoforms within the AMPK complexes have been shown to influence 
sensitivity to AMP (Cheung et al. 2000), and therefore may be differentially 
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sensitive to pharmacological AMPK activators. Using known compositions of AMPK 
complexes as a starting point, it could be possible to screen for selective 
activators which have an anti-inflammatory effect in adipocytes or macrophages. 
Important considerations when developing an AMPK activator to target 
inflammation would be firstly, that it should elicit anti-inflammatory effects 
without inducing hypoglycaemia which would not necessarily be desirable for all 
patients. Secondly, the drug should not cross the blood-brain barrier, considering 
that CaMMK-mediated AMPK activation in the hypothalamus is a key mechanism 
by which ghrelin stimulates appetite and feeding responses (Kola and Korbonits 
2009). 
Activating AMPK in adipose tissue macrophages in particular could represent an 
effective way in which obesity-related inflammation and subsequent insulin 
resistance could be ameliorated. As discussed (1.2.3), while hypertrophic 
adipocytes release proinflammatory cytokines and chemokines, they do so to a far 
lesser degree than activated macrophages. Furthermore, while macrophages are 
recruited to adipose tissue and M1-activated in response to chemokines and 
cytokines secreted from adipocytes, they have also been proposed to be recruited 
and activated by increased FA and necrotic adipocytes. Thus, while activating 
AMPK in adipocytes would be beneficial in terms of suppressing adipocyte 
production of proinflammatory mediators, it could potentially be insufficient to 
ablate macrophage recruitment and M1 activation. Importantly, directly 
activating AMPK in adipocytes has been reported to inhibit insulin-stimulated 
glucose uptake (Salt, Connell, and Gould 2000). As described (1.1.2), glucose 
enters adipocytes in the fed state and is stored as TG. Therefore inhibition of 
glucose uptake into adipocytes subsequently suppresses FA and TG synthesis which 
is an energy-consuming process. It could therefore be reasoned that AMPK 
activation inhibits insulin-stimulated glucose uptake in adipocytes in order to 
reduce the ATP-dependent synthesis of FA and TG, and moreover allow glucose to 
be utilised as an energy source by tissues other than adipose, which could simply 
use the TG stored in adipocytes. Thus, while direct AMPK activation in adipocytes 
could reduce inflammation, it would also inhibit insulin-stimulated glucose 
uptake. In contrast, if AMPK could be selectively activated in adipose tissue 
macrophages, this would promote their polarisation towards an M2 anti-
inflammatory phenotype, ameliorating secretion of proinflammatory cytokines; 
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thus AMPK activation in adipose tissue macrophages could potentially overcome 
cytokine-induced insulin resistance. 
A significant limitation in this study is that adipocytes are relatively genetically 
intractable, thus there is a marked difficulty associated with using standard 
molecular biology techniques such as siRNA or adenoviruses to up- or down-
regulate AMPK in terminally differentiated adipocytes. In the current study, 
attempts to elucidate the effects of adenovirus-mediated up- or down-regulation 
of AMPK in whole cell lysates were unsuccessful; however, the inhibition of NFB 
nuclear translocation was demonstrated to be AMPK-dependent using Ad.1CA and 
Ad.1DN adenoviruses.  In addition, siRNA-mediated knockdown of AMPK in 
HUVECs demonstrated that inhibition of STAT3 phosphorylation was AMPK 
dependent. Moreover, analysis of adipose tissue from AMPK1-deficient mice 
provided evidence supporting a role for AMPK in the regulation of inflammatory 
signalling. The 3T3-L1 preadipocyte cell line is a model system for investigating 
adipocyte biology and differentiation, as upon induction of differentiation they 
accumulate the biochemical and morphological characteristics of adipocytes. One 
limitation of using cultured adipocytes is that they do not represent adipocytes 
from a specific type of depot, thus it is not possible to extrapolate findings to 
SCAT or VAT in vivo. As discussed (1.1.1) different fat depots are associated with 
differential metabolic risk. VAT has been widely proposed to be particularly 
pathogenic as it exhibits enhanced lipolysis and endocrine activity. Indeed, VAT is 
more strongly associated with an increased risk of the metabolic syndrome and 
cardiovascular disease (Fox et al. 2007). The current study provides evidence in 
adipose tissue suggesting that the basal proinflammatory profile of both visceral 
and subcutaneous depots may be altered in AMPK1-/- mice. 
Published studies of AMPK function in adipose tissue tend to be based on isolated 
rodent adipocytes or cells that have been differentiated to adipocytes in vitro, 
and also rely on less-specific methods of transiently activating or inhibiting AMPK. 
Similarly, in vivo data generated using animals which are genetically deficient in 
one isoform of AMPK have alluded to potential actions of AMPK in adipose tissue; 
however as discussed above, there is an urgent need for the development of 
animals in which AMPK is specifically deleted in adipocytes to confirm the role of 
AMPK in adipose. 
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Future work 
Currently the mechanism by which AMPK activation in 3T3-L1 adipocytes inhibits 
TNF-/IL-1-stimulated proinflammatory signalling remains to be elucidated. As 
previously discussed, TAK1 is the point at which TNF- and IL-1 signalling 
pathways converge; furthermore TAK1 is an upstream kinase of IKK, and MAPKs 
JNK and p38. Thus, the potential regulation of TAK1 activation by AMPK could be 
investigated by immunoblotting with phospho-specific TAK1 antibodies. If TAK1 
phosphorylation appears to be regulated by AMPK, in vitro kinase assays with TAK1 
immunoprecipitates could also be performed to assess whether it is a direct target 
of AMPK. The association of MAPKs with scaffolding proteins has been proposed to 
underlie the specificity of MAPK activation and action (Brown and Sacks 2009), 
thus the potential for AMPK activation to alter MAPK association with scaffolds 
could be investigated in immunoprecipitates under basal and stimulated 
conditions. The AMPK-mediated activation of a phosphatase could potentially 
inhibit phosphorylation of TNF-/IL-1 pathway intermediates, thus it would be 
of interest to assess whether AMPK-mediated inhibition of phosphorylation could 
be reversed by preincubation with the general phosphatase inhibitor vanadate.  
Results from the current study suggest that mTOR may suppress IL-6-stimulated 
STAT3 phosphorylation via TC-PTP and potentially independently of AMPK 
activation. This should be further explored using cells lacking components of the 
mTOR complex to establish whether this is altered by prior AMPK activation. 
Results from this study also suggested that the inhibition of STAT3 phosphorylation 
by AMPK may be mediated via JAK. Once potential target protein(s) (such as JAK) 
that underlie the AMPK-mediated anti-inflammatory effects have been identified, 
in vitro kinase assays of purified proteins to establish whether they are bona fide 
AMPK substrates and peptide arrays to identify potential phosphorylation sites 
targeted by AMPK could be undertaken. Site-specific antibodies and mass 
spectrometry could also be used to investigate AMPK-regulated phosphorylation in 
vivo, and mutants to establish the consequences on activity. 
To further investigate whether AMPK activation can overcome cytokine-induced 
insulin resistance, western blotting to determine expression and phosphorylation 
of insulin signalling pathway intermediates including IRS1, IRS2 and PKB in lysates 
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obtained from 3T3-L1 adipocytes incubated with TNF-, IL-1, IL-6 or activated 
macrophage conditioned medium,  and AMPK activators in the presence and 
absence of insulin. Furthermore, the effect of AMPK on the migration of 
macrophages towards 3T3-L1 conditioned medium could be assessed in a Boyden 
chamber. 
Finally, as preliminary results from this study showed AMPK activation ameliorated 
STAT3 phosphorylation and lipid accumulation during 3T3-L1 adipogenesis, it 
would be interesting to establish whether inhibition of STAT3 phosphorylation 
during the early phase of adipocyte differentiation is the mechanism by which 
AMPK suppresses adipogenesis. 3T3-L1 preadipocytes could be infected with 
adenovirus expressing a constitutively active mutant STAT3 or JAK2 prior to 
treatment with an AMPK activator and induction of differentiation to assess 
whether AMPK-mediated inhibition of adipogenesis is STAT3-mediated. 
Adipose tissue inflammation contributes to insulin resistance and the development 
of Type 2 diabetes. Thus, elucidation of the molecular mechanisms by which AMPK 
may inhibit inflammatory pathways in adipocytes could uncover novel potential 
therapeutic targets, which could lead to the development of novel therapies for 
treating Type 2 diabetes. 
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